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ABSTRACT 
 
STEVEN WESLEY COTTEN: Profiling the Protein Targets of the Novel Anticonvulsant 
(R)-lacosamide 
(Under the direction of Professor Rihe Liu) 
 
 
 
 The full spectrum of proteins that interact with the anticonvulsant (R)-lacosamide 
remain unknown despite the compound’s approval in both Europe and the United States 
for treatment of partial seizures.  This dissertation seeks to identify proteins from the 
mouse brain proteome that bind to (R)-lacosamide by integrating chemical biology 
approaches coupled with mass spectrometry for drug-target discovery.  (R)-Lacosamide 
probes functionalized with reactive units and chemical reporters are used to selectively 
label, detect, and capture target proteins from complex mixtures of mouse brain lysate.  
Several proteins identified were further evaluated using recombinant protein technology, 
and the adduction site of the DPYSL2 protein was identified using mass spectrometry.  
Computational studies modeled the interaction of (R)-lacosamide with the known crystal 
structure of the DPYSL2 protein.  One predicted confirmation is consistent with known 
structure activity relationships of (R)-lacosamide in vivo.  Data evaluating labeling of an 
(R)-lacosamide derivative with a mutant protein lacking the identified adducted residue 
are presented. 
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CHAPTER 1 
 
FUNCTIONALIZED AMINO ACIDS, LACOSAMIDE, AND CANDIDATE 
ANTICONVULSANTS 
 
1.1 Epilepsy and seizure disorders 
Epilepsy is one the most common neurological disorder of the brain worldwide.  It 
is estimated that 50 million people are affected, and epilepsy accounts for 1 % of the 
global burden of disease.1  In developing countries, 80-90% of those affected receive no 
treatment at all.  Much like a headache, epilepsy is simply a symptom of an underlying 
neurological dysfunction.  The relationship between the causative disease and manifested 
symptoms is often complex and currently not fully understood.  This in turn creates 
challenges for the proper treatment and control of epilepsy due to a myriad of potential 
causes. 
The attempt to classify epileptic syndromes highlights the challenge in categorizing 
such variable conditions.  Efforts in classification have used approaches to segregate 
epilepsies based on seizure origin, frequency, age, idiopathic versus symptomatic, and 
genetics.  Despite these efforts, any current classification system fails to provide insight 
into choosing treatment, prognosis, or responsiveness to therapy.  The International 
League Against Epilepsy (ILAE) developed the most commonly used classification 
system in 1981 based on clinically presented manifestations and electroencephalography 
(EEG) abnormalities (Table 1.1).2  According to the ILAE classification system, seizures 
are divided into 3 main  groups, namely, partial, generalized, and unclassifiable.   
  2 
Partial seizures are defined as arising from a specific loci in the cortex of one 
hemisphere in the brain.  These partial seizures are sub-divided into 3 groups: simple, 
complex, and secondary generalized.  A simple partial seizure is defined as a seizure in 
which consciousness is not impaired with symptoms typically lasting only a few seconds.  
Complex partial seizures are associated with altered consciousness in the form of 
motionlessness or a total loss of consciousness.  Secondary generalized seizures are 
initiated as partial seizures but evolve into one form of generalized seizures. 
 Generalized seizures are the second type of classification.  These seizures are 
exclusively associated with impaired consciousness from the onset and when present, 
uncontrollable movement.  EEG patterns during generalized seizures show strong 
synchronous and symmetrical activity over both hemispheres of the brain.  Generalized 
seizures are subdivided into 6 categories: absence, myoclonic, clonic, tonic, tonic-clonic, 
and atonic.  Absence seizures are characterized by of a loss of consciousness followed by 
cessation of motor activity.  Myoclonic seizures are brief muscle contractions varying 
from a twitch to severe jerking with immediate recovery.  Clonic seizures consist of rapid 
jerking with EEG showing fast activity.  In contrast to clonic seizures, tonic episodes 
consist of sustained muscle contraction of the neck, face, eyes and limbs with EEG 
showing desynchronized fast activity.  Tonic-clonic is the most well known form of 
epileptic seizure initiated by loss of consciousness followed by a tonic phase of muscle 
contraction preceding a clonic phase of convulsions.  Atonic seizures are characterized by 
an abrupt loss of posture, resulting in a collapse to the ground accompanied by a short 
seizure. 
  3 
 Seizure profiles that do not match the typical clinical manifestation or EEG 
patterns are considered to belong in the unclassifiable category.  These epileptic episodes 
may exhibit partial loss of consciousness, novel EEG patterns or altered tonic, atonic, and 
clonic phases.  Up to one-third of seizures are considered unclassifiable using the 1981 
ILAE system, a fact that highlights the need for improvement of seizure stratification 
through investigation into the underlying neurological dysfunction. 
Table 1.1 International League Against Epilepsy Seizure Classification System 
1981 International League Against Epilepsy Seizure Classification 
Partial Generalized Unclassifiable 
Simple Absence  
Complex Myoclonic  
Secondary generalized Clonic  
 Tonic  
 Tonic-clonic  
 Atonic  
 
1.1.1 Neurotransmission and epilepsy pathophysiology 
The central nervous system (CNS) is comprised of highly specialized neuronal 
cells that transmit chemical and electrical signals and glial cells that support, protect, and 
to some extent communicate with neuronal cells.3  Neurons are highly polarized cells 
consisting of a single, often branched projection termed axon, that transmits electrical 
signals in the form of action potentials to other target neurons and numerous projections 
from the cell body.  These projections, termed dendrites, receive signals from adjacent 
cells and subsequently relay the electrical signal.  Conversely, glial cells do not fire 
action potentials but instead communicate via gap junctions and calcium signaling.  Glial 
cells encase neuronal cells in myelin to speed action potentials and form tripartite 
synapses with pre-synaptic and post-synaptic neuron terminals.4 
  4 
Rapid communication between neurons is mediated by the release of excitatory 
amino acids glutamate and aspartate and the inhibitory amino acids γ-aminobutyric acid 
(GABA) and glycine.  Other neurotransmitters such as serotonin, dopamine, 
norepinephrine, histamine, and acetylcholine, as well as neuropeptides such as oxytocin 
mediate their effects on longer time scales.  The balance between inhibitory and 
excitatory signals are tightly regulated through numerous proteins that dynamically 
respond to changes in membrane potential, intracellular and extracellular concentrations 
of ions such sodium, potassium, and calcium, and the release of neurotransmitters. 
Signal propagation between neurons in the brain relies on the depolarization and 
subsequent repolarization of membrane potential mediated by ion channels in the plasma 
membrane.  Ion channels are classified as ligand-gated or voltage-gated based on what 
type of stimuli open and close the pore of the channel.  Ligand-gated channels respond to 
the binding of small molecules such as ATP, zinc, and the neurotransmitters serotonin, 
GABA, and glycine, resulting in a conformational change that leads to channel opening.5 
This class of receptors is sub-divided into 3 categories based on the channel 
structure.  The Cys-loop receptor superfamily includes nicotinic acetylcholine (nACh), 5-
hydroxytryptamine type 3 (5HT3), glycine, γ-aminobutyric acid (GABAA/C), and zinc 
activated receptors which form pentameric channels from assembled subunits at the 
plasma membrane.6  The glutamate receptor family forms tetrameric channels and 
includes the N-methyl-D-aspartic acid (NMDA), α-amino-3-hydroxyl-5-methyl-4-
isoxazole-propionate (AMPA), and kainate acid receptors.  The final group is the P2X 
receptors that form trimeric channels.  Upon binding to ATP, these channels open and 
allow Na+ and Ca2+ ions to enter the cell. 
  5 
Voltage-gated ion channels are the second class of receptors responsible for 
depolarization of neurons.  These include voltage-gated sodium, potassium, and calcium 
channels.  Voltage-gated ion channels sense changes in membrane potential that can 
occur after stimulation of ligand-gated ion channels resulting in an influx of ions at the 
post-synaptic terminal.  Propagation of the signal occurs when the localized 
depolarization triggers activation of nearby channels resulting in a new influx of sodium 
ions followed by rapid inactivation of the channel and repolarization through an 
expulsion of potassium ions.  This series of events generate an action potential that 
travels down the length of the axon ultimately reaching the presynaptic terminal. 
To date, a variety of molecular, genetic, environmental, and developmental 
factors have been attributed to the development of seizure disorders.  In developing 
countries, endemic diseases such as tuberculosis (TB), cysticerosis, human 
immunodeficiency virus (HIV), and metabolic conditions related to nutrition are common 
causes of seizures.  In addition to these environmental and developmental factors, several 
single gene mutations have been described that result in “pure epilepsy,” or seizures with 
unrelated neurological disorders which are thought to account for only 1-2% of all cases 
of epilepsy.7 
Mutations have been found in genes encoding ligand and voltage gated channels 
such as the GABA receptor (GABAR), neuronal nicotinic acetylcholine receptor (CHRN), 
voltage-gated potassium channels (KCNA1, KCNQ2, KCNQ3), and voltage-gated sodium 
channels (SCN1A, SCN1B).  Four mutations in the GABAA receptor channel have been 
linked with inherited forms of epilepsy.8-12  Consequences of the mutations range from 
  6 
alteration of channel gating, decreased current amplitude, loss of current enhancement by 
benzodiazepines, and lack of receptor transport to the plasma membrane. 
Investigation of the genetics related to autosomal dominant nocturnal frontal lobe 
epilepsy (ADNFLE) identified at least 11 mutations in the nicotinic acetylcholine 
receptor.13-22  Modifications are almost exclusively found in the α3 and β2 subunits that 
result in a gain of function from increased sensitivity to acetylcholine and increased Ca2+ 
permeability.23  Benign Familial Neonatal Convulsions (BFNC), another rare form of 
inherited epilepsy, correlates with mutations in 2 voltage-gated potassium channels.24  
BFNC is characterized by frequent, but brief generalized or multifocal seizures starting 
the third day after birth and resolving spontaneously after several weeks to a month. 
A variety of missense, frameshift, and splice mutations have been identified as 
giving rise to BFNC.25-29  These genetic changes reduce current amplitude of the 
expressed channels affecting proper repolarization of the membrane after stimulation 
resulting in hyperexcitability.24,30  The mutations do not affect channel selectivity, gating, 
or expression of wild-type subunits, suggesting the phenotype arises simply from 
haploinsufficiency. 
The voltage-gate sodium channel type 1 alpha subunit is the most frequent 
clinically encountered gene mutation associated with epilepsy.31  One-hundred-forty-two 
mutations have been characterized that give rise to a variety of seizure disorders 
including: Generalized Epilepsy with Febrile Seizures Plus (GEFS+), Severe Myoclonic 
Epilepsy of Infancy (SMEI), Borderline SMEI, and Infantile Spasms (IS).  The 
compendium of mutations includes truncations, missense, mis-splicing, and deletions 
within the gene affecting a wide range of features including channel gating, proper 
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folding, expression, ion permeability, and recovery.  Despite the large number of 
identified mutations, the correlation between genotype and phenotype is variable between 
conditions.  SCN1A mutations only account for 5-10% of GEFS+ cases while mutations 
in this gene account for 50% for SMEI.  This highlights the concept of a polygenic origin 
for epilepsy in which multiple alterations at the genetic level contribute to seizure 
susceptibility. 
Cryptogenic epilepsy accounts for up to 40% of cases in which the underlying 
cause of the syndrome is unknown.7  This exceeds single gene disorders, trauma, 
infection, congenital malformations, degenerative disorders, and idiopathic epilepsies that 
may be related to larger genetic syndromes.  In these cases, conditions leading to neuron 
hyperexcitability may occur from a collection of unknown factors leading to seizure 
susceptibility that makes targeted treatment difficult. 
 
1.1.2 Disease management 
Currently there are four broad approaches to managing seizure disorders.  The 
most common and often first choice for therapy are medications that seek to control 
seizure frequency and severity.  In addition to medications, vagus nerve stimulation 
(VNS), surgery, and a ketogenic diet are used to control seizures.  In VNS therapy, a 
small electrode is implanted in the neck that directly stimulates the vagus nerve, a major 
afferent fiber that relays sensory information to the brain.  Regular pulses administered 
by an implanted generator send a 30 Hz signal to the nerve for 30 seconds followed by a 
5 minute rest period.32  A 12 year study of VNS therapy showed a 26% decrease in 
seizures after 1 year, 30% after 5 years, and 52% after 12 years.33  The precise 
  8 
mechanism for seizure reduction may involve increased levels of GABA, increased 
GABAA receptor density, or an increase in the release of norepinephrine.34 
In cases in which seizure genesis is consistently localized at one focal point in the 
brain, surgery can provide an effective treatment.35  Cortical resection of a small area of 
the brain is possible only if the affected area is not critical for speech, movement, 
memory or eyesight.  Additionally, corpus collosotomy (severing the nerve bridge 
between the hemispheres of the brain) can block the spread of synchronous epileptic 
waves across lobes. 
The third alternative to medication is a ketogenic diet (KD).  Elimination of 
carbohydrates and substitution with fat in the patient’s diet changes cellular metabolism 
from glycolysis to ketosis to generate energy.36  In addition to the generation of ATP, the 
metabolism of fatty acids ultimately generates acetone, acetoacetic acid, and β-
hydroxybutyric acid termed ketone bodies (Figure 1.1).  In patients with 
pharmacoresistant epilepsy, greater than half show at least a 50% reduction in seizures 
when they follow a ketogenic diet.37 
Several hypotheses have been proposed to explain the efficacy of a ketogenic diet 
in seizure reduction.  First, KD has been shown to increase the number of mitochondria 
in the cell potentially resulting in increased energy available in the brain.38  Glucose 
restriction from a KD may also activate ATP-sensitive potassium channels (KATP) leading 
to hyperpolarization of neurons as intracellular ATP concentrations fall thereby 
increasing the threshold for seizure development.39 
It has been proposed that the change from glycolysis to ketosis may also result in 
a shift in biochemical pathways affecting amino acid metabolism that favor the 
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production of GABA.  Anticonvulsant activity of the ketone bodies, acetone, acetoacetic 
acid, and β-hydroxybutyric that accumulate to millimolar concentrations in the blood 
during a KD, may mediate seizure suppression directly or indirectly.  Increased levels of 
norepinephrine (NE) are also observed during a KD and are correlated with 
anticonvulsant activity.  Norepinephrine agonists generally tend to have anticonvulsant 
activity and NE reuptake inhibitors decrease seizure susceptibility in epileptic prone 
rats.40,41   
 
Figure 1.1 The three ketone bodies generated during ketosis. 
 
1.1.3 Current drugs and candidates for epilepsy treatment 
Currently there are approximately 20 approved medications in the United States 
for the treatment of epilepsy, of which 15 are distinct chemical entities.42  
Carbamazepine, its 10-keto analog oxcarbazepine, and the prodrug for the active 
metabolite of oxcarbeazepine, eslicarbazepine acetate, all belong to a class of compounds 
that bind site II of voltage-gated sodium channels and inhibit their activity (Figure 1.2).43  
While all 3 compounds share a similar mode of action, differences resulting from 
metabolism result in increasingly superior therapeutic profiles for the second generation 
(oxcarbazepine) and third generation (eslicarbazepine acetate) agents. 
Carbamazepine is metabolized in the liver to carbamazepine-10,11-epoxide which 
also exerts anticonvulsant activity but is associated with cytochrome P450 induction that 
results in various side effects and drug interactions.  Oxacarbazepine bypasses epoxide 
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formation to the active metabolite 10,11-dihydro-10-hydroxycarbamazepine and shows 
decreased induction of cytochrome P450 enzymes.44  Eslicarbazepine acetate, currently 
approved only in Europe, is a prodrug of  (S)-licarbazepine, also know as 10,11-dihydro-
10-dihydroxycarbamazepine, the major metabolite of oxacarbazepine.  Metabolism of 
eslicarbazepine acetate generates a 95:5 R to S ratio in vivo that results in a 16% greater 
bioavailability compared to an equivalent dose of oxacarbazepine.45 
 
Figure 1.2 Structures of carbamazepine, oxcarbazepine and eslicarbazepine 
 
Phenytoin inhibits activity of voltage-gated sodium channels 
through binding to the fast-inactivation state following 
depolarization.46  The clinical use of phenytoin is complicated by a 
variety of drug interactions and wide variability rates of metabolism 
in vivo.47  Despite these consequences, it is predicted that phenytoin 
is the most commonly prescribed anticonvulsant in the U.S.48 
Topiramate is a sulfated fructose-derived monosaccharide 
originally developed as an antidiabetic drug.  Multiple cellular 
activities are thought to be responsible for its anticonvulsant activity.  
In addition to inhibiting sodium currents through an interaction with 
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voltage-gated sodium channels, topiramate is a selective inhibitor for activity of the 
GluR5 kainate receptor, promotes GABA release, and enhances GABA induced Cl- 
influx.49-53  Topiramate likely acts indirectly on presyntapic GluR5 kainate receptors, 
evident through its slow-inactivation of the receptor.  It is postulated that the drug binds 
the receptor in the unphosphorylated state acting as a negative allosteric regulator.54 
Phenobarbital and the prodrug primidone have been used clinically for the 
treatment of epilepsy since 1912 and 1950, respectively.55  Primidone is metabolized to 
phenobarbital and phenylethylmalonamide in vivo, but it remains unclear whether 
phenylethylmalonamide exerts activity independent of the major metabolite 
phenobarbital (Figure 1.3).  The anticonvulsant property of phenobarbital is attributed to 
extending the duration of GABAA channel opening without affecting firing frequency.56-
58  This results in enhanced activation of GABAA receptors by suppressing epileptic 
transmissions and hyperpolarizing neurons. 
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Figure 1.3 Routes of metabolism for primidone.  The major route is metabolism to 
phenobarbital that exerts anticonvulsant action by affecting GABAA channel opening.  It 
is unclear whether the minor metabolite phenylethylmalonamide has activity independent 
of phenobarbital. 
 
Valproic acid was originally synthesized as an organic solvent in 1882 and was 
serendipitously discovered as an effective anticonvulsant while being used as a solvent 
for drug screening in the 1960s.7  The simple branched chain fatty acid structure has been 
shown to possess numerous biological activities that contribute to its efficacy.  Valproic 
acid has been shown to increase GABA concentrations in the brain via inhibition of 
succinic semialdehyde dehydrogenase that results in accumulation of succinic 
semialdehyde, an inhibitor of GABA transaminase.59 
Modulation of voltage-gated sodium channels by valproic acid 
resulting in inhibition of repetitive high frequency firing in neurons has 
also been observed.60  Recent reports also show valproic acid is an 
inhibitor of protein kinase C epsilon (PKC-ε), brain microsomal long-
chain fatty acyl-CoA synthetase, and histone deacetylase (HDAC).61-63  Inhibition of 
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these enzymes has ramifications in cellular signaling related to neurite outgrowth, 
arachidonic acid metabolism, and modulation of gene expression at the genomic level. 
Currently there are three approved therapies that are derivatives of the 
neurotransmitter GABA.  Although gabapentin, pregabalin, and vigabatrin were all 
rationally designed to act as GABA analogs, none of them show activity as agonists at the 
GABA receptor (Figure 1.4).  Gabapentin and pregabalin both bind the α2δ subunit of L-
type Ca2+ channels preventing proper trafficking to the plasma membrane resulting in 
decrease functional receptors at the synpase.64  Vigabatrin greatly elevates levels of 
GABA in the brain through inhibition of GABA transaminase, a GABA metabolizing 
enzyme present intracellularly in neurons and glial.65  Administration of vigabatrin (50 
mg/kg) results in elevated levels of GABA (> 1.8 mmol/kg) and a 50% decrease in 
seizure frequency.66 
 
Figure 1.4 GABA and anticonvulsant derivatives of GABA.   
 
  Clobazam and clonazepam belong to the family of benzodiazapine drugs that are 
commonly used for treatment of epilepsy and anxiety disorders.  Both compounds are 
GABAA receptor agonists that bind similarly as other benzodiazepines (Figure 1.5).  This 
results in enhanced chloride conductance of the channel by increasing the channel 
opening frequency thus hyperpolarizing the neuronal cells.67 
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Figure 1.5 The benzodiazepine derivatives clobazam and clonazepam. 
 
Ethosuximide is a succinimide drug specifically approved for the treatment of 
absence seizures.  The compound selectively blocks voltage-gated T-type calcium 
channels in the thalamus, preventing bursts of absence seizure activity.68  
Originally developed in the 1950s as a member of a family of 
anticonvulsant compounds, ethosuximide is the only remaining 
succinimide drug still used for the treatment of epilepsy and is 
considered the first-line therapy for absence seizures. 
 Approved in 2003, the sulphonamide derivative zonisamide inhibits T-type 
calcium channels, voltage-gated sodium channels, and binds to the benzodiazepine site 
on GABAA receptors.  Clinically relevant concentrations of 
zonisamide have been shown to prevent Ca2+-dependent low-
threshold spikes from calcium channels as well as stabilize the fast-
inactivated state of voltage-gated sodium channels.69-71  Furthermore, 
zonisamide has been shown to block muscimol binding to the GABAA receptor and 
modulate its function similar to benzodiazepines.72 
Lamotrigine was first developed in the 1960s as an antifolate agent to mimic the 
properties of phenytoin and phenobarbital.73  Despite these intentions, the compound 
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showed little activity with regard to folate biosynthesis but remarkable anticonvulsant 
activity.74  Research showed that lamotrigine, similar to phenytoin, 
blocks sustained repetitive firing of voltage-gated sodium channels 
by stabilizing the fast-inactivated state.75  Subsequent work has 
demonstrated a conserved motif responsible for binding to voltage-
gated sodium channels and identified conserved interacting residues among lamotrigine, 
phenytoin, and carbamazepine.46 
Tiagabine is a derivatized version of the GABA uptake inhibitor nipecotic acid 
(Figure 1.6).  Attachment of the lipophilic side chain allows for permeability across the 
blood brain barrier not afforded by the parent compound.76  As predicted, tiagabine 
elevates GABA levels through inhibition of GABA reuptake in the synaptic cleft by 
GABA transporters present on both neuronal and glial cells.77  The results of lingering 
GABA retained in the synaptic cleft allows for sustained inhibitory signaling on the 
postsynaptic cell. 
 
Figure 1.6 The structures of nipecotic acid and tiagabine. 
 
Felbamate was approved in 1993 in the United States for the treatment of partial 
seizures and Lennox-Gastuat Syndrome, a difficult form of childhood epilepsy appearing 
between the ages of 2 and 6.  A year after approval, concerns over severe hepatic toxicity 
and the development of aplastic anemia greatly limited widespread adoption of 
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felbamate.78  The drug inhibits voltage-gated sodium channels in vitro, specifically binds 
and blocks NR2B containing NMDA receptor complexes, and 
intracellularly mediates GABAA receptor activity.79-83  
Felbamate is unique in that it directly modulates both 
glutametergic and GABA signaling through two distinct 
mechanisms. 
Levetiracetam and the current drug candidate brivaracetam belong to a family of 
chemically distinct pyrrolidine compounds that show anticonvulsant activity (Figure 1.7).  
Using photoaffinity labeling of crude synaptosomes, the synaptic vesicle protein SV2A 
was identified as the target for levetiracetam.84  This glycoprotein found on the 
membranes of synaptic vesicles is implicated in the coordination of vesicle exocytosis 
and presynaptic neurotransmitter release.  SV2A knockout mice develop severe seizures 
and die postnatally, and cultured cells lacking SV2 proteins accumulate extracellular 
calcium causing abnormal increases in neurotransmitter release.85  Screening for SV2A 
ligands identified brivaracetam, a propyl derivative of levetiracetam, that shows a 10-fold 
higher affinity to SV2A than levetiracetam.86  In mouse models for epilepsy brivaracetam 
is 6-12 times more potent than levetiracetam suggesting that binding to SV2A is 
correlated with anticonvulsant activity.  Unlike levetiracetam, brivaracetam also inhibits 
sodium currents in cultured neurons.87 
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Figure 1.7 SV2A binding anticonvulsants levetiracetam and brivaracetam 
 
Rufinamide is a recently approved anticonvulsant showing broad efficacy in a 
variety of epilepsy models.88  Tentative evidence has been 
presented suggesting that rufinamide reduces sodium currents and 
limits repetitive firing of sodium channels in vitro.89  It is currently 
approved as an adjunct therapy for seizures associated with 
Lennox-Gastaut syndrome. 
Collectively, the anticonvulsants currently available for the treatment of epilepsy 
have varied modes of action.  Traditional therapies target suppression of glutametergic 
signaling or enhance GABA signaling via modulation of ion channels.  Emerging drugs 
have revealed new targets such as SV2A that could provide new approaches to seizure 
management.  New activities are also being discovered for old therapies such as the 
histone deacetylase inhibitor activity of valproic acid that may provide new avenues to 
explore novel mechanisms of actions for older drugs. 
 
1.2 Functionalized amino acids and (R)-lacosamide 
(R)-Lacosamide, commercially marketed as Vimpat® by UCB group, was approved 
by the Food and Drug Administration in 2008 as an adjunctive therapy for the treatment 
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of partial-onset seizures in adults.90  The development of (R)-lacosamide represents a 
collaboration among academia, government, and multiple pharmaceutical companies in 
both the United States and Europe.  In addition to possessing anticonvulsant activity, the 
drug’s effectiveness in models of neuropathic pain is also being evaluated.91  Despite 
receiving market approval in both the U.S. and Europe, its mechanism of action remains 
unclear. 
 
1.2.1 Rationale for the series 
(R)-Lacosamide, (R)-N-benzyl-2-acetamido-3-methoxypropionamide, is a 
member of a class of compounds showing anticonvulsant activity called functionalized 
amino acids (FAAs).  Structural requirements for the library of compounds were 
designed after careful observation of common motifs found in neurologically active 
agents such as hydantoins, piperazines, and benzodiazepines.  It was recognized that 
drugs such as phenytoin and diazepam contain 3 basic units: (1) two nitrogen atoms 
separated by two carbons, (2) an oxygen atom off the ethylene bridge between the two 
nitrogens, and (3) an aromatic ring one carbon removed from one of the nitrogens.92  The 
resulting criteria generate 3 amino acid-like scaffolds to derivatize (Figure 1.8). 
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Figure 1.8 Functionalized amino acid scaffolds and neurologic agents.  Three possible 
scaffolds can be generated with the criteria set forth for functionalized amino acids.  Both 
diazepam and pheyntoin contain the basic units of FAAs (outlined in red). 
 
 Approximately 300 FAAs have been synthesized and evaluated in the 
Anticonvulsant Screening Program by Eli Lily and the National Institute for Neurological 
Disorders and Stroke over 25 years.  Two acute seizure models have been used, the first 
being a maximal electroshock seizure (MES) model and the second a subcutaneous 
pentylenetetrazol seizure threshold (scMet) model.  In the MES test, corneal electrodes 
are used to administer high frequency electrical stimulation inducing characteristic tonic 
hind limb extension that is thought to provide a good model for primary and secondary 
generalized tonic-clonic seizures.93  The majority of the approved drugs for epilepsy 
show good protection in this model except for ethosuximide, tiagabaine, vigabatrin, and 
levetiracetam. 
 The generation of functionalized amino acids based on the first scaffold in Figure 
1.8 structural requirements for anticonvulsant activity were interrogated by using a 
variety of substitutions on the acyl, central amino acid, and terminal amine units.  
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Extension of the acyl unit and either extension or contraction of the N-benzyl group leads 
to a sharp drop in anticonvulsant activity.94 Substitutions on the central amino acid 
illustrated that the presence of a heteroatom one carbon away from the central backbone 
greatly enhances activity.92,95-98  There was no trend observed in potency whether the 
substitution was electron rich or deficient. 
The FAAs show an interesting trend when enantiomericly pure compounds are 
prepared containing substitutions off the central amino acid.  Greater potency is 
consistently observed in the amino acid derivatives possessing the D-configuration 
(corresponding to the (R)-stereoisomer) than those with the L-configuration 
(corresponding to the (S)-stereoisomer), with at least a 10-fold loss of activity when the 
chiral center is inverted.94  Small substitutions at the para and meta positions off the N-
benyzl ring can be tolerated such as electron withdrawing groups like fluorine as well as 
an isothiocyanate group.96,99 
 
1.2.2 (R)-Lacosamide 
The realization that substitution of heteroatoms one atom away from the C(2) 
position enhanced anticonvulsant activity led to the synthesis of 12 derivatives of N-
benzyl-2-acetamidopropionamide with 6 different heteroaromatic substitutients.98  One 
compound, (N-benzyl-2-acetamido-3-methoxypropionamide), showed remarkable 
activity in mice i.p. and rat p.o. MES models with ED50s of 4.5 mg/kg and 3.9 mg/kg, 
respectively (Figure 1.9).  Consistent with other FAAs, the corresponding (S) enantiomer 
was substantially less active with ED50 100-300 mg/kg and >30 mg/kg.  These activities 
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were superior to phenytoin (mice i.p. ED50 ~6.5 mg/kg) and the eudismic ratio between R 
and S was greater than 22-fold.   
 
Figure 1.9 Structure and antiseizure activity of (R)-lacosamide 
 
 (R)-Lacosamide has been extensively evaluated in a variety of rodent models for 
epilepsy.100  Initial screening in the MES test showed lacosamide effectively prevented 
seizures with ED50s of 4.5 mg/kg and 3.9 mg/kg for mice i.p. and rat p.o. respectively.  It 
was shown to be ineffective in protecting against seizures induced by the GABA 
antagonists pentylenetetrazol, bicuculline, and picrotoxin.  In the 6 Hz psychomotor 
seizure test, (R)-lacosamide showed good activity with an ED50 of 10 mg/kg, exceeding 
the potency of new antiepileptic drugs such as levetiracetam.  Activity in 6 Hz 
psychomotor seizure tests is often correlated with effectiveness in treating 
pharmacoresistant epilepsy. 
Evaluation of (R)-lacosamide in the rat kindling model for complex partial 
seizures demonstrated excellent protection (ED50 13.5 mg/kg).  Cobalt induced status 
epilepticus showed that lacosamide exhibited moderate protection of seizure induction 
(ED50 45.5 mg/kg) but activity was greatly potentiated by the addition of 0.75 mg/kg 
diazepam which lowers lacosamide’s ED50 by 90% to 3.85 mg/kg. 
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Collectively, the results of the animal models illustrate that (R)-lacosamide has 
broad-spectrum anticonvulsant action that is markedly different from current therapies.  
Lacosamide’s excellent activity both in the MES and 6 Hz seizure models is unqiue 
compared to most traditional anticonvulsants, and the potent synergy between lacosamide 
and diazepam in the cobalt induced status epilepticus model warrants further 
investigation. 
 
1.2.3 Clinical progression and market approval 
Phase I clinical trials of (R)-lacosamide were carried out by Harris FRC and 
subsequently picked up for phase II by Schwarz Pharma.101  A total of 7 clinical trials 
were carried out by Schwarz Pharma and UCB group, evaluating (R)-lacosamide as an 
adjunct therapy for the treatment of partial-onset seizures.102  Quantities of 200, 400, 600 
mg per day were initially evaluated, but doses above 400 mg/day were discontinued due 
to slight risk of fainting. 
 
 
Figure 1.10 Major metabolism of (R)-lacosamide in humans. 
 
The drug’s half-life in humans is estimated at 11-16 hours. The major metabolite 
(SPM12809) observed in vivo results from the conversion of the methoxy group to a 
hydroxyl group that is excreted in the urine (Figure 1.10).102  No significant conversion 
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between R or S is observed in vivo.  The median reduction in seizure frequency relative 
from lacosamide was between 23-35% for 200 mg/day, 35-40% for 400 mg/day, and 35-
40% for 600 mg/day with placebo groups between 8-20%.  Patients enrolled were 
previously uncontrolled on 1-3 concomitant anticonvulsants and almost half had tried 7 
or more currently marketed drugs. 
The most common side effects of (R)-lacosamide include dizziness, headache, and 
nausea.  There is an association with increased cardiac risk potentially associated with a 
prolonged PR interval (the time corresponding to the onset of atrial depolarization but 
preceding ventricular depolarization) and chest pain with several patient populations 
although no predicting factors such as age, race, or gender could be identified.  As a 
result, the 600 mg/day dose was withdrawn from the new drug application.  Lacosamide 
was approved in 2008 by the EMEA and FDA as an adjunct therapy for the treatment of 
partial-onset seizures in patients over 17.  The drug is marketed as Vimpat® in both the 
United States and Europe.  Currently there are several clinical trials completed that 
evaluated lacosamide as a treatment for fibromyalgia and diabetic neuropathy showing 
mixed results. 
 
1.2.4 Potential mechanism of action 
Despite gaining approval in both the U.S. and Europe for partial-onset seizures, a 
clear understanding of the mechanism of action responsible for (R)-lacosamide’s efficacy 
has not been developed.  To date, lacosamide has been implicated to interact with slow-
inactivated voltage-gated sodium channels, dihydropyrimidinase-like protein 2 
(DPYSL2) (also known as CRMP-2), and various isoforms of human carbonic 
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anhydrase.103-106  Errington and coworkers initially showed (R)-lacosamide enhanced 
entry of sodium channels into the slow-inactivated state after sustained depolarization (10 
or 30 s) in N1E-115 neuroblastoma cells.105  Additionally, (R)-lacosamide induced 
hyperpolarization of slow-inactivation voltage curves but did not affect recovery of 
sodium channels out of the inactive state.  No effect was seen when the (S)-enantiomer 
was used. 
Sheets and coworkers used HEK293 cells expressing individual sodium channels or 
cultured dorsal root ganglion cells (DRGs) from adult male Sprague-Dawley rats to 
investigate the effect of (R)-lacosamide on the slow inactivation of individual receptor 
populations.104  The effects of (R)-lacosamide, lidocaine, and carbamazepine on slow-
inactivated sodium channels was investigated for Nav1.3-, Nav1.7-, and Nav1.8-type 
channels.  IC50 values for inhibition of slow-inactivated Nav1.3-type channels for (R)-
lacosamide, lidocaine, and carbamazepine were 415 µM, 284 µM, and 900 µM, 
respectively.  Inhibition of slow-inactivated Nav1.7 currents was calculated to be 182 µM, 
44 µM, and 406 µM for (R)-lacosamide, lidocaine, and carbamazepine.  (R)-Lacosamide 
also exhibited a similar ability to inhibit inactivated Nav1.8 type channels in DRG cells.  
The inhibition values of (R)-lacosamide for the resting state of the sodium channels were 
100-257 larger compared to the inactivated channel state. 
The results show that (R)-lacosamide can selectively discriminate between slow-
inactivated versus fast-inactivated sodium channels to a greater extent than lidocaine and 
carbamazepine.  This finding has implications in selectively blocking neurons that are 
chronically depolarized in neurological disorders such as epilepsy and neuropathic pain. 
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Recently a systematic screening of newer anticonvulsants against inhibition of 
carbonic anhydrase in vitro revealed (R)-lacosamide shows potent to moderate activity 
against a variety of human isoforms.106  Inhibition constants ranged from 331 nM (CAII) 
to 4.56 µM (CAXII).  X-ray crystallography identified that (R)-lacosamide binds to the 
coumarin binding region on the CAII enzyme, a region distal to the site occupied by 
traditional anticonvulsants such as sulfonamides and sulfamates. 
It has also been implicated that (R)-lacosamide interacts with DPYSL2, a protein 
involved in growth cone guidance and neuronal outgrowth.103  No evidence for direct 
binding has been reported, but recently we reported that endogenous and recombinant 
DPYSL2 can be labeled in vitro by affinity bait containing derivatives of (R)-
lacosamide.107  DPYSL2 and its potential role in epilepsy and the interaction with (R)-
lacosamide are discussed in detail in chapter 4. 
 
1.3 Concluding remarks 
The discovery, development, and approval of (R)-lacosamide are the result of 
collaboration among academia, government, and industry.  The anticonvulsant profile of 
(R)-lacosamide shows the compound has broad-spectrum anticonvulsant activity with a 
potentially complex network of interactions that contribute to its efficacy.  Investigating 
the full spectrum of proteins that interact with (R)-lacosamide is crucial to understand 
how its effects are exerted in models for both epilepsy and potentially neuropathic pain, 
as well as the development of the next generation anticonvulsant derivatives.   
 
CHAPTER 2 
 
PROFILING SMALL MOLECULE PROTEIN INTERACTIONS AND DRUG 
TARGET DISCOVERY: CONVENTIONAL AND EMERGING STRATEGIES 
 
 
2.1 Introduction 
Chapter 1 discussed the pharmacological complexity of currently approved 
anticonvulsants in the context of their numerous interacting proteins and subsequent 
effects on the central nervous system.  New applications for simple molecules such as 
valproic acid that have been approved for decades continue to emerge in the literature.63  
Such diverse pharmacology highlights the challenges of elucidating a clear mode of 
action when target proteins are unknown. 
In the case of (R)-lacosamide, discovery in an animal model circumvented insight 
into molecular actions with specific proteins in the brain.  This lack of drug-target 
information can be common in pharmaceutical development, especially with neurological 
agents.  Because many neurological disorders are multifactorial, the benchmark for 
efficacy is often beneficial outcomes, rather than targeted protein interactions.  A variety 
of approaches have been developed that seek to identify proteins that interact with small 
molecules in a meaningful way and contribute to their efficacy. 
 
  27 
2.2 Direct identification 
The most commonly used approach in small molecule-target identification involves 
biochemical purification of interacting proteins from complex cell lysates or tissues 
coupled with some form of mass spectrometry.  Efficient capture usually requires 
structural modification of the target compound for immobilization on a solid surface or 
enhancement of binding affinity through the introduction of reactive groups.  Both 
approaches have been used as a means to identify drug targets. 
 
2.2.1 Immobilized affinity chromatography 
Isolation and enrichment of target proteins using immobilized ligands dominate 
efforts in drug-target identification.  Using this approach, drug derivatives are 
synthesized to introduce linkers at a site that allows for chemical modification without 
disrupting biological activity.  Such linkers can facilitate the coupling of the drug 
derivatives via assorted chemistry to various types of resins.  Conjugation of the drug 
linker to the resin allows for display of the ligand on the solid surface that can then bind 
to target proteins within complex protein mixtures.  Numerous examples illustrate the 
utility of this approach. 
  Using this methodology, target proteins for the diarylquinoline R207910 
(TMC207), a candidate for the treatment of tuberculosis, were recently identified.108  
Immobilization of an amine functionalized R207910 analog on sepharose resin captured 
the α and β subunits of ATP synthase from M. smegmatis membrane lysate.  
Interestingly, analysis of binding using BIAcore of the recombinant α and β subunits to 
immobilized R207910 showed no direct interaction.  Only subunit γ showed binding to 
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the diarylquinoline with Kd value of 500 nM.  The authors suggest that the hydrophobic 
nature of the γ subunit prevented 2D electrophoresis prior to mass spectrometry, thereby 
inhibiting peptide identification. 
 The EGFR tyrosine kinase inhibitor gefitinib (Iressa) is approved for the 
treatment of non-small cell lung cancer and as a third line chemotherapuetic.  Originally 
developed specifically to target EGFR tyrosine kinase, affinity chromatography of 
sepharose-conjugated gefitinib identified 25 additional kinases with low micro to 
nanomolar IC50 values for the compound.109  The proteomic screen did not identify 
related receptor tyrosine kinases, which is consistent with the in vitro selectivity of 
gefitinib.   
 Numerous other protein targets have been identified for small molecules and drug 
candidates using affinity chromatography.  Schreiber and coworkers identified the protein 
target of the macrolide immunosuppressant FK506 (Tacrolimus) as cis-trans peptidyl-
proplyl isomerase and the antiproliferative cyclotetrapeptide trapoxin as histone 
deactylase 1 (HDAC-1) using a similar approach.110,111 
 
2.2.2 Photocrosslinking 
A second method for direct identification of protein targets uses photoreactive 
groups that upon light activation form covalent adducts with adjacent residues on the 
target proteins.  A variety of photoreactive groups can be incorporated in the biologically 
active compound.  Aryl azides, benzophenones, and diazirines are frequently used as 
photoaffinity probes for crosslinking small molecules and proteins (Figure 2.1).112  Aryl 
azides can be activated under mild conditions (>300 nm) but maximum absorption is 
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characterized at 280 nm, which is generally considered undesirable due to protein 
degradation. 
The major route after excitation results in ring expansion, then subsequent attack by 
a local nucleophile.113  Benzophenones are activated at ~350 nm generating a reactive 
diradical which can form C-C bonds with unreactive C-H bonds on target proteins. 
Diazirines, specifically 3-(trifluoromethyl)diazirines, have been adopted as useful 
photoaffinity reagents for the selective labeling of proteins.114  Activation at 360 nm 
results in the formation of highly reactive but short-lived carbenes that form covalent 
adducts with adjacent residues. 
 
Figure 2.1 Common photoaffinity probes for drug-protein labeling (adapted from ref. 113) 
 
 Photoaffinity labeling (PAL) with various probes has been used extensively to 
identify target proteins, discover binding sites, and understand binding kinetics for drug-
receptor complexes.115  Fuks and coworkers identified the synaptic vesicle protein 2 
(SV2A) as the binding site for the levetiracetam in rat brain membranes using a 
radiolabeled analog containing an aromatic azide.116,117  Validation showed levetiracetam 
  30 
and the photoaffinity probe exclusively bound to SV2A with no appreciable binding to 
SV2B or SV2C.  All other anticonvulsants tested showed no binding to SV2A. 
Similarly, using a leucine analog containing a diazirine moiety incorporated into 
the antifungal cyclodespeptide HUN-7293, the integral ER membrane protein Sec61α 
was identified as a potential target.118  The Sec61 complex is a transmembrane channel 
responsible for regulating the translocation of newly synthesized proteins into the ER 
membrane.  HUN-7293 was previously reported to block translocation of vascular cell 
adhesion molecule (VCAM) expression and the identification of Sec61α provided a clear 
mechanism for its cellular activity.  The utility and specificity achievable with 
photoaffinity probes provide an alternative to direct affinity chromatography where 
binding may be conditional or weak. 
 
2.2.3 Electrophillic labeling 
In addition to light-activated probes as affinity labeling of target proteins, 
electrophilic probes targeting nucleophiles have been adopted for labeling strategies.  
This approach has traditionally been applied in two ways.  The first major application 
seeks to identify specific amino acid residues involved in binding between small 
molecules and target proteins.  The second application of electrophilic probes screens the 
proteome for small-molecule protein interactions based on selectivity toward various 
catalytically reactive nucleophiles. 
Traditionally, derivitized ligands for G-protein coupled receptors and ion channels 
have incorporated electrophilic moieties such as isothiocyanates and aldehydes to 
increase binding affinity.  Ligands for the opioid (µ, δ, and κ), NMDA, GABAA, 
  31 
cannabinoid, α-adrenergic, dopamine receptors and GABA chloride channels have been 
proven to be effective in forming covalent modifications with target proteins in the brain 
fractions in vitro and in vivo.119-129  For adduction to occur between the protein and 
chemical probe, an adjacent nucleophile such as lysine or cysteine must be present in 
order to form the covalent interaction.  The extent of labeling can be titrated by various 
controllable factors such as pH, temperature, and reaction time that control both reactivity 
and selectivity. 
The second application of electrophilic probes profiles protein reactivity.  This 
approach, often termed activity-based proteomics, targets specific enzyme super families 
sharing catalytic activity using various structural scaffolds paired with nucleophilic 
reactive units.130  Chemical probes targeting serine proteases, serine hydrolases, cysteine 
proteases, phosphatases, carbon electrophiles, and kinases have been used to identify 
numerous proteins via mass spectrometry.131-135 
The results provide insight into metabolic activation of proteins previously not 
known to be involved in disease states such as cancer.  Probing using a sulfonate ester 
library identified γ–glutathione-S-transferase to be highly activated in breast cancer 
cells.136  Activity profiling for inhibitors of cysteine proteases in Plasmodium falciparum 
identified a specific inhibitor falcipain-1, a protease active during the invasive stage of 
the malaria-causing parasite.137  The functional profiling against protease activity coupled 
with the chemical screen provided a new drug target for the treatment of malaria and a 
lead structure for the design of new therapeutics. 
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2.2.4 Limitations of affinity chromatography and affinity labeling 
Despite their effectiveness in identifying targets for approved drugs and drug-
candidates there are several drawbacks to direct identification with affinity 
chromatography and photoaffinity labeling.  The introduction of bulky tags required for 
immobilization may diminish or abolish drug binding to its cognate proteins.  The use of 
a biologically inactive compound may therefore prohibit the proper identification of 
target proteins.  Additionally, the drug scaffold may not be amenable to easy introduction 
of linkers regions for immobilization.  Lack of SAR information regarding critical 
regions on the chemical structure necessary for biological activity further complicates the 
process.  The successful creation of an immobilized small molecule requires both the 
availability of a synthetic route and the retention of biological activity (binding) despite 
structural modification. 
Another drawback to affinity chromatography is the potential for proteins to 
interact non-specifically with the solid surface used to display the small molecule.  This 
can greatly decrease the chance of proper identification if the target protein is in low 
abundance.  Non-specifically bound proteins on the resin often overwhelm mass 
spectrometry signals thereby masking rare peptide sequences.  Using ampicillin as a 
model system for affinity chromatography, Rechenberg and coworkers evaluated the 
ability of various resins to capture ampicillin-binding proteins from E. coli.138   Agarose, 
acrylamide, and magnetic beads were amine coupled with ampicillin followed by 
incubation with E. coli lysate.  After extensive washing, enriched proteins were identified 
with mass spectrometry via on bead digestion followed by LC-MS/MS.  Although all 
resins correctly identified a variety β-lactamase isoforms, their relative ratios between 
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resins were not equal.  The acrylamide resin showed very high enrichment of non-
specifically bound ribosomal proteins that were much lower in the magnetic and agarose 
bead samples.  This study highlights the potential for biased identification of proteins 
based on the type of solid surface used for immobilization. 
Photoaffinity labeling for protein target identification possesses similar limitations.  
Incorporation of the photolabile moiety may decrease affinity between the small 
molecule and protein target(s).  If an aromatic group is present on the small molecule 
then it may be possible to introduce an azide of diazirine without substantial loss of 
binding.  If no aromatic ring is present, however, incorporation of the large 
benzophenone, aromatic azide, or aromatic diazirine units into the scaffold could 
significantly alter the activity.  Efficient labeling of target proteins versus non-specific 
proteins must be carefully titrated based on intensity of the light used for activation, 
reaction time and temperature, and the amount of target protein present.  Finally, the 
presence of appropriate nucleophiles inside the binding pocket of the target protein may 
be required with some photo probes for successful adduction. 
 
2.3 Indirect identification 
The second strategy for drug-target identification uses indirect methods to 
deconvolute biochemical pathways altered by drug treatment.  Changes at the RNA, 
protein, and metabolite level can be monitored in the presence or absence of drugs to 
identify specific pathways or genes that respond to drug treatment.  More recently, 
phenotypic assays using model organisms has allowed for rapid screening of the 
responsiveness of known genotypic knockouts following drug treatment.  All methods 
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generate large volumes of data making analysis labor-intensive, yet can provide 
meaningful insight into a drug’s mode of action. 
 
2.3.1 Gene expression profiling 
One frequent approach to validate drug targets is to monitor changes in gene 
expression profiles using microarray analysis.  Whole genome chips for both human and 
yeast provide a means to observe global changes in gene expression as a result of drug 
treatment.  Comparison with untreated samples can reveal which signaling pathways the 
target compound alters.  This approach was used to discriminate between the modes of 
action of the immunosuppressant drugs cyclosporin and FK506.139  RNA from wild-type 
yeast strains treated with FK506 and cyclosporin exhibited a specific gene expression 
profile relative to untreated samples.  It was found that thirty-six genes changed 
expression at least 2 fold upon drug treatment. 
Both compounds have been shown to inhibit the calcineurin-signaling pathway, 
and mutant analysis of a calcineurin deletion strain showed strong correlation with the 
genotypic profiles of FK506 and cyclosporin.  Because pharmacological inhibition of the 
calcineurin signaling might occur at multiple steps, individual protein targets in the 
pathway were analyzed in the presence or absence of compounds.  Deletion stains of the 
most abundant immunophilins in yeast (CPH1 and FPR1) upstream of calcineurin were 
profiled to discriminate individual target proteins.  In the FPR1 deletion mutant, FK506 
was not able to generate a gene expression profile similar to that in the wild type or the 
calcineurin deletion, suggesting that FPR1 is the target for FK506.  Conversely, when the 
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CPH1 deletion mutant was used, cyclosporin did not produce the signature expression 
profile. 
Taken together, this illustrates that FK506 targets FPR1, while cyclosporin targets 
CPH1.  In addition to identifying the proteins responsible for calcineurin inhibition, 
several other genes showed induction by treatment with FK506.  These proteins, 
implicated in drug-resistance, illustrate that gene expression profiling for drug-target 
discovery can provide insight into both primary and off-target effects. 
Gene expression profiling has also been used for generating models to predict 
drug action.  Gunther and coworkers generated microarray profiles from primary human 
neuronal precursor cells treated with 36 neurological agents including antidepressants, 
antipsychotics, and opiates.119  Using the compendium of drug-efficacy profiles, 
computational models were built with the objective of predicting the class of drug 
(antidepressant, antipsychotics, or opiate) to which an “unknown” drug may belong.  
Each class of drug contained chemically and functionally diverse compounds.  The 
models were able to assign the correct drug class with more than 80% accuracy based 
upon the expression profile of unknown samples.  Even though the biochemical class 
could be determined, specific proteins could not be definitively assigned.  Comparisons 
with subclasses of chemically or mechanistically similar compounds could further detail 
the mechanism of action. 
 
2.3.2 RNAi 
RNA interference (RNAi) has been adopted as another powerful tool in drug 
discovery that allows for silencing gene expression of specific genes and observation of 
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knock-down phenotypes at both the cellular and organism levels.140  This phenomenon 
involves the delivery of 21-23 long double stranded RNA sequences to cells that are 
complementary to target messenger RNA.  Degradation of the mRNA is induced by 
activation of the RNA induced silencing complex (RISC) whose endonuclease activity 
cleaves the target mRNA strand, ideally resulting in a decrease of protein expression.  
This method has been used generally to validate known drug targets by evaluating the 
drug efficacy in the knock-down phenotype.  Recent efforts have attempted to couple 
RNAi platforms with chemical screens to identify new drug targets.  This approach does 
not provide a means, however, to deorphanize drugs with unknown binding partners.    
 
2.3.3 Metabolomics 
Recently, advances in mass spectrometry have enabled the development of 
platforms that simultaneously detect and quantify hundreds of metabolites as a means to 
understand changes in cellular biochemistry.  This technology has been applied to drug-
target discovery and is proving to be a useful new tool in drug development.  Using this 
approach, Watson and coworkers identified the protein target of the GMX1777, a prodrug 
in Phase I clinical trials for the treatment of cancer.141  A total of 88 metabolites were 
measured in IM-9 cells after 6 h treatment with 30 nM GMX1777.  Comparative 
biochemical profiles between treated and untreated cells revealed that NAD levels 
dropped 1.5 fold after drug treatment.  To understand which branch of the NAD 
biosynthetic pathway was specifically targeted, [14C] labeled substrates of nicotinamide 
(NM) and nicotinic acid (NA), enzymes feeding into NAD biosynthesis, were used to 
measure the generation of [14C]NAD.  Analysis revealed that phosphoribosyltransferase 
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(NAMPT), the enzyme upstream of the NM branch of the NAD pathway, is specifically 
targeted by the drug. 
 
2.4 Limitations of indirect target identification approaches 
Despite success using indirect methods for drug target identification, these 
approaches have several drawbacks.  First, most indirect methods generate large amounts 
of data that require extensive analysis.  Gene expression profiling and metabolomics can 
be computationally intensive, and identification of candidate targets requires careful 
experimental design with proper controls.  Phenotypic based methods such as RNAi 
generally are not amenable to drug target identification unless comprehensive screening 
with a large pool of potential targets is performed.  For all approaches, the results need to 
be validated using a more direct method to confirm relevance of the putative target(s). 
 
2.5 Concluding remarks 
Several methods have been described for identifying unknown drug targets.  Direct 
methods aim at physically enriching relevant proteins from complex mixtures through the 
use of reactive groups and immobilized ligands.  Indirect methods look for changes in 
biochemistry measured by gene expression profiling, cellular metabolites, or phenotypic 
screens to identity signaling pathways affected by the drug.  These approaches have a 
variety of drawbacks and biases, including non-specific interactions with solid surfaces, 
proper display of immobilized ligands, and intensive data analysis.  Novel methods are 
therefore needed that minimize these drawbacks while utilizing their advantages. 
CHAPTER 3 
 
CHEMICAL BIOLOGY APPROACHES FOR (R)-LACOSAMIDE DRUG 
TARGET DISCOVERY 
 
3.1 Introduction 
Sixty percent of the currently marketed anticonvulsants have a complex or unclear 
mechanism of action.  This fact highlights the need for new approaches in drug target 
discovery, particularly for neurological agents.  Conventional technologies for direct 
identification of protein targets can be biased for stable or abundant proteins and do not 
account for protein complexes present in vivo.  Indirect methods such as microarray 
analysis tend to generate more questions regarding modes of action from the sheer 
volume of data generated rather than providing biochemical insight.  Therefore, 
improvement in approaches for drug target discovery are needed that allow for selective 
and specific investigation of protein-drug interactions. 
Immobilization of small molecules on a solid surface for affinity purification of 
targets can potentially limit the ability of target proteins to correctly recognize the small 
molecule as well as introduce surfaces for non-specific interactions.  Liberation of the 
molecule from the solid surface allows greater conformational flexibility for both the 
small molecule and protein that can greatly enhance the affinity between the two 
interacting partners.  The ligand also potentially has access to binding pockets in intact 
protein complexes that may not be accessible when immobilized on a solid surface.  
Recent advances in chemical biology have permitted the capture and detection of protein-
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ligand complexes using the Cu(I)-catalyzed Huisgen 1,3 cycloaddition between an azide 
and alkyne to form a triazole as a tool for drug discovery (Figure 3.1).142,143  This 
reaction, also known as “click chemistry,” is a superior tool for drug-target discovery 
because of the chemoselectivity between the azide and alkyne, mild reaction conditions 
in water and ambient temperature, and the small functional groups involved.144  The azide 
and alkyne functional units have been installed on intracellular constituents such as 
proteins, lipids, and glycans for in vivo capture and detection of a variety of 
biomolecules.145-148  These bioorthogonal ligations have also been exploited to target and 
detect various protein classes in a proteome.  Alkynes have been incorporated into 
chemical probes for histone deaceytlases, serine hydrolases, and other proteases to map 
enzyme activity based on their substrate specificity.131-133  In addition to this activity-
based proteomics, affinity-based proteomics seeks to profile binding partners for small 
molecules in complex protein mixtures.  Probes for the cancer biomarker galectin-3 and 
an irreversible inhibitor of RSK1/RSK2 have been evaluated using this chemoselective 
ligation method.146,149  
 
Figure 3.1 The click chemistry reaction. Cu(I) promotes the formation of a triazole ring 
under mild aqueous conditions. 
 
The mutually exclusive reactivity between the azide and alkyne circumvents the 
need to immobilize the small molecule drug/candidate, thereby allowing specific capture 
of the drug-protein complex after binding has occurred unhindered in solution.  Using 
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this approach we applied the click chemistry reaction to identify potential protein targets 
of (R)-lacosamide. 
 
3.2 Results and Discussion 
3.2.1 Rationale and design strategy 
Like other anticonvulsants, (R)-lacosamide’s efficacy may result from multiple 
specific protein interactions that affect multiple pathways involved in epilepsy and 
neuropathic pain.  Previous efforts failed to observe any appreciable binding after 
screening a variety of cloned receptors, suggesting that (R)-lacosamide may exhibit weak 
or modest binding to its endogenous protein target(s).150  Based on the simple structure of 
(R)-lacosamide, we suspect that the potential for identifying strong affinity interactions 
may be low.  Therefore a method to stabilize the interaction between (R)-lacosamide and 
its protein targets is needed to enhance the chance of target identification. 
To address this need, we designed a series of drug analogs that allow for a two-
step process of labeling and capture of (R)-lacosamide binding proteins (Figure 3.2).  
Labeling of proteins is enhanced by the addition of a moderately reactive group, termed 
affinity bait (AB), allowing for the formation of irreversible covalent drug-protein 
adducts under selective controllable conditions.  This affinity bait assists in labeling 
under conditions where binding is modest or protein abundance is low.  Post-labeling, the 
drug-protein adducts are detected by utilizing the paired azide and alkyne functional 
units, termed chemical reporters (CR), installed on the drug analogs and probes used for 
detection or purification. 
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Figure 3.2 Chemical structures of (R)-lacosamide analogs and probes for detection and 
purification of target proteins.  Two derivatives of lacosamide were synthesized 
containing reactive affinity bait groups to form covalent adducts with target proteins and 
chemical reporter groups to detect and purify the drug-protein adducts using click 
chemistry.  Compound 3 contains a reactive isothiocyanate and a biotin group that can be 
used directly to label and purify proteins from mouse brain lysate.  Two probes were 
synthesized, one containing a fluorescent TAMRA group and the other a biotin group, to 
detect and purify the labeled proteins. 
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 Compound 1 contains an isothiocyanate at the 4’-benzylamide that is expected to 
react with lysines or cysteines to form thioureas and dithiocarbamates, respectively.  
Compound 2 contains an aromatic azide at the 4’-benzylamide that upon exposure to UV 
light (312 nm) undergoes either ring expansion followed by nucleophilic attack or C-H 
insertion with target proteins.  Placement of the AB and CR groups within the lacosamide 
scaffold was selected based on previous pharmacologic data for other lacosamide 
derivatives that had been extensively examined in the Kohn laboratory.151-154  
Perturbation of the (R)-lacosamide scaffold at the meta-position for the N-benzyl amide 
and the N-acetamido group results in modest loss of pharmacological activity.153  To 
minimize loss of activity from addition of the chemical moieties, the AB group was 
installed at the para position of the N-benzyl amide ring and the CR group at the (C)2 
side chain, both of which can tolerate modification while retaining modest activity in vivo 
as shown previously. 
 
3.2.2 Affinity bait (AB) reactivity 
The electrophilic isothiocyanate affinity bait in compound 1 provides a pH- and 
temperature-dependent probe for potential nucleophiles present inside the protein binding 
pocket (Figure 3.3).  Presumably the moderately basic ε-amine present on lysine residues 
is protonated at a neutral pH making it partially reactive towards electrophilic adduction.  
At pH 8.0 and above, the deprotonation of the terminal ammonium group greatly 
increases reactivity leading to increased adduction.  Raising the pH or temperature and 
increasing the labeling time allows for control over the extent of modification. Lowering 
the pH below 8.0 results in protonation of the terminal amines present on lysines, 
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reducing their reactivity toward the isothiocyanate affinity bait.  Improving reactivity by 
raising the pH, however, does make the affinity bait more susceptible to inactivation 
through hydolysis in the presence of water. 
 
Figure 3.3 Reactivity of an (R)-lacosamide analog containing an AB (isothiocyanate) 
group with lysine residues in the drug-binding pocket on target proteins.  Incubation of 
the affinity bait containing drug analog is expected to react with nucleophilic lysine 
residues to form a stable thiourea creating the drug-protein adduct. 
 
 To capture those protein targets lacking nucleophiles in the binding pocket, we 
designed an aromatic azide photoaffinity bait (compound 2).  Activation of the affinity 
bait by excitation with UV light (312 nm) can generate adducts through three 
mechanisms (Figure 3.4). 
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Figure 3.4 The three routes of adduction by activation of compound 2 with UV light.  
Activation by UV light generates a reactive nitrene that favorably undergoes ring 
expansion followed by nuceophilic attack from adjacent residues. 
 
 Activation of the aromatic azide can occur under relatively mild conditions (> 300 
nm) but absorption is characterized by λmax < 280 nm.  Upon exposure to UV light, 
formation of the reactive nitrene can undergo insertion into C-H or N-H bonds.  The most 
favored pathway, however, is considered ring expansion followed by rapid reaction with 
adjacent nucleophiles on binding proteins.  The half-life for the nitrene intermediate is 
estimated between 0.1-5 msec during which the intermediate can undergo ring expansion 
or react with O2 forming less reactive species.  The reaction time can be adjusted 
according to the extent of labeling desired, however, protein degradation may result from 
long crosslinking times and an increase in temperature. 
 
3.2.3 Chemical reporter (CR) reactivity 
Selective capture of the drug-protein adducts utilizes installation of cognate 
partners for the click chemistry reaction on the drug analogs and chemical probes.  Non-
specific side reactions resulting in background labeling of proteins occur in association 
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with both the alkyne and azide functional units when added to lysate mixtures.  
Nevertheless, slightly lower background has been reported for the azide unit when it is 
installed on the chemical probe.155  The alkyne functional unit was incorporated, 
therefore, in the lacosamide scaffold and the azide into the chemical probes (probes 1 and 
2) to reduce non-specific labeling of proteins by the probe during the click chemistry 
reaction. 
The cycloaddition reaction between the alkyne containing lacosamide analog and 
azide containing reporter probes is greatly accelerated by the presence of Cu(I) in 
aqueous solution.156,157  Generation of Cu(I) under aqueous conditions requires copper 
sulfate (CuSO4), a reducing agent tris (2-carboxyethyl) phosphine (TCEP) and the Cu(I) 
stabilizing ligand tris [(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] amine (TBTA).  
Generation of the triazole product begins by the association of two Cu(I) atoms forming a 
copper acetylide species from Cu(I) and activated azide.  Simultaneous complexation of 
the intermediates with the stabilizing TBTA ligand brings the acetylide and activated 
azide together allowing for cyclization to form the triazole product (Figure 3.5).158 
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Figure 3.5 The mechanism of the click chemistry reaction.  Formation of the copper 
acetylide species allows for complexation with the stabilizing TBTA ligand (red).  This 
brings the alkyne and azide in close proximity, promoting cyclization. 
 
Two reporter probes were synthesized in the Kohn laboratory to fluorescently 
detect (probe 1) or purify (probe 2) affinity-labeled drug-protein adducts using click 
chemistry.  Probe 1 contains a tetramethylrhodamine (TAMRA) fluorophore with a C3 
azide. Drug-protein adducts reacted with probe 1 can be detected by excitation with UV 
light at 532 nm and absorption at 580 nm.  Probe 2 contains a biotin group, which after 
reacting with drug-protein adducts, allows for enrichment and purification of labeled 
proteins using immobilized streptavidin. 
 
3.2.4 Validation of the AB & CR strategy 
Prior to investigation of the lacosamide analogs containing AB and CR units in 
mouse brain lysate, suitability of the compounds to undergo click chemistry was 
evaluated using an enzyme linked immunosorbent assay (ELISA).  The affinity bait in 
compound 1 is designed to react with lysine residues on target proteins; therefore, a 
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polylysine plate was used as a solid surface to immobilize the drug.  Specifically, 
compound 1 was incubated overnight at 4 °C in the poly-lysine coated 96-well plate to 
immobilize the lacosamide AB and CR through reaction with its affinity bait.  Click 
chemistry was performed with the biotin containing probe (probe 2) for 4 h.  The plate 
was washed extensively and streptavidin-HRP conjugate was incubated to detect the 
presence of biotin.  After removing unbound streptavidin-HRP, HRP substrate was added 
and color intensity measured (Figure 3.6).  The right column shows wells where DMSO 
was substituted for compound 1 as a negative control.  The reactions were performed in 
triplicate.  Probe 2 was omitted in row four to illustrate the background signal of the 
streptavidin-HRP conjugate.  The results show that the signal is dependent on the 
presence of the alkyne and that it appears the drug scaffold does not hinder the 
cycloaddition. 
 
Figure 3.6 Evaluation of click chemistry using an ELISA assay.  Compound 1 (1 mM) 
was immobilized in lane 1 on a poly-lysine plate through its affinity bait by incubation 
overnight at 4 °C.  Click chemistry was performed for 1 hour at room temperature by the 
addition of Probe 2 (40 µM), TCEP (500 µM), TBTA (250 µM), and CuSO4 (1 mM) to 
introduce a biotin group.  Probe 2 was omitted from the click chemistry step for samples 
in the bottom row.  Streptavidin-HRP was added to detect the presence of biotin.  The 
reactions were performed in triplicate. 
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Assessment of the pharmacological activity of compounds 1 and 2 is critical to 
ensure that their usage for the labeling and identification of candidate proteins can 
provide meaningful results.  Modified compounds such as compounds 1 and 2 with poor 
activity may be indicative of abolishment of binding to endogenous protein receptors and 
are perhaps unsuitable for target identification.  Drug analogs containing single AB or CR 
units as well as the fully functionalized (AB and CR) compounds 1 and 2 were evaluated 
for anticonvulsant activity in the maximal electroshock seizure (MES) mouse model 
through a collaboration with the National Institute for Neurological Disorder and Stroke’s 
Anticonvulsant Screening Program.  This test is an acute electroshock seizure models that 
provide mechanistic independent insight for protection against tonic-clonic (MES). 
Results of the pharmacological evaluation are summarized in Table 3.1.  
Introduction of a single AB or CR unit resulted in a modest loss of activity compared to 
(R)-lacosamide.  Subsequent evaluation of bi-functionalized compounds 1 and 2 in a 
mouse (i.p.) MES test for electroconvulsant seizures showed good activity (ED50 = 45 
mg/kg, 20 mg/kg respectively).107  Consistent with lacosamide derivatives, diminished 
activity is observed with the S enantiomer (L-configuration).  Collectively, the results 
indicate that compound 1 and 2 remain biologically active in vivo in a manner consistent 
with (R)-lacosamide.  Activity is not abolished by installation of the AB and CR units 
that are designed for labeling and capture of (R)-lacosamide binding proteins during 
screening.  
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Table 3.1 Pharmacological evaluation of AB and CR lacosamide derivatives  
 
Compound Mice (ip), (mg/kg) 
Compd Stereo X Y MES, ED50 Tox, TD50 6 Hz, ED50 
1 R NCS  45 110 53 
 S NCS  > 300 > 300 ND 
(AB) R NCS CH3 24 47 ND 
(AB) S NCS CH3 > 100, < 300 > 30, < 100 ND 
(CR) R H  16 59 29 
(CR) S H  > 300 > 300 > 100 
       
2 R  N3 20 82 < 10 
 S  N3 160 >300 ND 
(AB) R CH3 N3 8.4 46 ND 
(AB) S CH3 N3 > 100, < 300 > 300 ~ 100 
(CR) R  H 16 59 < 30 
(CR) S  H > 300 > 300 > 100 
ND: not determined                    adapted from Ref 107 
 
3.2.5 TAMRA-based probe for in-gel fluorescence 
After confirmation of biological activity in vivo and aptness to undergo click 
chemistry via an ELISA assay, compounds 1 and 2 were evaluated in mouse brain lysate. 
The tetramethylrhodamine (TAMRA) containing probe (probe 1) was used to label 
adducted proteins in crude homogenates of mouse brain lysate.  The soluble fraction from 
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the crude homogenate of mouse brain lysate was used for initial in-gel fluorescence 
studies.  Mouse brains were homogenized to a final protein concentration of 4 mg/ml in 
50 mM HEPES pH 7.4 and 150 mM NaCl followed by centrifugation at 14,000 rpm for 
30 minutes.  The supernatant (soluble fraction) was removed and used for labeling 
experiments.  Small aliquots (50 µl) were labeled with compound 1 or 2 for a defined 
period of time, followed by addition of probe 1, TCEP, TBTA, and CuSO4 for click 
chemistry.  The reaction was allowed to proceed for 1 h followed by addition of SDS-
PAGE loading buffer to terminate the reaction.  Samples were resolved on a 10% SDS-
PAGE gel and scanned for fluorescence (excitation 532 nm and emission 580 nm). 
Labeling of soluble mouse brain lysate for 1 hour at room temperature with 
compound 1 showed dose dependent adduct formation that could be detected with probe 
1 (Figure 3.7).  Discrete TAMRA labeled protein bands were observed in proteins with a 
wide range of sizes (<25 and >175 kDa).  Nine major bands showed intense labeling 
compared to other protein bands within the gel.  In the absence of compound 1 or the 
chemical reporter unit (AB-R-LCM), minimal background fluorescence appeared to be 
generated by the TAMRA chemical reporter probe.  A small amount of background 
fluorescence is observed in the control lanes potentially corresponding to highly abundant 
proteins such as actin and tubulin. 
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Figure 3.7 Dose dependent labeling of soluble mouse brain lysate with compound 1.  
After labeling the lysate with compound 1, adducted proteins were detected using click 
chemistry with the TAMRA chemical probe.  Proteins were resolved on a 10% SDS-
PAGE gel and detected using in-gel fluorescence (excitation 532 nm / emission 580 nm).  
Compound 1 shows dose dependent labeling across the concentrations studied and very 
little background labeling is observed when the chemical reporter is absent from drug 
analog. 
  
 Compound 2 was designed to react with proteins lacking a nucleophile in the 
binding pocket.  Therefore, the reactivity of the photoaffinity bait was separately 
evaluated in soluble mouse brain lysate.  Controlling the extent of labeling by varying 
labeling time was first investigated with compound 2.  Activation of the aromatic azide 
by UV light allows for temporal control of the adduct formation.  Incubation of soluble 
mouse brain lysate with compound 2 (50 µM) for 30 minutes followed by activation of 
the aromatic azide by using UV at 312 nm for various times showed a positive correlation 
between activation time and the extent of labeling as detected by the TAMRA probe 
(probe 1).  Maximal labeling at 50 µM for compound 2 was achieved between 5 and 10 
minutes (Figure 3.8).  Banding patterns generated with compound 1 and compound 2, 
although similar, were not identical, indicating each affinity bait labeled distinct proteins.  
These differences illustrate that compounds 1 and 2 provide a more comprehensive 
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coverage of potential (R)-lacosamide targets by reacting with both nucleophillic and 
electrophillic residues present on potential (R)-lacosamide binding proteins in the mouse 
brain proteome. 
 
Figure 3.8 Time dependent labeling of mouse brain lysate with compound 2. After 
activation of compound 2 (50 µM) at 312 nm for various times, adducted proteins were 
detected using click chemistry with the TAMRA chemical probe (probe 1).  Proteins 
were resolved on a 10% SDS-PAGE gel and detected using in-gel fluorescence 
(excitation 532 nm / emission 580 nm). 
 
 The specificity of compound 1 and sensitivity of the TAMRA probe (probe 1) 
were evaluated using mouse brain lysate spiked with bovine serum albumin (BSA) 
functionalized to contain an alkyne chemical reporter unit (BSA-alkyne).  Labeling of 
compound 1 in mouse brain lysate was compared with samples containing 1 µg BSA-
alkyne or 3 µg enolase protein.  After click chemistry, TAMRA labeled proteins were 
resolved on an SDS-PAGE gel and individual band intensities were quantified.  Protein 
samples containing the BSA-alkyne showed very strong detection with the TAMRA 
probe (probe 1) (Figure 3.9).  If we assume the click reaction was 100% efficient, the 
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band represents 28.9 ng of BSA protein, which is equivalent to approximately 17% of the 
total 1 µg input. 
Integration of pixel intensity for the BSA band and band 1 was 4404 and 291 
respectively.  Using the integrations to compare relative protein amounts, quantification 
of the protein amount for band 1 was estimated to be 2 nanograms.  Therefore, most of 
the bands may represent picogram amounts of individual proteins in the lysate labeled by 
compound 1.  No reactivity was seen toward enolase (lane 2) despite the fact that it was 
the most abundant protein in the lysate mixture.  This suggests that the isothiocyanate 
group shows minimal non-specific reactivity toward abundant proteins under the 
conditions used and labeling most likely occurs through a specific interaction with a 
nucleophillic lysine or cysteine side chain present inside a pocket within the interacting 
protein.  The detection limit of probe 1 to discriminate individually labeled proteins was 
estimated to be in the sub-nanogram range. 
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Figure 3.9 The selectivity of compound 1 and sensitivity of probe 1 in mouse brain lysate 
assayed through in-gel fluorescence.  Soluble mouse brain lysate samples (142 µg) spiked 
with enolase protein (0.51 µg) and/or alkyne functionalized BSA protein (28.9 ng) or 
lysate alone were reacted with compound 1 for 1 hour at room temperature followed by 
click chemistry with probe 1 for 1 hour.  Samples were resolved on a 10% SDS-PAGE 
gel and scanned for fluorescence (ex.: 532 nm, em.: 580 nm).  Molecular weight makers 
are shown for BSA (69 kDa) and enolase (82 kDa). 
 
 Collectively, the in-gel fluorescence results demonstrate that the 
pharmacologically active compounds 1 and 2 can label potential target proteins present in 
the soluble fraction of the mouse brain proteome.  Both affinity baits show dose and time 
dependent labeling which can be controlled through drug concentration or labeling 
reaction time. 
 
3.2.6 Enrichment of target proteins with the biotin probe 
Previous efforts using probe 1 to detect proteins adducted with compound 1 or 2 
demonstrated that sub-nanogram quantities of adducted proteins in mouse brain lysate 
were detected via in-gel fluorescence after labeling.  The adducted proteins remained in 
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the complex mixture of mouse brain lysate and were therefore unsuitable for mass 
spectrometry.  Absolute identification of protein targets is not possible without 
purification and enrichment of adducts prior to mass spectrometry analysis.  Detection 
limits for mass spectrometry vary by application and analysis conditions but picomolar or 
potentially low femtomolar quantities are sufficient for protein identification through 
MALDI and ESI, respectively.159  Despite these sensitivities, enrichment is paramount for 
detection of (R)-lacosamide labeled proteins that may be present in low abundance in the 
mouse brain. 
The preparation of the mouse brain lysate should include as many proteins as 
possible to increase the likelihood of finding the putative targets.  Exclusion of membrane 
or nuclear fractions will reduce the complexity of the lysate mixture, potentially 
eliminating many protein targets relevant to epilepsy.  Fractionation may also disrupt 
native protein complexes present in vivo.  For instance, omission of proteins in the 
membrane fraction would eliminate targets such as GABA receptors, sodium channels, 
AMPA receptors, and calcium channels; all of which are known targets for 
anticonvulsants.  Subsequently, omission of the soluble fraction would remove targets 
such as carbonic anhydrase and GABA transaminase; also targets for the treatment of 
seizure disorder. 
Simultaneous screening of isolated protein fractions is labor intensive and likely 
disrupts protein complexes present in vivo.  A rapid, facile method that incorporates both 
membrane and soluble proteins without denaturation is ideal for our proteomic search.  
The water-soluble ionic detergent deoxycholate is often used to solubilize components of 
cellular membranes. Deoxycholate has been used to solubilize and purify native NMDA 
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receptor complexes from brain tissue, illustrating its suitability to retain native protein 
conformations.160  Unlike Triton X-100 or octylglucoside, the presence of deoxycholate 
does not inhibit tubulin polymerization in vitro indicating it is a mild non-denaturing 
detergent.161  Because the NMDA receptor and related synaptic protein complexes 
represent classes of proteins that are validated drug targets, 1% deoxycholate was used to 
partially solubilize intact membrane complexes in the preparation of mouse brain lysate.  
For the NMDA receptor, it is estimated that 35% of the total receptor complexes present 
in lysate can be solubilized using 1% deoxycholate.160   
Our initial studies evaluated the ability to enrich with the biotin probe proteins 
that were labeled with compounds 1, 2 and 3.  Lysate labeled with compounds 1 and 2 
(40 µM) were reacted with the biotin probe (probe 2), after which biotin labeled adducts 
were captured with beads coated with streptavidin or mutein streptavidin, a streptavidin 
mutant with a lower affinity for biotin.  After extensive washing, captured proteins were 
eluted with SDS-PAGE loading buffer (for streptavidin bead samples) or buffer 
supplemented with 1 mM biotin (for mutein streptavidin bead samples).  Proteins were 
resolved via SDS-PAGE, followed by transferring to a nitrocellulose membrane and 
detected with a streptavidin Alexa Fluor® 488 conjugate (Figure 3.10). 
The results in lane 6 indicate the presence of two endogenously biotinylated 
proteins above 52 kDa present in the mouse brain lysate that require removal before 
labeling experiments are performed.  Comparison of the capture and elution efficiency 
between the streptavidin and mutein streptavidin beads revealed much lower enrichment 
with the mutein beads.  Despite the theoretical advantage for milder elution conditions 
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with the mutein beads resulting from a lower Kd with biotin (1.3 x 10−7 versus 4 x 10−14), 
a lower recovery was observed compared to streptavidin beads. 
Contrasting lanes 2 and 5 revealed that the efficiency of the click chemistry step 
to introduce biotin residue (lane 2) substantially lowered the yield compared to 
compound 3.  The two-step labeling and capture afforded by compounds 1 and 2 should, 
however, provide sufficient material for mass spectrometry identification.  Banding 
patterns between the two samples appeared identical, but overall yield was higher in lane 
5 when the click chemistry step was circumvented. 
 
Figure 3.10 The enrichment of biotinylated proteins using probe 2.  Lysate incubated 
with compound 1 or compound 3 for 1 hour at room temperature were clicked with probe 
2 followed by capture with streptavidin beads.  Purified proteins were resolved on a 10% 
gel then transferred to a nitrocellulose membrane followed by detection of biotinylated 
proteins using streptavidin Alexa Fluor® 488.  Two endogenously biotinylated bands 
were strongly enriched using both mutein and streptavidin beads.  Compounds 1 and 2 
showed a lower number of proteins captured compared to compound 3 where click 
chemistry is not necessary for enrichment. 
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 Based on these findings, the protocol was modified so the lysate was precleared 
by incubating with streptavidin beads to remove any endogenously biotinylated proteins.  
Additionally, washing steps utilized regular streptavidin beads coupled with stringent 
washing (2X with 50 mM HEPES + 150 mM NaCl + 0.2 % SDS, 2X 6 M urea, 2X 50 
mM HEPES + 150 mM NaCl) to strip the non-specifically bound proteins from the 
matrix.  Activation of the affinity bait by UV light at 312 nm for compound 2 was 
extended to 20 minutes to ensure maximal labeling.  Application of such conditions for 
purification resulted in the enrichment of more bands compared to previous experiments 
(Figure 3.11).  Distinct differences in enriched proteins were observed between lysate 
labeled with 40 µM of compounds 1 and 2.  Furthermore, the two endogenous 
biotinylated proteins were effectively eliminated.  (S)-Lacosamide (2 mM) was added to 
the lysate as a way to reduce the labeling and capture of non-specific proteins.  It is 
assumed that the presence of the inactive stereoisomer of the drug will saturate off-target 
proteins that may have non-specific interactions with the lacosamide scaffold.  
Surprisingly, no differences were observed when a competing excess of (S)-lacosamide 
was added to the labeling reaction. 
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Figure 3.11 Proteins purified from mouse brain lysate using the optimized enrichment 
conditions with compounds 1 and 2.  Mouse brain lysate was incubated with 40 µM of 
compound 1 or 2 followed by click chemistry with probe 2.  S-Lacosamide (1 mM) was 
added to investigate the non-specific labeling by the isothiocyanate affinity bait.  Proteins 
adducted with the biotin probe were captured using streptavidin beads followed by 
washing 2X (1 ml) with 50 mM HEPES + 150 mM NaCl + 0.2 % SDS, 2X (1 ml) 6 M 
urea, and 2X (1 ml) 50 mM HEPES + 150 mM NaCl.  The beads were boiled for 5 
minutes in 40 µl of SDS-PAGE loading buffer.  Samples were resolved on SDS-PAGE 
gels then transferred to a nitrocellulose membrane followed by detection of biotin using 
streptavidin Alexa Fluor 488®. 
 
 The successful development of a protocol that achieves enrichment of discrete 
bands from mouse brain lysate containing both soluble and membrane solubilized 
proteins allowed for the preparation of high quality samples for mass spectrometry. 
 
3.2.7 Mass spectrometry identification of enriched proteins 
The sensitivity of mass spectrometry to identify proteins using nanogram to 
femtogram quantities provides an excellent tool for identification of protein-drug targets.  
Despite this sensitivity, challenges remain for purification of individual proteins using a 
multistep process of labeling, tagging, purifying, and eluting proteins from complex 
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mixtures.  Regulatory proteins are often rare or in low abundance compared to the total 
protein content of the cell.  These classes of proteins embody attractive drug targets due 
to their ability to amplify signal transduction cascades. 
Identification of regulatory proteins poses challenges because their expression 
remains tightly controlled and they tend to have rapid turnover in the cell. Degradation 
and stability may hinder enrichment of sufficient quantities needed for mass 
spectrometry.  Once removed from an environment with a high protein concentration, 
target proteins may precipitate in the absence of chaperones, binding partners, or co-
factors.  One of the major challenges in preparing samples for mass spectrometry is 
elution off the matrix used for enrichment.  The strong affinity between biotin and 
streptavidin creates an almost covalent interaction between the matrix and target proteins.  
Even with harsh solvents and high temperatures it is estimated that only 10-20% of the 
bound material is released; therefore, we developed two approaches for preparation of 
samples for identification by mass spectrometry (Figure 3.12).162  
In method 1, SDS-PAGE loading buffer supplemented with 1 mM biotin was 
added to the beads followed by boiling at 95ºC for 5 minutes.  Supernatant containing the 
eluted proteins was loaded to an SDS-PAGE gel and proteins were detected via silver 
stain.  Visualized bands were cut and submitted for in-gel trypsinization. 
In method 2, the beads were washed once with water after purification from the 
lysate and the proteins were directly trypsinized off the streptavidin bead matrix.  Method 
1 could potentially provide information regarding the site of adduction on the protein 
because the intact protein would be released, allowing for identification of signature 
lacosamide ions associated with adduction; the efficiency of release is expected to be 
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low, however.  Method 2 does not allow for identification of the modification site 
because the adducted portion of the protein will remain immobilized on the matrix.  Rare 
or non-abundant proteins that are captured, however, have a better chance of being 
identified from the release of trypsinized peptides.  Both methods were used to 
interrogate the proteins that interact with compounds 1 and 2.   
 
Figure 3.12 Strategies for processing enriched samples for protein identification with 
mass spectrometry.  Method 1 relies on separation of enriched proteins on SDS-PAGE 
gels followed by excision of silver stained gel bands.  Method 2 uses trypsinization of 
captured proteins directly off streptavidin beads. 
 
Mouse brain lysate was labeled with compounds 1 and 2 or their inverse 
entantiomers ((S)-configuration) followed by reaction with the biotin containing probe 
(probe 2) and enriched with streptavidin beads.  Purified drug-protein adducts were either 
submitted directly for trypsinization off the streptavidin beads or boiled with loading 
buffer and resolved on an SDS-PAGE gel.  Silver stained gel bands were cut and 
submitted to the Michael Barber Centre for Mass Spectrometry at the University of 
Manchester.  Results of the mass spectrometry analysis identified approximately 73 
unique proteins from methods 1 and 2.  These are listed in Table 3.2. 
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Table 3.2 Complete list of proteins identified during the proteomic screen 
Ref Seq ID Protein Description MW (kDa) 
NP_034053 2',3'-cyclic-nucleotide 3'-phosphodiesterase 46.992 
NP_061223 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta/alpha 27.955 
NP_033562 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon 29.058 
NP_035868 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta 28.081 
NP_061359 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma 28.172 
NP_061224 3-monooxygenase/tryptophan 5-monooxygenase activation protein sigma 27.575 
NP_035869 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta 27.647 
NP_035870 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta/delta 27.64 
NP_766549 4-aminobutyrate aminotransferase, mitochondrial precursor 56.321 
NP_071864 Abhydrolase domain-containing protein 8 48.158 
NP_031419 Actin, cytoplasmic 1 41.606 
NP_031476 ADP/ATP translocase 1 32.773 
NP_031477 ADP/ATP translocase 2 32.8 
NP_848473 ADP/ATP translocase 4 35.157 
NP_075608 Alpha enolase 47.01 
NP_033809 AP-2 complex subunit mu-1 49.524 
NP_034454 Aspartate aminotransferase, cytoplasmic 46.117 
NP_031531 ATP synthase subunit alpha, mitochondrial precursor 59.622 
NP_058054 ATP synthase subunit beta 56.17 
NP_081671 Brain acid soluble protein 1 21.955 
NP_001074767 Calcium-independent alpha-latrotoxin receptor 166.504 
NP_033931 Carbonic anhydrase 2 28.901 
NP_080720 Citrate synthase 51.606 
NP_001003908 Clathrin heavy chain 191.426 
NP_083146 Clathrin light chain B 23.043 
NP_031713 Cofilin 1 18.428 
NP_067248 Creatine kinase B type 42.582 
NP_034027 Creatine kinase, ubiquitous mitochondrial precursor 46.873 
NP_031791 Dihydropyrimidinase related protein 1 62.037 
NP_034085 Dihydropyrimidinase related protein 2 62.147 
NP_034195 Dynamin 1 97.154 
NP_034236  Elongation factor 1-alpha 1 49.983 
NP_001070982 Excitatory amino acid transporter 2 61.899 
NP_031464 Fructose-bisphosphate aldolase A 39.225 
NP_033787 Fructose-bisphosphate aldolase C 39.264 
Q8R050 G1 to S phase transition protein 1 homolog 68.396 
NP_038537 Gamma enolase 47.166 
NP_032159 Glutamate dehydrogenase 1, mitochondrial precursor 61.206 
NP_032110 Glyceraldehyde-3-phosphate dehydrogenase 35.679 
NP_032110 Glyceraldehyde-3-phosphate dehydrogenase 35.679 
NP_001106855 Guanine nucleotide-binding protein G(o) subunit alpha 1 39.905 
NP_034609 Heat shock 70 kDa protein 69.948 
NP_112442 Heat shock cognate 71 kDa protein 70.74 
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NP_080784 Heat shock protein 75 kDa 80.078 
NP_034610 Heat shock protein HSP 90-alpha 84.657 
NP_032328 Heat shock protein HSP 90-beta 83.15 
NP_032246 Hemoglobin subunit beta-1 15.617 
NP_835582 Histone H4 (MW 11360) 11.236 
NP_032644 Malate dehydrogenase, cytoplasmic 36.337 
NP_035253 Myelin proteolipid protein 29.946 
NP_032933 Peptidyl-prolyl cis-trans isomerase A 17.84 
NP_598429 Phosphate carrier protein, mitochondrial precursor 39.501 
NP_032854 Phosphoglycerate kinase1 44.42 
NP_112467 Phosphoglycerate kinase2 44.752 
NP_033853 Plasma membrane calcium-transporting ATPase 2 132.457 
NP_035229 Pyruvate kinase isozymes M1/M2 57.714 
NP_083770 Ras related protein Rab-30 22.927 
NP_033027 Ras related protein Rab-3A 24.839 
NP_035377 Retinoblastoma-binding protein 6 199.457 
NP_035627 Serine/threonine-protein kinase 6 47.042 
NP_033784 Serum albumin precursor 68.562 
NP_659149 Sodium/potassium-transporting ATPase subunit alpha 112.852 
NP_848492 Sodium/potassium-transporting ATPase subunit alpha-2 112.087 
NP_659170 Sodium/potassium-transporting ATPase subunit alpha-3 115.838 
NP_033851 Sodium/potassium-transporting ATPase subunit beta-1 35.064 
NP_849245 Spermatogenesis-associated protein 7 homolog 65.524 
NP_084477 Stress-70 protein, mitochondrial precursor 51.578 
NP_062684 Structural maintenance of chromosomes protein 1A 143.085 
NP_075770 Succinate dehydrogenase [ubiquinone] flavoprotein subunit 72.455 
NP_080881 Symplekin 142.49 
NP_077725 Syntaxin-1B 33.114 
NP_001107041 Syntaxin binding protein1 68.605 
NP_033441 Triosephosphate isomerase 26.582 
NP_035783 Tubulin alpha-1A chain 50.005 
NP_033476 Tubulin beta-2A chain  49.776 
NP_075768 Tubulin beta-3 chain 50.288 
NP_080175 Ubiquinol-cytochrome-c reductase complex core protein 2 48.104 
NP_277044 Vang like protein 2 59.64 
NP_032766 N-ethylmaleimide sensitive fusion protein 82.483 
 
 The number of proteins identified from method 1 was significantly less than from 
method 2.  Only 3 proteins were identified exclusively through method 1 and all were 
from samples labeled with compound 2 or its enantiomer (Table 3.3).  Conversely, 32 
proteins were found exclusively from method 2, including 7 different protein isoforms 
from 3 protein families previously identified by method 1 (Table 3.4). 
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Table 3.3 Proteins identified exclusively from method 1 
Ref Seq ID Protein Description MW (kDa) Compound 
NP_033931 Carbonic anhydrase 2 28.901 2 (S) 
NP_080175 Ubiquinol-cytochrome-c reductase complex core protein 2 48.104 2 (S) 
NP_032766 N-ethylmaleimide sensitive fusion protein 82.483 2 (R) 
 
Table 3.4 Proteins identified exclusively from method 2 
Ref Seq ID Description MW (kDa) 
NP_035086 2-oxoglutarate dehydrogenase E1 component, mitochondrial precursor 112.53 
NP_033562 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon 29.058 
NP_061359 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma 28.172 
NP_061224 3-monooxygenase/tryptophan 5-monooxygenase activation protein sigma 27.575 
NP_766549 4-aminobutyrate aminotransferase, mitochondrial precursor 56.321 
NP_071864 Abhydrolase domain-containing protein 8 48.158 
NP_058054 ATP synthase subunit beta 56.17 
NP_001003908 Clathrin heavy chain 191.426 
NP_031713 Cofilin 1 18.428 
NP_067248 Creatine kinase B-type 42.582 
NP_034195 Dynamin 1 97.154 
NP_001070982 Excitatory amino acid transporter 2 61.899 
Q8R050 G1 to S phase transition protein 1 homolog 68.396 
NP_080784 Heat shock protein 75 kDa, mitochondrial precursor 80.078 
NP_034610 Heat shock protein HSP 90-alpha 84.657 
NP_032328 Heat shock protein HSP 90-beta 83.15 
NP_032246 Hemoglobin subunit beta 1 15.617 
NP_835582 Histone H4 11.236 
NP_032933 Peptidyl-prolyl cis-trans isomerase A 17.84 
NP_033853 Plasma membrane calcium-transporting ATPase 2 132.457 
NP_035229 Pyruvate kinase isozymes M1/M2 57.714 
NP_083770 Ras related protein Rab-30 22.927 
NP_033027 Ras related protein Rab-3A 24.839 
NP_035377 Retinoblastoma-binding protein 6 199.457 
NP_035627 Serine/threonine-protein kinase 6 47.042 
NP_659149 Sodium/potassium-transporting ATPase subunit alpha 112.852 
NP_848492 Sodium/potassium-transporting ATPase subunit alpha-2 precursor 112.087 
NP_033851 Sodium/potassium-transporting ATPase subunit beta-1 35.064 
NP_062684 Structural maintenance of chromosomes protein 1A 143.085 
NP_075770 Succinate dehydrogenase [ubiquinone] flavoprotein subunit 72.455 
NP_080881 Symplekin 142.49 
NP_277044 Vang like protein 2 59.64 
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 The results of screening the deoxycholate solublized mouse brain lysate with 
compounds 1 and 2 identified various nuclear, cytoplasmic, and membrane associated 
proteins.  Several proteins were identified as mitochondrial precursor isoforms suggesting 
that the deoxycholate detergent preparation was able to solubilize not only plasma 
membrane associated proteins, but proteins found in organelles such as the mitochondria 
and endoplasmic reticulum.  The number of unique proteins identified was surprising due 
to the stringent washing conditions applied to the streptavidin beads during purification.  
The strong denaturing property of 6 M urea is expected to eliminate most non-specific 
interactions between proteins and the streptavidin matrix.  Therefore, most proteins 
identified by mass spectrometry should have been retained on the matrix through their 
biotin-streptavidin interaction. 
 
3.2.8 Selectivity of enantiomers and affinity baits 
Comparison of the enantioselectivity of compounds 1 and 2 to capture individual 
proteins could potentially provide insight into which targets are most likely responsible 
for (R)-lacosamide’s efficacy.  Pharmacological data for (R)-lacosamide and other 
functionalized amino acids clearly show biological activity is enantioselective for the (R) 
stereoisomer (D-configuration).  This trend of enantioselective biological activity could 
be extended to correlate with the binding affinity of (R)-lacosamide to its cognate protein 
targets.  We could expect the (R) stereoisomers for compounds 1 and 2 to preferentially 
interact and label the correct protein targets better than the (S) stereoisomers.  For this 
hypothesis to be true, increased biological activity resulting from differences in 
pharmacokinetics, metabolism, transport, or efflux must be considered negligible.  
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Currently no studies exist evaluating any of these factors for individual enantiomers.  The 
number of peptide fragments identified for each protein from individual entantiomers 
with compound 1 is listed in Table 3.5. 
 
Table 3.5 The number of peptides identified with R versus S for compound 1. 
 Protein Description (R) (S) 
 2',3'-cyclic-nucleotide 3'-phosphodiesterase 5 6 
 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon  7 
 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma  4 
 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta  3 
 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta/delta 5 8 
 4-aminobutyrate aminotransferase, mitochondrial precursor  1 
 Actin, cytoplasmic 1 15 17 
 ADP/ATP translocase 1 7 5 
* ADP/ATP translocase 2 2  
* ADP/ATP translocase 4 5 3 
 ATP synthase subunit alpha, mitochondrial precursor 4 4 
 ATP synthase subunit beta 9 4 
 Clathrin heavy chain 3 9 
 Cofilin 1 1  
 Creatine kinase B-type 2 5 
* Dihydropyrimidinase related protein 2 8 5 
 Dynamin 1  2 
* Elongation factor 1-alpha 1 1  
 Excitatory amino acid transporter 2  2 
* Fructose-bisphosphate aldolase A 6  
* Gamma enolase 2  
 Glyceraldehyde-3-phosphate dehydrogenase 2 6 
 Guanine nucleotide-binding protein G(o) subunit alpha 1 3 3 
 Heat shock 70 kDa protein (can not identify isoform)  2 
 Heat shock cognate 71 kDa protein 2 6 
 Heat shock protein HSP 90-alpha 2 2 
 Hemoglobin subunit beta-1 3 3 
 Histone (can not identify isoform) 1 2 
 Malate dehydrogenase, mitochondrial precursor  4 
 Myelin proteolipid protein 3 3 
* Peptidyl prolyl cis trans isomerase A 3  
* Plasma membrane calcium-transporting ATPase 2 1  
 Potassium transporting ATPase alpha chain 1 2 3 
 Pyruvate kinase isozymes M1/M2 2 2 
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 Ras related protein (can not identify isoform)  1 
* Ras related protein Rab-30 2  
* Ras related protein Rab-3A 2  
 Serine/threonine-protein kinase 6  1 
* Sodium/potassium-transporting ATPase subunit alpha-1 precursor  17 6 
* Sodium/potassium-transporting ATPase subunit alpha-2 precursor 21 9 
* Sodium/potassium-transporting ATPase subunit alpha-3 25 22 
 Sodium/potassium-transporting ATPase subunit beta-1 2 1 
 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial precursor  2 
 Syntaxin binding protein 1 2 3 
 Triosephosphate isomerase 3 4 
* indicates proteins where more peptides were identified with the R than the S 
 
For several proteins, more peptides were identified with the R enantiomer versus 
the S enantiomer.  Although the mass spectrometry approaches used in methods 1 and 2 
are not quantitative, identification of more peptides with one enantiomer versus another 
may represent a trend in the preference of one configuration to label certain proteins in 
the lysate.  The proteins with the largest enrichment (i.e. number of peptides) for the R 
enantiomer using compound 1 were the sodium/potassium-transporting ATPase subunit 
alpha 1, sodium/potassium-transporting ATPase subunit alpha 2, fructose bisphosphate 
aldolase A, ATP synthase subunit beta, and dihydropyrimidinase related protein 2. 
Compound 2 labeled and captured a distinct set of proteins compared to 
compound 1 (Table 3.6).  The enantiomeric preference for the sodium/potassium-
transporting ATPase subunits, fructose bisphosphate aldolase A, and ATP synthase 
subunit beta was not observed with compound 2.  The R versus S preference for 
dihydropyrimidinase related protein 2 was the only protein that showed a common stereo-
specificity between compound 1 and 2.  Additionally, triosephosphate isomerase, 
syntaxin binding protein 1 (also known as MUNC18-1), N-ethylmaleimide sensitive 
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fusion protein, and pyruvate kinase isozymes M1/M2 showed a preference of (R) versus 
(S) when compound 2 was used. 
 
Table 3.6 The number of peptides identified with R versus S using compound 2 
 Protein Description (R) (S) 
 2 oxoglutarate dehydrogenase E1 component, mitochondrial precursor  2 
 2',3' cyclic nucleotide 3' phosphodiesterase  4 
 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma 3 3 
 3-monooxygenase/tryptophan 5-monooxygenase activation protein sigma 2 2 
 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta/delta 3  
 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta/delta  6 
 Actin, cytoplasmic 1 23 21 
 ADP/ATP translocase 1  8 
 ADP/ATP translocase 2  5 
 Alpha-enolase  2 
 ATP synthase subunit alpha, mitochondrial precursor  9 
 ATP synthase subunit beta  3 
 Carbonic anhydrase 2  3 
 Clathrin heavy chain  4 
 Creatine kinase B-type  1 
* Dihydropyrimidinase related protein 2 6  
 Elongation factor 1-alpha 1  3 
 Fructose-bisphosphate aldolase A  2 
 G1 to S phase transition protein 1 homolog  1 
 Gamma enolase 2 3 
 Glyceraldehyde-3-phosphate dehydrogenase 1 6 
 Guanine nucleotide-binding protein G(o) subunit alpha 1  2 
 Heat shock cognate 71 kDa protein 4 3 
 Heat shock protein 75 kDa, mitochondrial precursor  1 
 Heat shock protein HSP 90-alpha  2 
 Heat shock protein HSP 90-beta  2 
 Hemoglobin subunit beta 1  1 
 Histone (can not identify isoform)  2 
 Malate dehydrogenase, cytoplasmic  1 
 Malate dehydrogenase, mitochondrial precursor  3 
 Myelin proteolipid protein 3 5 
* Pyruvate kinase isozymes M1/M2 3  
 Retinoblastoma-binding protein 6 1  
 Sodium/potassium-transporting ATPase subunit alpha 1 precursor   5 
 Sodium/potassium-transporting ATPase subunit alpha 2 precursor 7 6 
 Sodium/potassium-transporting ATPase subunit alpha 3 9 13 
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 Sodium/potassium-transporting ATPase subunit beta 1  1 
 Structural maintenance of chromosomes protein 1A  1 
* Symplekin 2  
* Syntaxin binding protein 1 3  
* Triosephosphate isomerase 4  
 Ubiquinol cytochrome-c reductase complex core protein 2,  3 
 Vang like protein 2 1  
* N-ethylmaleimide sensitive fusion protein 3  
* Indicates proteins where more peptides were identified with the R versus the S 
 
3.2.9 Prioritization of candidate target proteins 
The proteomic search using mass spectrometry methods 1 and 2 identified 
numerous proteins that were labeled and enriched by compound 1 and 2 from mouse 
brain lysate.  Each affinity bait identified a set of unique proteins, some of which showed 
apparent enrichment when the R enantiomer was used for labeling.  Because it is 
impossible to study all these proteins simultaneously, the identified proteins were 
prioritized to choose the best potential drug target candidates for further examination.  
For every identified protein, a precedent for role in epilepsy or neurotransmission, pattern 
of expression in the brain, and involvement in signaling pathways were investigated 
further.  The identified proteins were classified into five major groups based on their role 
in the cell: pre-synaptic vesicle regulation, actin/cytoskeleton dynamics, signaling 
proteins, cellular energetics, and housekeeping proteins (Figure 3.13). 
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Figure 3.13 Classes of (R)-lacosamide interacting proteins identified from the proteome 
search.  Proteins identified via mass spectrometry were grouped based on their cellular 
functions. 
 
Eight proteins are involved in pre-synaptic regulation of neurotransmitter loaded 
vesicles and receptor mediated endocytosis: clathrin heavy chain (CLTC), clathrin light 
chain B (CLTB), ras related protein Rab 3A (RAB3A), ras related protein Rab 3D 
(RAB3D), syntaxin binding protein 1 (STXBP1), N-ethylmaleimide sensitive fusion 
protein (NSF), dynamin 1 (DNM1), and syntaxin 1B (STX1B).  Of these 8 proteins, 
RAB3A, RAB3D, STXBP1, NSF, and STX1B are all intimately involved in the 
coordination of vesicle exocytosis via the soluble NSF attachment protein receptor 
(SNARE) complex.163  RAB3A and RAB3D are small GTPases found on the outer 
membrane of synaptic vesicles that contribute to maintaining the pool of filled vesicles 
for release at the plasma membrane.164  STXBP1 regulates SNARE complex formation 
and maturation while NSF dissembles the SNARE complex after exocytosis.165,166  The 
identification of a number of synaptic proteins suggests that (R)-lacosamide may 
(R)-
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modulate the rate of synaptic vesicle maturation and release, providing a novel 
intracellular mechanism for control of neurotransmission. 
Eight proteins involved in cytoskeleton dynamics within the cell were identified: 
actin (ACTB), tubulin alpha 1A (TUBA1A), tubulin beta 2A (TUBB2A), tubulin beta 3 
(TUBB3), cofilin 1 (CFL1), vang like protein 2 (VANGL2), dihydropyrimidinase related 
protein 2 (DPYSL2), and dihydropyrimidinase related protein 1 (DPYSL1).  Actin and 
tubulin are ubiquitously expressed proteins that make up the cytoskeleton of all cells.  In 
the brain, these proteins undergo constant remodeling at synapse terminals in response to 
stimuli and provide the scaffold for branching and connectivity during neurite outgrowth.  
CFL1 disassembles actin filaments in neurons and its inactivation through 
phosphorylation by LIM kinase 1 results in increased neurite outgrowth.167 
VANGL2 mediates planar cell polarity as it relates to neural tube formation 
during development.168  Microarray data has recently suggested a role for VANGL2 in 
nociception and may represent a novel drug target for pain management.169  DPYSL1 and 
DPYSL2 are members of a protein family that are highly expressed during development 
and contribute to axon guidance.170  Phosphorylation of DPYSL2 by glycogen synthase 
kinase-3β (GSK-3β) inactivates DPYSL2 and results in decreased axon outgrowth.171  
The identification of a group of proteins involved in remodeling of the cytoskeleton and 
their potential role in synaptic plasticity highlights the possibility that (R)-lacosamide 
may affect a neuron’s response to repeated stimuli through alteration of cellular 
architecture. 
A variety of other signaling proteins were also identified during the proteomic 
search including 2-monoxygenase/tryptophan 5-monooxygenase activation protein 
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(YWHA), calcium-independent alpha-latrotoxin receptor (LPHN2), guanine nucleotide-
binding protein Go subunit alpha 1 (GNAO1), and brain abundant membrane attached 
signal protein (BASP1).  Several isoforms of YWHA, also known as 14-3-3, were 
captured with compounds 1 and 2.  These proteins form dimers that bind phosphoserine 
or phosphothreonine residues in conserved motifs of target proteins.  Recently, isoforms 
of YWHA have been shown to reduce inactivation of voltage dependent 2.2 calcium 
channels (Cav2.2).172  Calcium-independent alpha-latrotoxin receptor (LPHN2) is a 
member of the latrophilin subfamily of G-protein coupled receptors.  The endogenous 
ligand remains unknown, but the family of receptors has been shown to bind the 
latrotoxin, a black widow spider venom peptide, triggering vesicle exocytosis of GABA, 
glutamate or acetylcholine in a calcium independent fashion.173 
Guanine nucleotide-binding protein Go subunit alpha 1 (GNAO1) belongs to a 
class of signal transduction proteins coupled to transmembrane receptors that upon 
agonist activation switch from the inactivated GDP bound form to the activate GTP 
bound state and modulate downstream effector proteins.174  Gαo and Gαi can comprise 
almost 1% of the total membrane protein in the brain.  The major downstream effector of 
Gαo is adenylyl cyclase that upon binding, blocks the generation of the secondary 
messenger cyclic adenosine monophosphate (cAMP).175 
Brain abundant membrane attached signal protein (BASP1) plays a role in neurite 
outgrowth through organization of lipid rafts at the plasma membrane.176  Recruitment of 
BASP1 to the membrane via myristoylation results in reorganization of secondary 
messengers such at PIP2 affecting the dynamics of the actin cytoskeleton.  Collectively, 
  73 
the identified signaling proteins provide numerous possible avenues for regulation of a 
variety of signaling pathways by (R)-lacosamide. 
In the class of identified candidates involved in cellular energetics, 3 proteins 
stand out as interesting targets.  Creatine kinase B (CKB) is a cytoplasmic enzyme 
responsible for generating energy reservoirs of rapidly accessible ATP through the 
synthesis of phosphocreatine.177  Energy homeostasis has been shown to be important for 
proper neuron function and knockdown of creatine kinase in mice results in a decrease in 
seizures.  It is hypothesized that the lack of available ATP required for energy intensive 
periods during seizure development and spread could play a role in the knockdown 
phenotype.178 
Carbonic anhydrase 2 (CAR2), a validated target for other anticonvulsants such as 
topiramate and zonisamide, was also identified from the screen.  In the cell, CAR2 and 
other carbonic anhydrase isoforms control pH and CO2 homeostasis affecting 
biosynthetic pathways such as gluconeogenesis, lipogenesis, and ureagenesis.  (R)-
Lacosamide was shown recently to be a potent inhibitor (331 nM) of human CAR2, by 
interacting with the coumarin binding site on the protein.179 This result suggests that 
CAR2 can interact with a structurally diverse set of ligands with various affinities. 
In addition to CAR2, the alpha and beta subunits of the sodium/potassium-
transporting ATPase (ATP1A, ATP1B) were identified.  These proteins are involved in 
maintenance of electrochemical gradients in the cell by transporting monovalent cations 
across the plasma membrane.  Mutations in ATP1A3 have been linked to a 
hyperexcitability phenotype in neurons of mice.180  Clinically observed mutations in 
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ATP1A3 have also been attributed to a variety of neurological disorders, including rapid-
onset dystonia, bipolar disorder, and Parkinsonism.181 
Of the proteins discussed, DPYSL2, STXBP1, NSF, and ATP1A were chosen for 
further study because of their implications in epilepsy pathogenesis based on current 
literature.  DPYSL2 was selected for additional study because an interaction with (R)-
lacosamide has been suggested previously.103  Its role in axonal guidance and neuronal 
sprouting also provides an interesting and novel mechanism for seizure control.  STXBP1 
and NSF were elected for further study because regulation of the SNARE complex could 
affect seizure development or pathways involved in neuropathic pain.  Recent genetic 
analysis demonstrated that heterozygous missense mutations in the stxbp1 gene could be 
associated with early infantile epileptic encephalopathy (EIEE).182  STXPB1 and NSF 
were exclusively identified with the R enantiomer when compound 2 was used, a 
phenomenon that is consistent with the pharmacological data related to (R)-lacosamide 
and other functionalized amino acids.  Finally, ATP1A was chosen because of the 
extensive clinical data associated with mutations in the protein resulting in neurological 
disorders as well as the availability of an enzymatic screen to assay protein function.  The 
validation and characterization of these proteins with (R)-lacosamide are discussed in the 
following chapter. 
 
3.3 Alternative approach to target discovery 
The results of the proteomic screen identified numerous potential protein targets 
through affinity bait labeling and enrichment followed by mass spectrometry. The 
possibility of missing the endogenous target does remain, however.  Biases from lysate 
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preparation, age of the animal tissue used, or instability of proteins may not provide 
comprehensive coverage of rare or non-abundant proteins.  An alternative strategy was 
designed, therefore, to provide a means for candidate protein identification that allows for 
iterative enrichment of interacting proteins. 
 
3.3.1 mRNA-display technology 
mRNA-display is a protein selection technology that uses a protein-mRNA fusion 
molecule as the unit for in vitro selection.  Creation of the mRNA-protein fusion is 
accomplished by synthesis of an mRNA template attached to a short DNA adapter 
molecule containing a 3′ puromycin, an antibiotic that mimics the 3′ end of aminoacyl 
tRNA.  During in vitro translation, when the ribosome reaches the DNA linker, 
translation pauses and the puromycin enters the ribosomal “A” site and reacts with the C-
terminus of the growing peptide.  Incorporation of puromycin as the last amino acid in 
the nascent peptide results in the mRNA-protein fusion. 
This fusion molecule is then purified from the ribosome complex and used for 
selection.  Because the genotype and phenotype are covalently linked in a single 
molecule, target proteins isolated can be amplified and enriched through the mRNA 
portion of the molecule after each round of selection.  Furthermore, because the mRNA-
protein complex is created entirely in vitro, it circumvents the need for bacterial 
transformation allowing for rapid generation of large comprehensive libraries. 
There are several advantages to using mRNA-display to identify drug-protein 
targets.  The covalent linkage of the genotype to the phenotype allows for rapid 
identification of isolated proteins and enrichment of proteins that bind specifically to the 
  76 
target of interest.  No bacterial transformation is needed; large libraries can thus be 
generated easily from different experimental conditions.  The diversity of each library 
may easily reach 1013 displayed proteins reflecting the diversity of all of the proteins and 
their domains in the proteome.  Each gene will be represented multiple times in the 
library, allowing for a greater likelihood of retaining rare genes during selection.  mRNA-
display also allows for greater flexibility in selection conditions.  In vitro selection 
permits for adjustments in cofactors, temperature, metal ions, chelating agents, pH, 
detergents, and ionic concentrations.  Furthermore, in vitro protein expression also 
minimizes biases from mis-folding, post translation modification, or transport in vivo. 
It is possible that some of the targets of (R)-lacosamide could be membrane bound 
receptors.  Previous selections using mRNA-display for both human and C. elegans 
proteome libraries indicate that membrane bound proteins could be well displayed.183,184 
Selection of binding to calmodulin (CaM) identified many membrane bound proteins, 
including plasma membrane Ca2+-ATPase, mitochondrial H+ transporting ATP synthase, 
voltage gated sodium channel, receptor 5-hydroxytryptamine 2C, neurotransmitter-gated 
ion-channel subunit, and a receptor from the nicotinic family.  Of these isolated 
membrane bound proteins, only the intracellular domains were identified during 
selection, presumably because calmodulin is a cytosolic intracellular protein.  Moreover, 
proper folding of membrane bound proteins could be encouraged during in vitro 
translation in the presence of microsomal membrane, a technique that is widely used for 
in vitro expression of proteins whose function may rely on membrane insertion. 
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3.3.2 Library construction 
Four mRNA-displayed mouse brain proteome libraries were created from four 
experimental conditions: normal (sham stimulated), (R)-lacosamide treated (20 mg/kg), 6 
Hz stimulated (32 mA 3 sec), and 6 Hz stimulated (R)-lacosamide treated.  Psychomotor 
seizure was induced in 3 to 5-month-old mice through corneal electrodes.  After 
stimulation, the mice were sacrificed and brain tissue prepared according to established 
procedures.  Total RNA was isolated from brains of mice treated with each experimental 
condition using Trizol RNA isolation followed by purification of mRNA with oligo d(T) 
cellulose from Ambion.  Novagen’s Orient Express cDNA synthesis kit was used for 
creation of cDNA. 
Mouse brain mRNA (0.5 µg) was reversed transcribed by MMLV reverse 
transcriptase with 0.125 µg of a random hexamer oligo T primer (T2N6) at 37 °C for 1 
hour, followed by second strand synthesis and digestion of RNA at 15 °C for 90 minutes 
with DNA polymerase I and RNase H respectively.  Methylated dNTPs were used for 
first and second strand synthesis.  DNA ends were flushed with T4 DNA polymerase in 
the presence of unmethylated dNTPs for 20 minutes at 11 °C.  Flushed cDNA was ligated 
with directional linkers containing a 5’ EcoR I and partial 3’ Hind III site.  Upon ligation, 
ends were digested with EcoR I and Hind III for 1 hour.  Digested ends were ligated to 
the upstream (containing a T7 promoter, E Tag, and PKA recognition site) and the 
downstream anchor sequences (containing a His Tag, and Flag Tag, respectively).  The 
resulting ligation products were size fractionated using SizeSep400 Spun Columns (GE 
Healthcare) pre-equilibrated with ligation buffer.  The library was then amplified with 
Roche Expand Long Template PCR kit. Figure 3.14 shows total RNA, mRNA and the 
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cDNA libraries created for selection.  The size distribution for each library ranges from 
transcripts below 500 bp to approximately 3 kb, suggesting each library contains 
complete coverage of all potential proteins in the mouse proteome.   
Figure 3.14 Total RNA, mRNA and cDNA libraries generated from individual tissue 
treatments.  RNA was extracted from four experimental tissue treatments followed by 
generation of cDNA libaries using Orient Express cDNA synthesis kit (Novagen).   
 
Each tissue treatment received a unique nucleotide tag incorporated into the 
downstream consensus region during PCR amplification of the ligated libraries  (Figure 
3.15).  After incorporation of the tissue specific tag, the libraries were pooled.  Following 
a potential selection the nucleic acid tag could be used to identify the library of origin for 
genes isolated. 
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Figure 3.15 Strategy for encoding proteins displayed from individual libraries.  cDNA 
from each tissue treatment was amplified with a primer containing a unique sequence in 
the region near the HIS tag. 
 
3.3.3 Preparation of the libraries for in vitro selection 
 An mRNA-displayed library was generated using mRNA from four experimental 
treatments.  One round of selection consists of seven major steps: transcription, 3’ 
conjugation of a DNA-puromycin linker [psoralen-(ATAGCCGGTG)2'-Ome-dA15-CC-
puromycin], in vitro translation and fusion, purification of fusion molecules based on 
FLAG tag, binding to target, capture of bound molecules, and PCR amplification of 
eluted molecules  (Figure 3.16).   
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Figure 3.16 Selection scheme for identification of (R)-lacosamide-binding targets using 
mRNA-display.  RNA is transcribed in vitro from the mouse brain cDNA library 
followed by conjugation with a puromycin containing DNA linker.  The linked RNA is 
used for in vitro translation in rabbit reticulocyte lysate and purified using oligo d(T) and 
FLAG affinity tags.  The purified fusion molecules are incubated with a lacosamide 
analog and captured using biotin streptavidin chemistry.  The selected cDNA library is 
regenerated using the nucleic acid portion of the enriched molecules. 
 
 Prior to initiation of selection, out of frame transcripts were removed through 
generation and purification of the individual mRNA-displayed libraries, followed by 
regeneration of the new cDNA library.  Each library was individually transcribed, fused, 
and translated, followed by purification using oligo d(T) and FLAG affinity tags.  
Efficiency of the purification steps was monitored by measurement of the radiolabeled 
fusion molecules.  Elution profiles of the oligo d(T) and FLAG purification are shown in 
Figure 3.17.  For the oligo d(T) purification, the percentage of counts was 4 times greater 
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for the library generated from the (R)-lacosamide/sham tissue treatment.  Upon FLAG 
purification the percent recovery of eluted molecules from all libraries were equal at 
approximately 10%.  Immediately following FLAG purification, the eluted cDNA 
libraries were regenerated and pooled together at equal molar concentrations. 
 
Figure 3.17 Elution profiles of individual cDNA libraries.  Fusion molecules generated 
during the in vitro translation reaction are purified using 1 mg of oligo d(T) beads.  The 
beads are washed four times with TBST buffer followed by elution of the captured 
molecules using distilled water.  One percent of each fraction is counted for radioactivity 
to monitor the purification efficiency (left panel).  Fusion molecules present in elution 1 
for each library were further purified using anti-flag (M2) resin.  After washing the resin 
six times with TBST, the bound molecules were eluted with TBST plus FLAG peptide (1 
mg/ml). One percent of each fraction is counted for radioactivity to monitor the 
purification efficiency (right panel).  The flowthrough fractions are omitted from the 
graph for clarity. 
 
 The results indicate successful creation of four libraries, each originating from 
separate experimental treatments that are suitable for an mRNA-display selection to 
identify (R)-lacosamide binding proteins.  The pooled libraries contain total coverage of 
mRNAs expressed in mouse brain tissue with sizes ranging from less than 500 bp to 
greater than 3 kb.  Utilization of the generated libraries for mRNA-displayed selection 
could be used to complement the mass spectrometry methods described here by 
identifying specific binding regions within individual proteins or by identifying rare 
proteins not found during the proteomic search. 
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3.4 Concluding remarks 
Chemical biology approaches were applied to drug target discovery for the 
approved anticonvulsant (R)-lacosamide.  Labeling techniques were developed for (R)-
lacosamide derived probes, allowing for discrimination of sub-nanogram quantities of 
individual proteins with a TAMRA fluorescent probe within a complex mixture of mouse 
brain lysate.  Using a preparation of mouse brain lysate containing both soluble and 
membrane bound proteins, proteins interacting with the lacosamide derived probes were 
specifically purified and enriched utilizing click chemistry with a biotin containing probe. 
The enrichment of proteins was paired with two approaches for protein 
identification with mass spectrometry.  Trypsinization of purified proteins captured on 
the beads provided the greatest diversity of identified proteins.  The proteomic screening 
with biologically active lacosamide related probes identified approximately 73 unique 
proteins via mass spectrometry.  The identified proteins included G-protein coupled 
receptors (GPCR), ion and small molecule transporters, cytosolic, and nuclear proteins. 
The identified proteins could be segregated into 5 classes of proteins involved in 
synaptic vesicle regulation, cytoskeletal dynamics, cellular energetics, and housekeeping 
functions.  Included in this list were two proteins that have already been validated or 
suggested to be (R)-lacosamide targets, CAR2 and DPYSL2 respectively.103,179  The 
implications of this finding suggest that the methods developed can provide insight into 
the physiologically relevant network of (R)-lacosamide interacting proteins. 
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3.5 Materials and Methods 
3.5.1 Synthesis of compounds and pharmacology 
Compounds 1, 3, 4, 5 were synthesized as previously described.107  Biological 
activity for compound 1 and 2 were evaluated by the National Institute of Health’s 
Anticonvulsant Screening Program.  Experiments were performed in male rodents (albino 
Carworth Farms no. 1 mice intraperitoneal route ip).  Housing and care were in 
accordance with recommendations from the “Guide for the Care and Use of Laboratory 
Animals”.  Anticonvulsant activity was evaluated using the MES test and scMET test 
using previously reported methods.153 
 
3.5.2 ELISA assay 
Compound 1 (20 mM) in DMSO was immobilized in the wells of poly-lysine 
plates (Corning 3665) overnight at 4 ºC.  The solution was removed and wells washed 
extensively with TBST (50 mM Tris pH 7.4, 150 mM NaCl, 0.1% Tween-20).  Non-
specific sites were blocked with 5% bovine serum album (Pierce) in TBST for 1 h at 4 
ºC.  After extensive washing with TBST, the cycloaddition reaction was initiated by 
sequential addition of probe 2 (20 mM) in DMSO, 500 µM TCEP (Pierce 20490) in 
water, 250 µM TBTA (Sigma-Aldrich 678937) in DMSO, and 1 mM CuSO4 (Sigma-
Aldrich 209201) in water.  The reaction was allowed to proceed for 4 h at room 
temperature.  After washing extensively (200 µl, 4 times) with TBST, streptavidin-HRP 
(Pierce N100) in TBST plus 5% BSA was added to each well.  After incubation for 1 h at 
room temperature, the wells were washed extensively (200 µl, 4 times) with TBST 
followed by addition of o-phenylenediamine (OPD) substrate, 1 mg/ml (Pierce #34005) 
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dissolved in stable substrate buffer (Pierce #34062).  The reaction was allowed to proceed 
for several minutes followed by addition of 10% H2SO4.  Color absorbance (440 nm) was 
quantified with a Nanodrop 2000 (Thermo Scientific). 
 
3.5.3 Preparation of mouse brain lysate 
Mouse brains (male, 2 month, ICR, euthanized by CO2, stripped of meninges 
(Rockland Immunochemicals)) were homogenized in 50 mM HEPES pH 7.4 followed by 
addition of 1% deoxycholate (Pierce 89904).  The slurry was rotated at 37 ºC for 1 h 
followed by centrifugation at 100,000g.  After centrifugation, 0.1% Triton X-100 was 
added to the supernatant and dialyzed overnight at 4 ºC against 3 L of 50 mM HEPES pH 
7.4, 150 mM NaCl and 0.1% Triton X-100.  The resulting liquid was centrifuged at 
100,000g for 1 hour.  The supernatant was collected and stored at -80 ºC until use. 
 
3.5.4 In-gel fluorescence with compounds 1 and 2 
For each reaction, 30 µl of mouse brain lysate was aliquoted into PCR strip tubes 
(VWR# 53509-304) followed by the addition of an appropriate amount of compound 1 or 
2 (in DMSO).  The reaction volume was brought up to 50 µl with distilled water.  The 
reaction for compound 1 was allowed to proceed for the designated time at room 
temperature.  For compound 2, the reaction was equilibrated in the dark at 4ºC followed 
by activation of the photoaffinity probe by exposure to UV light (312 nm Spectroline EB-
280C, 115V, 60 Hz, 0.4 Amps) at distance of 2 millimeters for 10 minutes.  The labeling 
reaction for compound 1 was terminated by addition of 4 mM methylhydrazine for 30 
minutes.  After labeling, cycloaddition reaction was initiated by 50 µM probe 1 (1 µl of 7 
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mM stock in DMSO), 500 µM TCEP (5 µl of 7 mM in water), 250 µM TBTA (0.87 µl of 
20 mM stock in DMSO), and 1 mM CuSO4 (5 µl of 14 mM stock in water).  Samples 
were wrapped in foil and rotated at room temperature for 1 h followed by addition of 20 
µl of 4X SDS-PAGE loading buffer.  The samples were boiled at 95 ºC for 5 minutes 
followed by loading 10 µl to a 10% SDS-PAGE gel.  Proteins were resolved at 180 volts 
for 50 minutes followed by washing the gel twice in distilled water for 5 minutes.  The 
gel was scanned using a Typhoon Scanner (GE Healthcare) (excitation 532 nm / emission 
580 nm). 
 
3.5.5 Enrichment of labeled proteins with probe 2 
Mouse brain lysate (500 µl per reaction) was pre-cleared of endogenously 
biotinylated proteins by the addition of 25 µl of high capacity streptavidin beads (Pierce 
20357) and incubation at 4 ºC for 1 hour.  Cleared supernatant was used for labeling with 
compounds 1 and 2 followed by cycloaddition with probe 2 as previously described.  
After the cycloaddition reaction, 25 µl of high capacity streptavidin resin was added and 
incubated for 2 hours at 4 ºC followed by centrifugation at 1,000 rpm for 1 minute.  The 
supernatant was removed and the beads were sequentially washed twice with 1 ml 50 
mM HEPES pH 7.4, 150 mM NaCl, 0.2 % SDS, then twice with 1 ml 6 M urea, and 
finally twice with 1 ml 50 mM HEPES pH 7.4, 150 mM NaCl.  For in-gel studies, the 
beads were resuspended in 50 µl of SDS-PAGE loading buffer and boiled at 95 °C for 5 
minutes.  For trypsinization directly off the beads for mass spectrometry, the beads were 
washed with 1 ml of water and submitted for mass spectrometry analysis. 
 
CHAPTER 4 
 
CHARACTERIZATION OF COLLAPSIN RESPONSE MEDIATOR PROTEIN 2 
AND OTHER CANDIDATE PROTEINS WITH LACOSAMIDE 
 
4.1 Introduction 
Chapter 3 described methods and experiments for selective labeling and capture of 
putative protein targets that interact with the anticonvulsant (R)-lacosamide via chemical 
biology and mass spectrometry methods.  This approach circumvented extensive 
structural modification and the need for direct immobilization of the drug in order to 
minimize potential loss of binding affinity to its cognate targets in vitro.  The proteomic 
screen generated a list of potential candidate drug targets, many of which provide 
plausible mechanisms for biological control of seizure disorder. 
DPYSL2 (CRMP2), STXBP1 (MUNC18-1), NSF, and ATP1A (Na+/K+ ATPase) 
proteins were chosen for further study.  Several general approaches are used to 
interrogate (R)-lacosamide’s interaction with these proteins.  This included tailoring 
experiments to individual protein biochemistry.  The effect of (R)-lacosamide on the 
DPYSL2 interacting protein calmodulin (CAM) is also investigated. 
 
4.2 Results and Discussion 
4.2.1 Identified proteins and their associated pathways 
Dihydropyrimidinase like Protein 2 (DPYSL2), also known as Collapsin 
Response Mediator Protein 2 (CRMP2) and Turned On After Division (TOAD-64), is a 
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member of a family of cytosolic regulatory proteins implicated in nervous system 
development and maintenance.  Sharing approximately 50-60% sequence homology with 
dihydropyrimidinase, the 5-member family represents a protein class that has 
evolutionarily transitioned from an enzymatic role in the cell to a regulator of protein-
protein interactions.  In the nervous system, DPYSL2 is localized in growth cones and 
terminal regions of growing axons.185,186  Its expression promotes axon outgrowth by 
modulating microtubule assembly through stimulation of tubulin GTPase activity.185,187 
Overexpression of DPYSL2 results in the formation of multiple axons from both 
immature and fully mature dendrites.  The C-terminal tail of DPYSL2 is a substrate for 
phosphorylation by CaMKII, Rho kinase, Cdk5 and GSK-3β.  Phosphorylation of 
DPYSL2 by Rho-kinase, Cdk5 and GSK-3β has been shown to prevent binding to tubulin 
dimers, thereby disrupting the protein’s association with microtubules.171,188,189  Calcium 
dependent phosphorylation of DPYSL2 by CaMKII occurs after glutamate stimulation of 
the NMDA receptor, triggering activation of the MAP kinase signaling cascade.190    
Glutamate stimulation of the NMDA receptor also activates the calpain protease that 
cleaves the DYPSL2 protein at the N-terminus, resulting in a decrease of surface NR2B 
containing NMDA receptors.191  The system provides a feedback loop for down 
regulation of the signaling cascade following glutamate insult and provides a potential 
mechanism for synaptic plasticity.  Increased phosphorylation of DPYSL2 has also been 
correlated with early stages of Alzheimer’s disease.192  
The crystal structure for a C-terminal truncated DPYSL2 has been resolved at 2.4 
Å and 1.9 Å in the presence and absence of the divalent cations Mg2+ and Ca2+.193,194  
Both solution and crystal structures suggested metal dependent formation of 
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homotetramers and heterotetramers exclusively in the presence of Ca2+ or Mg2+.  A 
knockout for DPYSL2 has not been reported.  DPYSL2 is also a reported calmodulin 
binding protein with affinities calculated in the low to mid micromolar range.195  
Mapping of the binding regions suggest the functional consequence of calmodulin-
binding to DPYSL2 prevents tetramer formation as well as calpain mediated proteolysis. 
In addition to its role in microtubule dynamics and axon development, DPYSL2 
has been shown to colocalize with N-type calcium channels (Cav2.2) in immature 
synapses, growth cones, and dorsal root ganglion (DRG) neurons.196  Overexpression of 
DPYSL2 enhanced calcium currents, activation kinetics and neuropeptide release, while 
siRNA-targeted knockdown of DPYSL2 reduced calcium currents. 
STXBP1 and NSF are both proteins involved in synaptic vesicle exocytosis.  This 
highly regulated process involves loading, docking, priming, and fusion of 
neurotransmitter-loaded vesicles in a calcium dependent fashion.163  The major 
machinery for any membrane fusion event includes the core SNARE (Soluble NSF 
Attachment Receptor) complex comprised of syntaxin-1, SNAP-25, and synaptobrevin 
proteins.  STXBP1 can bind syntaxin-1 in both the “closed” (SNARE inaccessible) 
conformation and the “open” (SNARE accessible) conformation acting as a key regulator 
of docking, priming, and fusion.  After vesicle fusion, NSF, present at the synapse 
terminal disassembles the SNARE complex in an ATP dependent fashion.  Genetic 
knockout of STXBP1 in mice leads to a complete loss of neurotransmitter secretion and 
animals die immediately after birth.197   
Several clinically observed mutations in STXBP1 have been reported with 
functional consequences related to seizures.  De novo mutations in several exons of 
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STXBP1 were identified in a patient suffering from early infantile epileptic 
encephalopathy.182  One mutation (C180Y) in exon 7 resulted in destabilization of the 
secondary structure of STXBP1 correlating to a decreased binding affinity to the open 
form of syntaxin-1A (STX1A). 
In a separate study, two mutations in STXBP1 were identified from a cohort of 95 
patients with mental retardation and non-syndromic epilepsy.198  One mutation resulted in 
alteration of the intron splicing site between exon 3 and 4 leading to a longer improperly 
processed allele transcript containing 7 new amino acids followed by a premature stop 
codon.  The second mutation identified resulted in a premature stop in the coding region 
of exon 14.  The mutations are located in domains that form the cavity for syntaxin-1 
binding.  Both patients suffered from seizures at early ages and were currently under 
treatment with anticonvulsants such as phenobarbital, carbamazepine, and clobazam.  
One patient continues to have 3 seizures per day despite a regimen of multiple 
anticonvulsants.  The clinical association between mutations in STXBP1 and epilepsy 
highlights its critical role in proper regulation of synaptic transmission and potential as a 
candidate protein for seizure control. 
N-Ethylmaleimide sensitive fusion protein (NSF) is a hexameric protein 
originally thought to be exclusively associated with membrane fusion but has recently 
been implicated in a variety of cellular processes.  NSF functions as a chaperone for the 
SNARE complex, regulating its recycling through ATP dependent disassociation of 
syntaxin, SNAP-25, and synatobrevin post-fusion.  The ATPase activity and oligomeric 
state of NSF is regulated via phosphorylation.  Phosphorylation by PKC at Ser237 slows 
ATP hydrolysis.199  CDK16 (Pctaire1) phosphorylates NSF at Ser569 within the interface 
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between monomers preventing oligomerization, thereby potentially providing a 
mechanism to regulate exocytosis.200  Overexpression of an ATPase dead mutant of NSF 
in neurons results in sprouting and overgrowth at neuromuscular junctions.201  This 
surprising phenotype is also observed with overexpression of DPYSL2. 
In addition to binding SNARE proteins, NSF interacts with cell surface signaling 
receptors, intracellular proteins, and cytoskeletal elements.  Using a yeast two-hybrid 
system, NSF was found to bind the C-terminal tail of the AMPA receptor, a ligand gated 
ionotropic excitatory glutamate receptor present in the CNS.202  The calcium dependent 
interaction helps tune synaptic strength by maintaining AMPA receptors at the 
membrane.203  Disruption of the interaction results in a decrease of miniature excitatory 
postsynaptic currents (mEPSCs) in cultured hippocampal neurons. 
NSF also binds to the intracellular domain of the GABAA and GABAB receptors 
forming a heterotrimeric complex at the postsynaptic membrane.204,205  Association 
among the three proteins allows for agonist induced desensitization after stimulation with 
GABA through recruitment of protein kinase C (PKC) to the membrane which 
phosphorylates the receptor complex.  This property, independent from its role in 
membrane fusion events, illustrates NSF’s role as a modulator of receptor function.  
Significant interactions have also been illustrated between NSF and D1 and D5 dopamine 
receptors, β2-adrenergic receptor, M1, M3, M4, and M5 muscarinic recptors.206-209  These 
interactions largely relate to receptor recycling and sorting through NSF binding to their 
intracellular domains. 
 NSF also binds several members of the small GTPase proteins of the ras-related 
in brain (Rab) family.  This class of proteins are expressed and targeted to different 
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organelles in the cell regulating the tethering of vesicles for a variety of membrane fusion 
events.210  NSF has been shown to intereact with Rab 3, 4, 5, 6 and 11 with NSF.  It has 
been found that Rab 3, 4 and 6 all bind and stimulate the ATPase activity of NSF in vivo.  
The physiological consequences of these interactions are not well understood, but the 
finding implicates NSF as a regulator of not only vesicle fusion but also intracellular 
vesicle trafficking. 
The final protein chosen for further study was the Na+/K+ Transporting ATPase 
(ATP1A).  These integral membrane protein pumps maintain electrochemical gradients 
through export of three sodium ions and import of two potassium ions at the plasma 
membrane during one exchange cycle.  The complete pump consists of a 110 kDa α-
subunit and a 41 kDa β-subunit.  Four genes encode the alpha subunit (ATP1A1, 
ATP1A2, ATP1A3, ATP1A4) that has 10 transmembrane regions.211  Cardiac glycosides, 
such as ouabain are natural inhibitors of pump activity that alter neuronal functions in 
vitro and in vivo.   
Extensive mutations have been identified in genes encoding ATP1A1, ATP1A2, 
and ATP1A3 that correlate with a variety of neurological disorders.  Mutations in 
ATP1A1, ATP1A2, and ATP1A3 are associated with bipolar disorder.212  Thirty-nine 
mutations have been clinically observed in ATP1A2 for patients suffering from familial 
hemiplegic migraine (FHM2), an autosomal dominant subtype of migraine characterized 
by migraines with aura including hemiparesis, ataxia, coma, or epileptic seizures.213,214  
The mutations are scattered throughout the proteins extracellular, transmembrane, ATP-
binding, and intracellular regions affecting a wide range of pump functionalities, 
including Na+ and K+ ion affinity, ATP-binding, and catalytic turnover. 
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Five mutations have been reported in ATP1A2 for sporadic hemiplegic migraine 
(SHM), a migraine disorder in which no first degree relative has similar symptoms.213  
Seven mutations in ATP1A3 are reportedly associated with rapid-onset dystonia 
Parkinsonism, a syndrome characterized by the abrupt onset of slow movement, altered 
speech and poor balance.  Collectively, the disregulation of pump activity observed by 
genetic mutation illustrates their effects on neuronal excitability and the importance of 
maintaining proper electrochemical gradients. 
 
4.2.2 Probing for DPYSL2 in mouse brain lysate 
Initial studies investigated the ability of compounds 1 and 2 to label DPYSL2.103  
Soluble mouse brain lysate was labeled with compound 1 (50 µM) for 1 hour followed by 
click chemistry with probe 1.  TAMRA labeled proteins were resolved on an SDS-PAGE 
gel followed by transfer to a nitrocellulose membrane.  After immunoblotting with an 
antibody recognizing DPYSL2, TAMRA labeled proteins and DPYSL2 were 
simultaneously detected.  The composite image reveals that one of the major bands in the 
lysate corresponds to DPYSL2 that was detected by both the anti-DPYSL2 antibody and 
the TAMRA probe (Figure 4.1).  The molecular weight of the band corresponds to a 
truncated version of DPYSL2, (52-55 kDa), suggesting that proteolysis of the full-length 
DPYSL2 may take place during lysate preparation or during the labeling reaction. 
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Figure 4.1 Fluorescent western blot detecting DPYSL2 (green) and TAMRA labeled 
proteins (red).  Soluble mouse brain lysate was incubated with compound 1 for 1 hour at 
room temperature followed by click chemistry with probe 1.  Proteins were resolved on a 
10% gel followed by transferred to a nitrocellulose membrane.  An antibody for DPYSL2 
was used to detect the presence of DPYSL2 protein.  A Cy5-labeled goat anti-mouse 
secondary antibody was used to visualize DPYSL2.  The nitrocellulose membrane was 
scanned for DPYSL2 (ex.: 633 nm / em.: 670 nm) and lacosamide adducted proteins (ex.: 
532 nm / em.: 580 nm). 
 
The ability of compound 3 to purify endogenous DPYSL2 from mouse brain 
lysate was investigated next.  It was shown previously through in-gel fluorescence that 
compound 1 labeled a variety of bands in mouse brain lysate as detected by the TAMRA 
probe (probe 1), including DPYSL2.  Fluorescent western blotting for DPYSL2 (Figure 
4.1) illustrated an overlap of signal between one strongly labeled protein in the mouse 
brain lysate and the DPYSL2 antibody signal suggesting that compound 1 labels 
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endogenous DPYSL2.  Without purification of the adducted proteins, however, a single 
band in the lysate mixture could contain numerous individual proteins. 
To evaluate more critically the labeling of endogenous DPYSL2 by the (R)-
lacosamide derived probes, adducted proteins were purified using biotin streptavidin 
chemistry followed by probing for the presence of DPYSL2.  Using 40 µM of compound 
3, proteins were labeled in the presence or absence of an excess of (S)-lacosamide 
followed by purification with streptavidin beads and immunoblotting for DPYSL2 
(Figure 4.2).  Results indicate that the isothiocyanate affinity bait captures DPYSL2 and 
that the presence of (S)-lacosamide blocks the protein recovery in a dose dependent 
fashion.  Furthermore, the destruction of the isothiocyanate by the addition of 
methylhydrazine completely blocks the capture of DPYSL2. The affinity bait is therefore 
essential for maintaining the interaction between DPYSL2 and compound 3.   
 
Figure 4.2 Western blot analysis of DPYSL2 from mouse brain lysate captured by 
compound 3.  Compound 3 (40 µM) was reacted with soluble mouse brain lysate (2 
mg/ml) for 1 hour at room temperature in the presence of absence of (S)-lacosamide.  
Methylhydrazine was incubated with compound 3 prior to its addition to the lysate for 
lane 2.  Adducted proteins were captured by the addition of 50 µl of streptavidin beads 
for 1 hour at 4 °C.  The beads were washed 10 times and proteins were resolved on a 
10% SDS-PAGE gel then transferred to a nitrocellulose membrane followed by 
immunoblotting for DPYSL2. 
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4.2.3 Expression and purification of DPYSL2 in E. coli 
Characterizeing more thoroughly the interaction between (R)-lacosamide and the 
candidate proteins requires a source for pure protein with high quality.  Overexpression 
of proteins in E. coli provides a rapid facile means to generate and purify recombinant 
protein suitable for a variety of biochemical studies.  Successful overexpression of 
DPYSL2 using both GST affinity tags and 6X histidine tags has been reported previously 
for biochemical investigation and crystal structure determination.193,188  For the 
biochemical studies described here, an N-terminal GST-tag and C-terminal HIS tag 
constructs were created.  DPSYSL2 was amplified from a mouse brain cDNA library and 
insert into pET41 (N terminal GST-tag) or pET28b (C terminal HIS-tag).  Sequence 
verified clones were transformed into Rosetta™ (BL21-DE3) cells for overexpression. 
Both constructs allowed for efficient expression and purification of recombinant 
DPYSL2 fusion protein.  The C-terminal HIS tag can purify more full-length DPYSL2 
protein by preventing purification of C-terminal truncated isoforms.  Column 
chromatography purification of the GST-DPYSL2 suggested the protein, in solution at 
high concentrations, migrates at an octamer based on comparison with the migration of 
known protein standards (Figure 4.3).  Stenmark and coworkers determined the crystal 
structure of DPYSL2 revealing that it forms homotetramers.  The apparent migration of 
the recombinant DPYSL2, therefore, may be an artifact of the tetramer migration on the 
column or the result of association of two tetramers in solution. 
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Figure 4.3 Purification of GST-DPYSL2. (A) Elution profile of GST-DPYSL2 suggests 
that it migrates as an octamer in solution.  (B) Kaverage of proteins with known sizes used 
to generate a standard curve for calculation of MW (from reference 215).  Calculation of 
MW using the elution volume of 48 mls suggests that in solution GST-DPYSL2 appears 
to migrate as an octomer with an apparent molecular weight of 676 kDa. 
 
4.2.4 Functionality of overexpressed DPYSL2 
The involvement of DPYSL2 in axonal growth and branching has been linked to 
its interaction with tubulin heterodimers.  The promotion of microtubule formation in 
vitro is considered one hallmark of DPYSL2 activity.185  To assess the functionality of 
the recombinant DPYSL2-HIS protein, tubulin polymerization as measured by a change 
in absorbance at 340 nm was used.  The change in OD of purified tubulin in the presence 
or absence of DPSYSL-HIS protein was evaluated over 1 hour.  The results showed an 
increase in polymerization when 10 µM of DPYSL2-HIS protein was added to the 
reaction (Figure 4.4). 
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Figure 4.4 DPYSL2-HIS promotes tubulin polymerization in vitro.  45 µl of purified 
tubulin (1 mg/ml) in 80 mM PIPES pH 6.9, 1 mM MgCl2, 1 mM EGTA, and 1 mM GTP 
was added to a 384 well plate prewarmed to 37 °C containing 10 µM DPYSL2-HIS 
protein.  After brief mixing, the change in OD340 was monitored every 30 seconds for 1 
hour.  
 
These results are consistent with previous reports that DPYSL2 shows modest 
polymerization of microtubules suggesting that the recombinant protein is properly 
folded and functional.187  Validation of functionality allows for characterization of the 
interaction between (R)-lacosamide and the recombinant protein. 
 
4.2.5 Fluorescent labeling of GST-DPYSL2 by lacosamide probes 
The purified recombinant protein permits utilization of the TAMRA probe (probe 
1) for in vitro labeling to evaluate quantitatively the amount of adduction via in-gel 
fluorescence.  The ability of compound 1 and 2 to label GST-DPYSL2 was evaluated in 
the induced soluble E. coli lysate, GST-column elution fractions, and glutathione free 
(buffer exchanged) fractions.  For induced soluble E. coli lysate, cells were collected by 
centrifugation at 1,000 rpm followed by resuspension of the pellet in a buffer containing 
50 mM HEPES pH 7.4 and 150 mM NaCl.  Cells were sonicated 3 times and insoluble 
material removed by centrifugation at 14,000 rpm.  Supernatant was used directly for 
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labeling reactions or purification of GST-fusion proteins with glutathione beads.  Elution 
fractions containing 10 mM glutathione from affinity purification were utilized for 
labeling reactions or buffer exchanged into 50 mM HEPES pH 7.4 and 150 mM NaCl 
with a size exclusion column. 
Labeling the lysate, elution fraction, and buffer exchanged fractions showed both 
the nucleophilic and photoaffinity baits resulted in labeling of GST-DPYSL in the soluble 
lysate using 50 µM of compounds 1 and 2 (Figure 4.5).  The nucleophilic isothiocyanate 
labels the fusion protein to a greater extent than the photoaffinity probe under the same 
conditions. 
 
Figure 4.5 In-gel fluorescent labeling of GST-DPYSL2 by compounds 1 and 2.  10µl of 
protein fractions from GST-DPYSL2 expression were incubated with compounds 1 or 2 
(50 µM) for 1 hour at room temperature.  Compound 2 was activated for 10 minutes at 
312 nm at 4 °C.  Adducted proteins were tagged using click chemistry for 1 hour with 
probe 1.  Proteins were resolved on a 10% SDS-PAGE gel followed by in-gel 
fluorescence (ex.: 532 nm / em.: 580 nm). 
 
Compound 1 also shows substantial reactivity to numerous proteins in the soluble 
E. coli lysate illustrating the high possibility that some of the proteins identified via mass 
spectrometry are false positives.  The reactivity of compound 1, however, does not 
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directly correlate with abundant proteins in the lysate based on stains for total protein, 
demonstrating that protein concentration alone does not confer reactivity to the probe.  It 
suggests instead that successful adduction requires a specific interaction between the 
chemical probe and protein in order for efficient labeling to occur.  Compound 2 shows 
less overall labeling of the lysate fraction with only modest labeling of GST-DPYSL2.  
Non-specific reactivity of compound 2 is difficult to judge based upon the overall low 
reactivity.  
Labeling of the GST-elution fraction with compounds 1 and 2 demonstrates that 
the presence of 10 mM glutathione completely blocks the labeling reaction.  The 
phenomenon likely results from destruction of the affinity bait present on each molecule 
by glutathione.  Reaction of glutathione with the isothiocyanate and aromatic azide 
generates a dithiocarbamate and aromatic amine, respectively, rendering them non-
reactive to proteins. Reaction of the activated nitrene with glutathione would also render 
the affinity bait inactive and reduces the effective labeling of compound 2.  Pre-removal 
of glutathione via buffer exchange restores reactivity of both compounds toward GST-
DPYSL2.  The extent of labeling between compounds 1 and 2 was equivalent in contrast 
to the E. coli lysate fraction in which a large difference in labeling toward the same 
protein was observed.  Collectively, the in-gel fluorescence results indicate that upon 
removal of glutathione, both affinity baits strongly label GST-DPYSL2 and that the 
protein can be successfully used to study the interaction with (R)-lacosamide. 
The sensitivity of probe 1 in detecting the drug-protein adducts and the amount of 
protein needed were investigated using purified proteins.  Dose dependent labeling from 
24 µM to 0.375 µM for compound 1 and 2 showed linear fluorescent labeling across the 
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dose range with adduction detectable using nanomolar concentrations of drug and 10 µM 
protein (Figure 4.6).  No background fluorescence was seen in the absence of either 
compound.  Using 3 µM of compound 1 the detection limit of protein was approximately 
1 µM. 
 
Figure 4.6 In-gel fluorescence illustrating dose dependent labeling of GST-DPYSL2. (A) 
10 µl of purified GST-DPYSL2 protein (10 µM in 50 mM HEPES, 150 mM NaCl pH 
7.4) was incubated with compound 1 or 2 for 1 hour at room temperature.  Samples 
incubated with compound 2 were activated with UV light (312 nm) for 10 minutes at 4 
°C.   Click chemistry was performed with probe 1 for 1 hour at room temperature.  (B) 
GST-DPYSL2 protein was diluted from 10 µM to 100 pM in 50 mM HEPES, 150 mM 
NaCl pH 7.4 then reacted with 3 µM of compound 1 for 1 hour at room temperature. 
Click chemistry was performed with probe 1 for 1 hour at room temperature.  For all 
samples 5 µl of SDS-PAGE loading buffer was added to reaction after click chemistry 
and samples boiled for 5 minutes at 95 °C.  Proteins were resolved on a 10% SDS-PAGE 
gel and scanned for in-gel fluorescence (ex.: 532 nm / em.: 580 nm). 
 
4.2.6 Competition with (R)-lacosamide and (S)-lacosamide 
The development of conditions for labeling and detection for GST-DPYSL2 
permitted the interrogation of competition with unmodified versions of (R)-lacosamide 
and (S)-lacosamide.  This approach is used frequently in radioligand binding assays 
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wherein a specific amount of radiolabeled drug is competed by varying amounts of 
unlabeled compound.  This method, termed homologous competition, has several criteria 
for accurate Kd measurement. 
First, the receptor must have equal affinity for both the labeled and unlabeled 
ligands.  In the case of the AB and CR modified compounds, affinity for the protein 
targets is unknown.  Biological activity provides the only insight for compound efficacy.  
Although the modified compounds 1 and 2 show diminished activity in animals (ED50 45 
and 20 mg/kg respectively, versus 4.5 mg/kg for (R)-lacosamide), it is not known whether 
these activity values represent decreased affinity for the cognate protein target(s) or 
contributing effects from altered metabolism, transport, pharmacokinetics, or efflux.  The 
homologous competition design provides, therefore, a simple though imperfect 
assessment of affinity. 
In addition to the assumption of equal affinity between radiolabeled and unlabeled 
ligands, the assay assumes that there is no cooperative binding, no ligand depletion from 
binding to the receptor, and that non-specific binding will increase proportionally with 
the amount of labeled ligand added.  Under the assay conditions described in the previous 
section, it is predicted that these assumptions will be true based on the fact that the drug 
is in molar excess to the protein and that dose dependent labeling is observed when the 
drug concentration is increased.  In the instance of these in-gel fluorescent experiments, 
the IC50 is the concentration of competing ligand at which fluorescent intensity is reduced 
by 50%.  The labeled ligand concentration equals the concentration of AB and CR probe 
used in the reaction. 
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Successful competition between an AB and CR probe and (R)-lacosamide or its 
enantiomer requires careful titration of probe reactivity toward the target protein.  
Competition between binding of (R)-lacosamide and the adduction of the AB and CR 
probe represent two distinct reactions, a reversible and an irreversible binding event.  The 
choice of the affinity bait used for competition reactions should afford tight temporal 
control of reactivity to allow for total equilibration between the reactive lacosamide 
analog and the unmodified drug with the target protein.  To this end, compound 2 
containing the photo-activated aromatic azide was chosen for use in these competition 
experiments.  The photoaffinity probe is unreactive to proteins until specific activation by 
UV light that can be controlled in both time and intensity.  In theory, this allows for a 
period of equilibration between the labeled and unlabeled compounds to find binding 
sites present on the protein followed by a short activation of the AB unit to create the 
adduct. 
The use of compound 2 to label GST-DPYSL2 in the presence of increasing 
concentrations of (R) or (S)-lacosamide ranging from 1.5 µM to 30 mM revealed a 
sigmoidal decrease in labeling in the presence of (R)-lacosamide but not (S)-lacosamide  
(Figure 4.7).  Each sample was repeated in duplicate were resolved on the same gel.  The 
graphed values represent the average normalized pixel intensities calculated for each 
concentration.  The IC50 for (R)-lacosamide under the assay conditions was calculated to 
be 451 µM.  The high IC50 might suggest that the assumptions required for the 
homologous competition experiment, such as equal affinity between labeled and 
unlabeled compounds, may not be met.  Furthermore, the irreversible adduction reaction 
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between compound 2 and the protein may mask true binding affinity of the unmodified 
compound. 
 
Figure 4.7 Homologous competition assay with GST-DPYSL2.  (A) Compound 2 (3 
µM) was added to a mastermix of GST-DPYSL2 protein diluted to 1 µM in 50 mM 
HEPES, 150 mM NaCl pH 7.4.  10 µl of master mix was aliquoted per reaction followed 
by addition of (R) or (S)-lacosamide (3 µM to 30 mM).  The reactions were incubated for 
3 hours at 4 °C followed by photoactivation at 312 nm for 10 minutes on ice.  
Cycloaddition was initiated by addition of 24 µM probe 1 (0.1 µl of 2.4 mM stock in 
DMSO), 500 µM of TCEP (5 µl of 1 mM stock in water), 250 µM TBTA (0.625 µl of a 4 
mM stock in DMSO) and 1mM CuSO4 (1 µl of a 10 mM stock in water).  The reaction 
was allowed to proceed for 1 hour at room temperature followed by addition of 5 µl of 
4X SDS-PAGE loading buffer.  Samples were boiled at 95 °C for 5 minutes and the 
entire sample was loaded to a 10% SDS-PAGE gel.  Gels were washed to twice with 
water for 5 minutes then visualized by fluorescent scanning (ex.: 532 nm / em.: 580 nm).  
(B) Pixel intensities were quantified using ImageJ (NIH) and curves generated using 
GraphPad (Prism). Each concentration was repeated in duplicate and graphed values 
represent the average pixel intensity calculated at each concentration. 
 
 In contrast to GST-DPYSL2, two control proteins were also analyzed for labeling 
by compound 2 in the presence of competing ligands.  Enolase, a protein identified 
during the proteomic screening, represents a potential false positive that was identified by 
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showing inherent reactivity toward the affinity bait and not a specific interaction with the 
lacosamide scaffold.  Under the same reaction conditions, commercial enolase protein 
showed modest labeling by compound 2 as detected by in-gel fluorescence.  In the 
presence of excess concentrations of (R) and (S) lacosamide, however, labeling was 
diminished in a linear fashion consistent with adduction resulting from a non-specific 
interaction (Figure 4.8).  This trend appears different from the apparent sigmoidal 
competition curves observed with GST-DPYSL2. 
 
Figure 4.8 Homologous competition assay using enolase protein. (A) Compound 2 (3 
µM) was added to a mastermix of enolase protein diluted to 1 µM in 50 mM HEPES, 150 
mM NaCl pH 7.4.  10 µl of master mix was aliquoted per reaction followed by addition 
of (R) or (S)-lacosamide (3 µM to 30 mM).  The reactions were incubated for 3 hours at 4 
°C followed by photoactivation at 312 nm for 10 minutes on ice.  Cycloaddition was 
initiated by addition of 24 µM probe 1 (0.1 µl of 2.4 mM stock in DMSO), 500 µM of 
TCEP (5 µl of 1 mM stock in water), 250 µM TBTA (0.625 µl of a 4 mM stock in 
DMSO) and 1mM CuSO4 (1 µl of a 10 mM stock in water).  The reaction was allowed to 
proceed for 1 hour at room temperature followed by addition of 5 µl of 4X SDS-PAGE 
loading buffer.  Samples were boiled at 95 °C for 5 minutes and the entire sample was 
loaded to a 10% SDS-PAGE gel.  Gels were washed to twice with water for 5 minutes 
then visualized by fluorescent scanning (ex.: 532 nm / em.: 580 nm).  (B) Pixel intensities 
were quantified using ImageJ (NIH) and curves generated using GraphPad (Prism). Each 
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concentration was repeated in duplicate and graphed values represent the average pixel 
intensity calculated at each concentration. 
 
 The second control protein evaluated, bovine serum album (BSA), represents a 
protein that was not identified during the proteomic screen and can be used to assess the 
unbiased reactivity of a general protein to the photoaffinity probe.  Results show only 
weak labeling by compound 2 and no obvious trend in competition (Figure 4.9).  This 
suggests that compound 2 does not indiscriminately label all proteins in the proteome 
equally.  Of the proteins that are labeled, some show sigmoidal dose dependent 
competition with (R)-lacosamide while others simply possess favorable interactions for 
adduction by the photoaffinity probe. 
 
Figure 4.9 Homologous competition assay using BSA protein. (A)  Compound 2 (3 µM) 
was added to a mastermix of enolase protein diluted to 1 µM in 50 mM HEPES, 150 mM 
NaCl pH 7.4.  10 µl of master mix was aliquoted per reaction followed by addition of (R) 
or (S)-lacosamide (3 µM to 30 mM).  The reactions were incubated for 3 hours at 4 °C 
followed by photoactivation at 312 nm for 10 minutes on ice.  Cycloaddition was 
initiated by addition of 24 µM probe 1 (0.1 µl of 2.4 mM stock in DMSO), 500 µM of 
TCEP (5 µl of 1 mM stock in water), 250 µM TBTA (0.625 µl of a 4 mM stock in 
DMSO) and 1mM CuSO4 (1 µl of a 10 mM stock in water).  The reaction was allowed to 
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proceed for 1 hour at room temperature followed by addition of 5 µl of 4X SDS-PAGE 
loading buffer.  Samples were boiled at 95 °C for 5 minutes and the entire sample was 
loaded to a 10% SDS-PAGE gel.  Gels were washed to twice with water for 5 minutes 
then visualized by fluorescent scanning (ex.: 532 nm / em.: 580 nm).  (B) Pixel intensities 
were quantified using ImageJ (NIH) and curves generated using GraphPad (Prism).  Each 
concentration was repeated in duplicate and graphed values represent the average pixel 
intensity calculated at each concentration. 
 
 The homologous competition assays collectively illustrated the reactivity of 
different classes of proteins to compound 2.  Three distinctive displacement profiles were 
observed in the presence of (R) or (S)-lacosamide.  BSA protein showed minimal labeling 
with compound 2 and no dose dependent competition, even with a large excess of ligand.  
Enolase protein showed modest labeling by compound 2, but linear abolishment of 
labeling with increasing concentrations of competing ligand.  This profile implies an 
inherent reactivity to the photoaffinity bait present in compound 2, but no specific 
interaction with the lacosamide scaffold.  DPYSL2 shows strong labeling by compound 2 
and dose dependent abolishment of labeling consistent with a drug-receptor interaction.  
Although the calculated affinity appears to be weak (451 µM), the results suggest a 
specific interaction. 
 
4.2.7 Adduction site of DPYSL2-HIS by lacosamide probes 
(R)-lacosamide and compounds 1 and 2 interact with DPYSL2 protein based on 
the in-gel fluorescent studies.  To understand this interaction better, the site of 
modification at which the affinity bait labels the protein was investigated.  Understanding 
the amino acid residue(s) provides insight into the interaction of DPYSL2 with (R)-
lacosamide.  In order to observe the modification site via mass spectrometry, a detectable 
amount of adducted DPYSL2 must be generated.  A panel of conditions was evaluated 
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that could generate maximal labeling of DPYSL2-HIS by compound 1 (Figure 4.10).  
Condition 5 provided the maximal labeling of DPYSL2-HIS protein and was used to 
create adducted samples for mass spectrometry analysis. 
 
Figure 4.10 Conditions for DPYSL2-HIS adduction by compound 1.  10 µl of DPYSL2-
HIS was reacted with the compound 1 under various conditions followed by click 
chemistry with probe 1 for 1 hour at room temperature.  Adducted proteins were resolved 
on a 10% SDS-PAGE gel followed by scanning for in-gel fluorescence (ex.: 532 nm / 
em.: 580 nm). 
 
Purified DPYSL2-HIS protein was reacted with 250 µM of (R)-lacosamide 
containing the isothiocyanate affinity bait as in compound 1 for 4 h at 37 °C (Figure 
4.11).  Unreacted drug was removed and the samples were subject to trypsinization 
followed by LC-MS/MS nano-electronspray quadrupole time of flight (QToF) mass 
spectrometry.  Comparison of chromatograms of mass to charge ratios (m/z) of 
trypsinized peptides derived from protein labeled with (R)-lacosamide and unlabeled 
protein identified a triply protonated species (m/z 535.2) corresponding to the modified 
peptide KPFPDFVYKR specifically present in the labeled sample (Figure 4.12A).  
Collision-induced disassociation (CID) further fragmented the peptide with the m/z ratio 
of 535.2 to identify lysine 472 (K472) as the site of modification by the drug analog 
  108 
within the modified peptide (Figure 4.12B).  In this method, the ionized fragments are 
accelerated in the gas phase to collide with argon gas resulting in the conversion of 
kinetic energy to internal energy within the peptide.  Fragmentation results from 
migration of a proton from the amino acid side chain to the peptide backbone generating 
cyclic and linear ionized fragments. 
 
Figure 4.11 (R)-Lacosamide analog used to generate modified DPYSL2 protein 
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Figure 4.12 Mass spectrometry identification of the modification site of DPYSL2 by (R)-
lacosamide.  DPYSL2-HIS protein was reacted with 250 µM (R)-lacosamide containing a 
reactive isothiocyanate for 4 hours at 37°C.  (A) Chromatograms of mass to charge ratios 
of the ions revealed a new adducted peptide species present in the adducted sample (red 
box) (B)  Collision-induced disassociation identified lysine 472 as the site of 
modification by (R)-lacosamide.   
 
Interestingly, this lysine residue (K472) is located on the surface of the protein 
adjacent to several regions of DPYSL2 known to be involved in various protein-protein 
interactions. (Figure 4.13)  Amino acids 479-500 are one of three regions in DPYSL2 that 
has been shown to bind N-type calcium channels (Cav2.2) using pulldown assays with 
GST-fusion mutants of DPYSL2.216  A peptide corresponding to amino acids 475-493 
has been shown to bind to calmodulin using isothermal titration calorimetry.195  The C-
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terminus of DPYSL2 has also been shown to be a strong activator of GTP hydrolysis for 
tubulin.187       
 
Figure 4.13 Regions adjacent to the K472 modification site involved in protein-protein 
interactions.  Residues 479-500 (red) of DPYSL2 have been shown to bind to the Cav2.2 
calcium channel.  Residues 475-493 (yellow) have been shown to bind to calmodulin.  
The C-terminus of DPYSL2 from 410 (purple) has been shown to have strong GAP 
activity towards tubulin polymerization of microtubules. 
  
The mapped modification site is close to the interface between monomers of the 
DPYSL2 protein that are thought to form tetramers in vivo.  Tetramer formation is 
dependent upon the presence of divalent cations such as Mg2+ and Ca2+.194  There are a 
total of 32 lysines in the full-length DPYSL2, of which 13 are located on the outer 
surface of the protein and not present at the interface between monomers.  There are 
several other lysines that are equally available in regards to solvent accessibility and 
exposure compared to K472, especially K292 and K422, but no adduction was observed 
at these residues.  The fact that a single lysine modification was found implies the 
reaction between DPYSL2 and (R)-lacosamide was not the result of non-specific reaction 
with lysines present on the protein surface. 
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4.2.8 Computational modeling of (R)-lacosamide analogs to DPYSL2 
Autodock Vina was used to predict the possible interactions that (R)-lacosamide 
might have with the DPYSL2 protein structure.217  Lysine 472 was identified as the site 
of modification by the (R)-lacosamide analog containing the isothiocyanate affinity bait, 
therefore initial docking studies used this region on a monomeric version of DPYSL2 for 
computational studies.  Four confirmations of the drug were predicted that positioned the 
affinity bait containing (R)-lacosamide toward lysine 472.  Three of the predicted binding 
sites are shallow pockets and there are few structural clues on the protein that could 
explain the enantioselective biological activity observed in vivo (Figure 4.14).  
Additionally, structure activity relationships suggest that extensive modifications are not 
tolerated at the C2 and acetamide positions. Despite this, no obvious steric hindrance is 
present at these two sites that would inhibit or abolish binding. 
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Figure 4.14 Unlikely interactions of the isothiocyanate (R)-lacosamide analog predicted 
by Autodock.  The (R)-lacosamide analog containing the isothiocyanate affinity bait was 
docked to the DPYSL2 monomer using AutoDock Vina.  Three predicted interactions 
between the (R)-lacosamide analog used for mass spectrometry using AutoDock Vina 
were generated near K472 (green).  
 
 Autodock predicted a fourth confirmation that positions the molecule in a narrow 
binding pocket located near the interface of two monomers (Figure 4.15).  Several polar 
contacts are predicted to occur (shown in yellow) with tyrosine 395 (Y395), aspartic acid 
(D476), and asparagine 393 (N393).  The ring is also pointed toward the K472, putting 
the isothiocyanate closer to the amino acid side chain than other predicted conformations, 
possibly facilitating adduction of the protein. 
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Figure 4.15 Favorable predicted conformation of (R)-lacosamide with DPYSL2.  The 
molecule is positioned within a pocket located adjacent to the interface between two 
monomers.  The isothiocyanate is pointed toward K472 (green) and shares several 
hydrogen bonds (yellow) (Y395, D476, N393) with the protein (red).   
 
 Structure activity relationships for (R)-lacosamide suggest that extensive 
modifications are not tolerated at the C2 or acetamide positions.  Consistent with these 
trends, the pocket predicted by AutoDock leaves little room for inversion of C2 side 
chain of the molecule without steric clash with aspartic acid 476 on DPYSL2.  
Furthermore, the depth of the pocket prohibits extension of the acetamide end of (R)-
lacosamide.  Based on the three predicted polar contacts, position of the N-benzyl group 
toward K472, and structural constraints consistent with known SAR, this fourth 
conformation represents the most likely interaction between the (R)-lacosamide analog 
and DPYSL2 calculated by AutoDock. 
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Figure 4.16 Predicted docked conformation of (S)-lacosamide with DPYSL2 protein. 
Conformations were generated with AutoDock Vina near lysine 472 (green).  Potential 
hydrogen bonding with N393 is shown in yellow. 
 
 (S)-Lacosamide was also docked to DPYSL2 to predicted possible conformations 
(Figure 4.16).  The ring is positioned in a similar fashion to the conformations predicted 
for the previous compound, but the acetamide group is positioned to hydrogen bond with 
Asp393 (N393).  The side chain, which was previously predicted to extend into the 
pocket, is now extened around aspartic acid 476 (D476).  This model suggests that 
although (S)-lacosamide may bind to DPYSL2, its conformation is distinct from (R)-
lacosamide. 
  
4.2.9 Evaluation of K472A DPYSL2-HIS mutant protein 
The identification of the site of modification of DPSYL2 by (R)-lacosamide 
provides great insight into the binding site for the molecule on the protein.  Therefore, we 
mutated lysine 472 to alanine and evaluated whether compound 1 could continue to label 
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the protein using in-gel fluorescence.  The point mutation was generated using mutagenic 
primers.  PCR was used to generate linear double-stranded plasmid DNA containing the 
point mutation followed by digestion of the methylated wild-type DNA by Dpn1.   A 
sequence confirmed construct was expressed and purified in a similar fashion to the wild-
type DPYSL2-HIS protein. 
 
Figure 4.17 In-gel fluorescent labeling of WT and K472A DPYSL2-HIS by compound 1. 
Compound 1 was added to WT or K472A DPYSL2 protein diluted to 1 µM in 50 mM 
HEPES, 150 mM NaCl pH 7.4. The reactions were incubated for 1 hour at room 
temperature.  Cycloaddition was initiated by addition of 24 µM probe 1 (0.1 µl of 2.4 
mM stock in DMSO), 500 µM of TCEP (5 µl of 1 mM stock in water), 250 µM TBTA 
(0.625 µl of a 4 mM stock in DMSO) and 1mM CuSO4 (1 µl of a 10 mM stock in water).  
The reaction was allowed to proceed for 1 hour at room temperature followed by addition 
of 5 µl of 4X SDS-PAGE loading buffer.  Samples were boiled at 95 °C for 5 minutes 
and the entire sample was loaded to a 10% SDS-PAGE gel.  Gels were washed to twice 
with water for 5 minutes then visualized by fluorescent scanning (ex.: 532 nm / em.: 580 
nm). 
 
 Dose dependent labeling (20 - 2.5 µM) was observed with both the wild-type and 
K472A mutant proteins after reaction with compound 1 for 30 minutes at room 
temperature in 50 mM HEPES and 150 mM NaCl pH 7.4.  Despite the removal of the 
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lysine residue identified as the adduction site for compound 1, the recombinant protein 
continued to be fluorescently labeled (Figure 4.17).  This demonstrates that the 
isothiocyanate affinity bait can react at multiple sites on the protein in addition to lysine 
472.  No preference was observed for labeling of the K472A-DPYSL2-HIS protein by the 
R enantiomer under the conditions used. 
There are two possible explanations for the continued labeling of K472A 
DPYSL2-HIS observed by in-gel fluorescence.  The sensitivity of the in-gel fluorescence 
is very high allowing for the detection of tiny amounts of labeled protein.  The observed 
labeling may therefore, be a very small amount of adduction occurring at other surface 
residues rather than the preferred site at lysine 472.  In the absence of K472, other 
random non-specific modifications would still be visible.  Secondly, the conditions used 
to generate the modified protein for mass spectrometry may have enhanced reactivity of 
K472 to become preferentially labeled relative to the other lysines that are labeled for in-
gel fluorescence.  The high concentration of drug (500 µM), increased pH (8.0 versus 
7.4), increased temperature (37 °C versus 25 °C) and reaction time (4 hours versus 30 
minutes) likely create unforeseen changes on affinity bait specificity and reactivity 
towards DPYSL2.  The harsh conditions used could have encouraged reaction of the high 
concentration of drug to adduct with lysine 472 instead of a site that is more reactive 
under lower drug, pH, and temperature conditions. 
 
4.2.10 Affinity evaluated via surface plasmon resonance 
An attempt was made to measure the affinity between (R)-lacosamide derivatives 
and DPYSL2 protein using surface plasmon resonance (SPR).  This technology relies on 
  117 
detecting the change in refractive index of a reflected light source from a metal film 
(plasmon) as a result of mass increase occurring during a binding event.  In order to 
determine the affinity between two molecules, one is immobilized on the metal film 
while the other is passed over the flow cell containing the immobilized component.  The 
refractive index is monitored in real-time allowing for observation of both association 
and disassociation between the components. 
Three biotinylated (R)-lacosamide derivatives were synthesized in the Kohn 
laboratory, each with the biotin group tethered to a different site on the lacosamide 
scaffold (Figure 4.18).  The commercial availability of a streptavidin coated sensor chip 
permitted facile immobilization of the three drug analogs using biotin-streptavidin 
chemistry. 
 
Figure 4.18 The 3 sites for incorporation of biotin for immobilization of (R)-lacosamide 
derivatives on the surface plasmon resonance chip. 
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 Because the lacosamide scaffold cannot tolerate extensive modification without 
substantial loss of activity, the three sites chosen for immobilization provide a more 
comprehensive view of the potential interactions that may be critical for binding.  Based 
on previous SAR, it is expected that site 1 can tolerate the most modification and should 
provide the best “display” of the compound on the sensor chip.  This is postulated 
because larger modifications are tolerated at site 1 without substantial loss of 
anticonvulsant activity in vivo. 
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Figure 4.19 The four biotinylated (R)-lacosamide derivatives synthesized for 
immobilization on the streptavidin sensor chip for SPR. 
  
 Figure 4.19 illustrates the biotinylated compounds synthesized for immobilization 
on the streptavidin sensor chip for SPR.  Compounds synthesized for sites 1 and 2 utilize 
azide containing (R)-lacosamide derivatives that were reacted with the biotin probe 
(probe 2) using the Cu(I) mediated Huisgen 1,3 cycloaddition, forming a triazole linkage 
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between the (R)-lacosamide scaffold and the biotin-PEG linker.  The compound 
synthesized for site 3 coupled the biotin-PEG NHS activated ester with (S)-N-Benzyl-2-
amino-3-methoxypropionamide.  For immobilization, each biotinylated compound was 
sequentially injected into their respective channels on the streptavidin functionalized 
chip. 
   The ability of GST-DPYSL2 to bind to the immobilized compounds was 
evaluated at 0.25 µM, 0.5 µM, and 1 µM (Figure 4.20).  Results showed no significant 
binding to any of the three immobilized compounds.  Although there was a change in 
refractory units (RU), this increase was also seen with the negative control channel 
(channel 1).  These results highlight the challenges of proper immobilization and display 
of small molecules on the sensor chip.  The density of components on the surface and 
immobilization strategy may have drastic impacts on correct drug-receptor recognition.  
Furthermore, specific binding conditions or unknown co-factors may be required for 
observation of the interaction. 
 
 
Figure 4.20 SPR binding results for GST-DPYSL2 to the biotinylated (R)-lacosamide 
derivatives.  Proteins were extensively dialyzed against the flow buffer (50 mM HEPES, 
150 mM NaCl pH 7.4) prior to experiments.  70 µl of protein (0.25 µM, 0.5 µM, and 1 
µM) were injected into all four channels at a flow rate of 50 µl/min and their binding 
kinetics were observed over 3 minutes. 
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4.2.11 Effect of (R)-lacosamide on DPYSL2 and calmodulin 
It was recently reported that DPSYL2 is a calmodulin binding protein with an 
affinity estimated in the low micromolar range.195  Using both recombinant DPYSL2 
protein and mouse brain lysate, we evaluated whether (R) or (S)-lacosamide affected the 
interaction between calmodulin and DPYSL2. 
Calmodulin immobilized on agarose beads was incubated with recombinant 
DPYSL2-HIS protein or soluble mouse brain lysate in the presence or absence of 1 mM 
(R) or (S)-lacosamide.  After washing to remove non-specifically bound proteins, 
captured DPSYL2 was eluted with 10 mM EGTA.  Samples were resolved on an SDS-
PAGE gel followed by western blotting for the DPYSL2 (Figure 4.21).  The results 
indicate that the presence of (R) or (S)-lacosamide did not disrupt the interaction between 
calmodulin and DPYSL2 under the conditions tested.  Eluted fractions from each sample 
showed that a similar amount of protein was present in all three conditions.  The 
concentration of the compounds evaluated exceeds clinically achievable concentrations 
and, therefore, it is unlikely that (R)-lacosamide affects this interaction in vivo. 
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Figure 4.21 Purification of DPYSL2 with calmodulin agarose.  (A)  Recombinant 
DPYSL2-HIS was incubated with calmodulin agarose in the presence and absence of (R) 
or (S)-lacosamide.  After washing, bound samples were eluted with 10 mM EGTA and 
resolved on a 10% SDS-PAGE gel followed by western blotting for DPYSL2. (B) 
Calmodulin agarose was added to soluble mouse brain lysate to capture endogenous 
DPYSL2.  Eluted proteins were resolved on a 10% SDS-PAGE gel followed by western 
blotting for DPYSL2. 
 
4.3 Studies with other candidate proteins 
Several other proteins identified during the proteomic screen were examined in 
addition to evaluating the interaction between (R)-lacosamide and DPYSL2.  The two 
proteins involved in the vesicle exocytosis, STXBP1 and NSF were chosen based upon 
their close association with modulation of neurotransmitter release and receptor 
trafficking. 
 
4.3.1 STXBP1 (Munc18-1) and NSF 
STXBP1 and NSF were overexpressed as N-terminal GST-fusion proteins in a 
manner identical to DPYSL2.  Both compound 1 and compound 2 efficiently labeled the 
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purified proteins (Figure 4.22).  Similar to DPYSL2, the detection limit of both proteins 
was around 1 µM.   
 
Figure 4.22 Dose dependent labeling of GST-STXBP1 and GST-NSF. (A)10 µl of 
purified GST-STXBP1 or GST-NSF protein (10 µM in 50 mM HEPES, 150 mM NaCl 
pH 7.4) was incubated with compound 1 or 2 for 1 hour at room temperature.  Samples 
incubated with compound 2 were activated with UV light (312 nm) for 10 minutes at 4 
°C.   Click chemistry was performed with probe 1 for 1 hour at room temperature.  (B) 
GST-DPYSL2 protein was diluted from 10 µM to 100 pM in 50 mM HEPES, 150 mM 
NaCl pH 7.4 then reacted with 3 µM of compound 1 for 1 hour at room temperature. 
Click chemistry was performed with probe 1 for 1 hour at room temperature.  For all 
samples 5 µl of SDS-PAGE loading buffer was added to reaction after click chemistry 
and samples boiled for 5 minutes at 95 °C.  Proteins were resolved on a 10% SDS-PAGE 
gel and scanned for in-gel fluorescence (ex.: 532 nm / em.: 580 nm). 
 
Homologous competition assays using excess (R) or (S)-lacosamide estimated the 
(R)-lacosamide IC50 for STXB1 at 694 µM (Figure 4.23) and NSF at 340 µM using 
compound 2 (Figure 4.24).  For these two proteins it appears that there are two sites that 
can interact with (R) or (S)-lacosamide in a stereospecific manner.  When the (R) 
stereoisomer was used in the competition experiments the blocking of labeling was much 
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more pronounced.  However when the (S) stereoisomer was used, the labeled is only 
partially block and plateaus when the competing ligand is at a concentration of 3 mM.   
 
Figure 4.23 Homologous competition assay using GST-STXBP1 protein. (A) Compound 
2 (3 µM) was added to a mastermix of GST-STXBP1 protein diluted to 1 µM in 50 mM 
HEPES, 150 mM NaCl pH 7.4.  10 µl of master mix was aliquoted per reaction followed 
by addition of (R) or (S)-lacosamide (3 µM to 30 mM).  The reactions were incubated for 
3 hours at 4 °C followed by photoactivation at 312 nm for 10 minutes on ice.  
Cycloaddition was initiated by addition of 24 µM probe 1 (0.1 µl of 2.4 mM stock in 
DMSO), 500 µM of TCEP (5 µl of 1 mM stock in water), 250 µM TBTA (0.625 µl of a 4 
mM stock in DMSO) and 1mM CuSO4 (1 µl of a 10 mM stock in water).  The reaction 
was allowed to proceed for 1 hour at room temperature followed by addition of 5 µl of 
4X SDS-PAGE loading buffer.  Samples were boiled at 95 °C for 5 minutes and the 
entire sample was loaded to a 10% SDS-PAGE gel.  Gels were washed to twice with 
water for 5 minutes then visualized by fluorescent scanning (ex.: 532 nm / em.: 580 nm).  
(B) Pixel intensities were quantified using ImageJ (NIH) and curves generated using 
GraphPad (Prism). Each concentration was repeated in duplicate and graphed values 
represent the average pixel intensity calculated at each concentration. 
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Figure 4.24 Homologous competition assay using GST-NSF protein. (A) Compound 2 (3 
µM) was added to a mastermix of GST-NSF protein diluted to 1 µM in 50 mM HEPES, 
150 mM NaCl pH 7.4.  10 µl of master mix was aliquoted per reaction followed by 
addition of (R) or (S)-lacosamide (3 µM to 30 mM).  The reactions were incubated for 3 
hours at 4 °C followed by photoactivation at 312 nm for 10 minutes on ice.  
Cycloaddition was initiated by addition of 24 µM probe 1 (0.1 µl of 2.4 mM stock in 
DMSO), 500 µM of TCEP (5 µl of 1 mM stock in water), 250 µM TBTA (0.625 µl of a 4 
mM stock in DMSO) and 1mM CuSO4 (1 µl of a 10 mM stock in water).  The reaction 
was allowed to proceed for 1 hour at room temperature followed by addition of 5 µl of 
4X SDS-PAGE loading buffer.  Samples were boiled at 95 °C for 5 minutes and the 
entire sample was loaded to a 10% SDS-PAGE gel.  Gels were washed to twice with 
water for 5 minutes then visualized by fluorescent scanning (ex.: 532 nm / em.: 580 nm).  
(B) Pixel intensities were quantified using ImageJ (NIH) and curves generated using 
GraphPad (Prism). Each concentration was repeated in duplicate and graphed values 
represent the average pixel intensity calculated at each concentration. 
 
4.3.2 Na+/K+ Transporting ATPase 
The effect of (R)-lacosamide, (S)-lacosamide, and an isopropyl derivative (Figure 
4.25) were evaluated in a commercial enzyme assay measuring the ATPase activity of the 
Na+/K+ Transporting ATPase.  The generation of inorganic phosphate (Pi) was measured 
using a malachite green photometric assay with tissue derived from porcine cerebral 
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cortex tissue.  Three compounds were tested in triplicate at 10 µM, 30 µM, and 100 µM 
for modulation of the enzyme activity. The compound ouabain was used as a positive 
control for inhibition of ATPase activity.  Recent research has linked mutations in the 
Na+/K+ ATPase alpha 3 gene with hyperexcitability and epilepsy due to inactivation of 
the pump.218 
 
Figure 4.25 Compounds evaluated in the ATPase assay. 
 
Potential rescue of pump activity may contribute to anticonvulsant activity.  
Therefore, in vitro, (R)-lacosamide might act as an activator of ATPase activity for the 
Na+/K+ transporting ATPase.  Results indicate, however, no significant change in ATPase 
activity at any concentration tested for all three compounds. (Table 4.1)  These findings 
suggest that in vitro (R)-lacosamide is not a modulator of the Na+/K+ transporting 
ATPase.   
 
Table 4.1 Evaluation of (R)-lacosamide derivatives for inhibition of ATPase activity of 
the Na+/K+ Transporting ATPase.  All samples were performed in triplicate. 
% of Control Values Compound Test  Concentration 1st Mean 
(R)-lacosamide 10 µM 104.1 104.1 
(R)-lacosamide 30 µM 104.8 104.8 
(R)-lacosamide 100 µM 103.3 103.3 
(S)-lacosamide 10 µM 100.0 100.0 
(S)-lacosamide 30 µM 102.0 102.0 
(S)-lacosamide 100 µM 103.5 103.5 
Compound 4 10 µM 102.1 102.1 
Compound 4 30 µM 103.7 103.7 
Compound 4 100 µM 101.8 101.8 
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4.3.3 Carbonic anhydrase II (CAR2) and 14-3-3 
The commercial availability of CAR2 and 14-3-3 allowed for rapid testing of 
binding to (R)-lacosamide using the same sensor chip generated for DPYSL2.  Injections 
of 1 µM, 0.5 µM, and 0.25 µM showed different association and disassociation profiles 
compared with GST-DPYSL2.  There was no difference, however, between the channels 
with immobilized lacosamide derivatives (channels 2-4) and the negative control biotin 
probe (channel 1) (Figure 4.27).  Additionally, the change in RUs was not dose 
dependent relative to the protein concentration for carbonic anhydrase II (Figure 4.26).  
The lack of appreciable binding (channels 2-4) relative to the control (channel 1) is 
surprising due to the fact that (R)-lacosamide has been shown to be a nanomolar inhibitor 
(IC50 = 331 nM) for human carbonic anhydrase II.  This suggests that the biotinylated 
lacosamide derivatives may not be properly displayed on the streptavidin chip allowing 
for recognition by carbonic anhydrase. 
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Figure 4.26 SPR binding results for human carbonic anhydrase II to the biotinylated (R)-
lacosamide derivatives.  Proteins were extensively dialyzed against the flow buffer (50 
mM HEPES, 150 mM NaCl pH 7.4) prior to experiments.  70 µl of protein (0.25 µM, 0.5 
µM, and 1 µM) were injected into all four channels at a flow rate of 50 µl/min and their 
binding kinetics were observed over 3 minutes. 
 
 
 
Figure 4.27 SPR binding results for 14-3-3-HIS to the biotinylated (R)-lacosamide 
derivatives.  Proteins were extensively dialyzed against the flow buffer (50 mM HEPES, 
150 mM NaCl pH 7.4) prior to experiments.  70 µl of protein (0.25 µM, 0.5 µM, and 1 
µM) were injected into all four channels at a flow rate of 50 µl/min and their binding 
kinetics were observed over 3 minutes. 
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4.4 Concluding remarks 
From the list of proteins identified in the proteomic screen, DPYSL2, STXBP1, 
NSF and Na+/K+ ATPase were chosen for in-depth analysis, with a major focus on 
DPYSL2.  In-gel fluorescence with several recombinant proteins illustrated a specific 
dose dependent interaction with (R)-lacosamide.  Homologous competition assays 
calculated IC50 values in the mid to high micromolar range (DPYSL2 = 451 µM, 
STXBP1 = 694 µM, NSF = 340 µM).  Attempts at accurate estimation of affinity using 
SPR with DPYSL2, STXBP1, NSF, CAR2, and 14-3-3 were performed through 
immobilization of several biotinylated derivatives of (R)-lacosamide that revealed a high 
degree of non-specific binding, for which the cause remains unknown.  It is possible that 
proper display or stability of immobilized compounds or the lack of required co-factors 
hinders observation of the binding events.  Screening of (R)-lacosamide’s activity on the 
Na+/K+ ATPase transporter in cellular assay demonstrated no inhibition or activation at 
the concentrations tested.   
Using an isothiocyanate containing analog of (R)-lacosamide, a site of modification 
on DPYSL2 was successfully identified using mass spectrometry.  Lysine 472 was the 
only amino acid detected that was modified by (R)-lacosamide.  The residue is located 
adjacent to domains involved in binding to N-type calcium channels (Cav2.2), 
calmodulin, and tubulin. 
Computational studies predicted four potential binding conformations for the (R)-
lacosamide analog using AutoDock Vina that could allow for adduction by the affinity 
bait to occur.  One model provides a plausible confirmation of (R)-lacosamide docked 
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into a pocket on DPYSL2 at the interface between two monomers of the crystal structure.  
The orientation of the molecule is favorable for adduction by the affinity with the 
modified residue identified via mass spectrometry.  Additionally, the SAR observed in 
mice, namely a dramatic loss of activity from extension of the acetamide end and the R 
versus S selectivity, could be explained by steric clash with residues surrounding the 
predicted binding pocket. 
A mutant of DPYSL2 containing an alanine at position 472 instead of lysine was 
generated.  In-gel fluorescent studies using recombinant DPYSL2-K472A-HIS protein 
showed that despite the mutation, the protein continued to be labeled to a similar extent 
as the wild type using compound 1.  Labeling in buffer alone or a complex mixture of 
lysate did not affect the extent of labeling.  These results demonstrate that the 
isothiocyanate affinity bait used may label multiple sites on the DPYSL2 protein under 
the conditions tested. 
Collectively, the work presented here successfully applied electrophilic and photo 
affinity labeling strategies to enrich and identify (R)-lacosamide interacting proteins from 
mouse brain lysate.  Mass spectrometry methods were developed to identify the identity 
of individual proteins from both gel slices and proteins immobilized on a solid surface.  
From this list of 73 potential targets, 3 proteins were chosen for further study using 
recombinantly expressed proteins.  Lysine 472 was identified as the likely adduction site 
of compound 1 on DPYSL2.  Furthermore, the mutation of the (R)-lacosamide adduction 
site on DPYSL2 did not abolish its labeling by compound 1 when measured by in-gel 
fluorescence. 
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The results illustrate the limitations of the affinity labeling strategy to definitively 
identify physiologically relevant protein targets for (R)-lacosamide.  Activity of (R)-
lacosamide to enhance slow inactivation of sodium channels continues to be the likely 
primary action responsible for its anticonvulsant activity, perhaps in association with one 
or more proteins identified during our screen.  During our proteome search, however, no 
sodium channels peptides were identified.  For that reason, the data obtained should be 
integrated with multiple data streams for (R)-lacosamide such as electrophysiology, 
animal activity, and gene expression profiling to generate a more comprehensive picture 
of the compound’s complex pharmacology. 
 
4.5 Materials and Methods 
4.5.1 Western blot for DPYSL2 
Mouse brain lysate was prepared as described in chapter 3 using deoxycholate.  
For each reaction, 500 µl of lysate was reacted with 40 µM of compound 3 for 1 h at 
room temperature.  For competition samples, (S)-lacosamide was added in excess and 
allowed to equilibrate for 30 minutes prior to addition of compound 3.  Methylhydrazine 
(1 mM) was incubated with compound 3 for 30 minutes prior to addition to lysate for 
sample 2 to destroy the isothiocyanate affinity bait. 
After labeling the lysate for 1 hour, 50 µl of streptavidin beads (Pierce) was added 
and the mixture rotated for 1 h at 4 °C followed by centrifugation at 1,000 rpm for 1 
minute.  The supernatant was removed and the beads were sequentially washed twice 
with 1 ml 50 mM HEPES pH 7.4, 150 mM NaCl, 0.2 % SDS, then twice with 1 ml 6 M 
urea, and twice with 1 ml 50 mM HEPES pH 7.4 and 150 mM NaCl.  50µl of 4X SDS-
  132 
PAGE loading buffer was added to the resin followed by boiling at 95 °C for 5 minutes.  
After a brief mixing, the beads were centrifuged and 20 µl of supernatant was loaded to a 
10 % gel and transferred to a nitrocellulose membrane followed by immunoblotting for 
DPYSL2. 
The membrane was probed with anti-DPYSL2 (Santa Cruz 30228) using a 1:1000 
dilution for 1 hour at room temperature followed by addition of secondary anti-rabbit-
HRP conjugate antibody (GE Healthcare) 1:1000 for 1 hour at room temperature.  HRP 
substrate was added and image developed immediately. 
 
4.5.2 Fluorescent western blot for DPYSL2 
For detection of DPYSL2, lysate was labeled as described previously (3.5.4) with 
compound 1.  After SDS-PAGE, the gel was transferred to a nitrocellulose membrane 
and blocked for 1 hour with TBST and 5 % milk.  The membrane was probed with anti-
DPYSL2 (Santa Cruz) using a 1:1000 dilution for 1 hour at room temperature followed 
by the addition of secondary anti-rabbit-HRP conjugate antibody (GE Healthcare) 1:1000 
for 1 hour at room temperature.  HRP substrate was added to the membrane and 
immediately scanned for Cy5 (ladder), TAMRA, and ECL.  The composite image was 
created in ImageJ (NIH). 
 
4.5.3 Construction, expression and purification fusion proteins 
PCR products were amplified from mouse brain cDNA library (Ambion) using 
KOD polymerase (Novagen).  GST-fusion proteins were created through insertion into 
pET41-LIC/Ek through ligation independent cloning according to the manufacturer’s 
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instruction (Novagen).  For HIS-tagged fusion proteins, complementary digested PCR 
products were ligated into pET28b plasmid (NEB) digested with Nco1 and Xho1.  
Sequence verified clones were transformed into Rosetta E. coli (Novagen). 
For expression, cultures were grown in LB to an OD600 of 0.7 then cooled to 20 
°C followed by addition of 1 mM IPTG.  Induction was carried out overnight (16 hours) 
at 20 °C.  For GST-fusion proteins, clarified lysate was passed over a 3 mls of GST-Bind 
resin (Novagen) and washed with 20 column volumes of 50 mM HEPES, 150 mM NaCl 
pH 7.4.  Bound proteins were eluted with 3 column volumes of 1 mM glutathione in wash 
buffer.  Free glutathione was removed using a NAP-10 column (GE Healthcare). 
For HIS-tagged fusion proteins, clarified lysate was passed over 3 mls of Talon 
cobalt resin (Clonetech) and washed with 20 column volumes of 50 mM HEPES, 150 
mM NaCl, and 10 mM imidazole pH 7.4.  Bound proteins were eluted with 3 column 
volumes of 100 mM imidazole, 50 mM HEPES and 150 mM NaCl pH 7.4.  Eluted 
fractions were dialyzed against 2 liters of 50 mM HEPES, 150 mM NaCl to remove 
imidazole.  Samples were aliquoted and stored at -80 °C until use. 
The K472A DPYSL2-HIS mutant was generated via mutagenic PCR.  Primers 
containing the mutation were used for amplification of pET28b vector containing the 
wild-type version of the DPYSL2 sequence. 
CRMP2K472A.F 
CTGGACGCTACATTCCCCGGGCGCCCTTCCCTGATTTTGTTTAC 
CRMP2K472A.R 
GTAAACAAAATCAGGGAAGGGCGCCCGGGGAATGTAGCGTCCAG 
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50 ng of pET28b vector containing DPYSL2 was amplified with 1.25 µg of each primer 
using clone Pfu Polymerase (Stratagene) for 16 cycles followed by digestion of 1 µl of 
Dpn1 at 37 C for 1 h. 95 °C for 2 minutes, (95 °C for 30 seconds, 55 °C for 30 seconds, 
72 °C for 10 minutes) 15 times, 72 °C for 7 minutes, 4 °C. 7 µl of plasmid was 
transformed into TOP10 cells and sequence verified clones were transformed into Rosetta 
E. coli (Novagen) for expression. 
 
4.5.4 Autodock Vina Docking Studies 
Autodock Tools 1.5.4 was used to generate PDBQT files with proper Gasteiger 
charges for DPYSL2 (2GSE.pdb) and (R)-lacosamide.  A monomeric crystal structure of 
DPYSL2 was used for docking studies.  Grid size and spacial orientation were estimated 
around K472 using Autodock Tools.  Autodock Vina (1.0) was run on Mac OS X 
Leopard using extensiveness set to 100 and a total of 30 conformations calculated.  The 
predicted conformations were visualized in MacPyMol with the 2GSE.pdb crystal 
structure of DPYSL2.   
 
4.5.5 Tubulin polymerization assay 
Tubulin (Cytoskeleton) was resuspended in 80 mM PIPES, 0.5 mM EGTA, 2 mM 
MgCl2, 0.05% glycerol pH 6.9 to a concentration of 1 mg/ml (10 µM).  GTP was added 
to 1 mM and the mixture was equilibrated on ice for 15 minutes.  Recombinant DPYSL2, 
taxol, (R)-lacosamide, or buffer were added to their respective wells of the 384 well plate 
followed by incubation in the microplate reader at 37 °C for 5 minutes.  Polymerization 
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was initiated by addition of 44 µl of tubulin to each well.  OD340 measurements were 
captured every 30 seconds for 1 hour at 37 °C. 
 
4.5.6 DPYSL2 pulldown using calmodulin agarose 
Calmodulin-agarose beads (25 µl resin) (Stratagene) were equilibrated in 50 mM 
HEPES pH 7.4, 150 mM NaCl, and 10 mM CaCl2.  Recombinant DPYSL2-HIS protein 
(100 ng in 500 µl of buffer) or deoxycholate treated mouse brain lysate (2 mg/ml) were 
added to the resin and rotated at 4 °C for 2 hours.  For those samples evaluating the effect 
of small molecules drugs, (R) or (S)-lacosamide was added to 1 mM.  Beads were 
pelleted at 1000 rpm for 1 minute and supernatant removed.  The beads were washed 5X 
with 167 µl of 50 mM HEPES pH 7.4, 150 mM NaCl, and 1 mM CaCl2.  Bound proteins 
were eluted with 50 µl of 50 mM HEPES pH 7.4, 150 mM NaCl, and 10 mM EGTA and 
resolved on a 10 % SDS-PAGE gel followed by western blotting for DPYSL2. 
 
4.5.7 In-gel fluorescent labeling of purified proteins 
For in-gel fluorescent studies, 10 µl of protein was diluted to various 
concentrations in 50 mM HEPES, 150 mM NaCl pH 7.4 and labeled with compound 1 or 
2.  For compound 1, reactions were incubated for 1 hour at room temperature.  For 
compound 2, reactions were incubated for 50 minutes at 4 °C followed by 
photoactivation at 312 nm (Spectroline EB-280C, 115V, 60 Hz, 0.4 Amps) at distance of 
2 millimeters for 10 minutes on ice.  Cycloaddition was initiated by addition of 24 µM 
probe 1 (0.1 µl of 2.4 mM stock in DMSO), 500 µM of TCEP (5 µl of 1 mM stock in 
water), 250 µM TBTA (0.625 µl of a 4 mM stock in DMSO) and 1mM CuSO4 (1 µl of a 
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10 mM stock in water).  The reaction was allowed to proceed for 1 hour at room 
temperature followed by addition of 5 µl of 4X SDS-PAGE loading buffer.  Samples 
were boiled at 95 °C for 5 minutes and 10 µl were loaded to a 10% SDS-PAGE gel.  Gels 
were washed twice with water for 5 minutes then visualized by fluorescent scanning 
using a Typhoon 9400 (GE Healthcare) with excitation at 532 nm and detection at 580 
nm. 
 
4.5.8 Homologous competition assay 
For homologous competition assays, 3 µM of compound 2 was added to a 
mastermix of GST-fusion protein diluted to 1 µM.  10 µl of master mix was aliquoted per 
reaction followed by addition of (R) or (S)-lacosamide (3 µM to 30 mM).  The reactions 
were incubated for 3 hours at 4 °C followed by photoactivation at 312 nm for 10 minutes 
on ice.  Cycloaddition was initiated by addition of 24 µM probe 1 (0.1 µl of 2.4 mM 
stock in DMSO), 500 µM of TCEP (5 µl of 1 mM stock in water), 250 µM TBTA (0.625 
µl of a 4 mM stock in DMSO) and 1mM CuSO4 (1 µl of a 10 mM stock in water).  The 
reaction was allowed to proceed for 1 hour at room temperature followed by addition of 5 
µl of 4X SDS-PAGE loading buffer.  Samples were boiled at 95 °C for 5 minutes and the 
entire sample was loaded to a 10% SDS-PAGE gel.  Gels were washed to twice with 
water for 5 minutes then visualized by fluorescent scanning using a Typhoon 9400 (GE 
Healthcare) with excitation at 532 nm and detection at 580 nm.  Images were quantified 
using ImageJ (NIH) and curves generated using GraphPad (Prism). 
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4.5.9 Surface plasmon resonance 
Biotinylated lacosamide compounds dissolved in DMSO were immobilized on a 
streptavidin chip (SA chip/GE Healthcare) using a BIAcore2000 according to the 
manufacturer’s instructions.  Proteins were extensively dialyzed against the flow buffer 
(50 mM HEPES, 150 mM NaCl pH 7.4) prior to experiments.  Proteins were injected at a 
flow rate of 50 µl/min and their binding kinetics were observed over 3 minutes.  Data 
were analyzed with BIAevaluation 3.0 software (BIAcore).   
 
 
CHAPTER 5 
 
FUTURE WORK AND FORWARD LOOKING STUDIES 
 
5.1 Introduction 
The previous chapters outlined efforts to identify the protein targets of the novel 
anticonvulsant (R)-lacosamide (Vimpat®).  A proteomic screen of the mouse brain 
proteome identified 73 proteins via mass spectrometry that were captured with 
nucleophillic and photoaffinity reactive groups installed on (R) and (S)-lacosamide 
derived probes.  DPYSL2 was chosen for further study using recombinant protein 
expressed in E. coli.  Lysine 472 on DPYSL2 was identified as the residue that was 
modified by reaction with an isothiocyanate containing (R)-lacosamide analog.  The 
residue is adjacent to several sites important for phosporylation by Rho-kinase, Cdk5 and 
GSK-3β.  Additionally, mapped adduction site is close to the C-terminus of the protein 
that has been implicated in a variety of interactions with other proteins such as 
calmodulin, tubulin, and Cav2.2.  Several approaches could expand upon the work 
presented to characterize better the physiologically relevant interactions with DPYSL2 
and other proteins identified during the proteomic screen with (R)-lacosamide. 
 
5.2 Effects of DPYSL2 phosphorylation on (R)-lacosamide binding 
It is predicted that phosphorylation of DPYSL2 protein in vivo modulates its 
functionality.171,188-190,192,219  DPYSL2 can be phosphorylated at Thr-555 by Rho kinase, 
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Ser-522 by Cdk5, and Ser-518 and Thr-514 by GSK-3β.  The phosphorylation status of 
recombinant DPSYL2 protein was never evaluated in our studies; therefore, binding to 
(R)-lacosamide may be conditional based on kinase phosphorylation.  To test this 
hypothesis, in vitro kinase assays can be used to phosphorylate recombinant DPYSL2 
protein prior to binding experiments.  Cdk5 (Upstate) and GSK-3β (New England 
Biolabs) are commercially available in sufficient quantities to be used for 
phosphorylation of purified recombinant DPYSL2 protein.  If normal ATP is added to the 
kinase reaction, the phosphorylated recombinant protein can be used for Isothermal 
Titration Calorimetry (ITC) or Surface Plasmon Resosance (SPR) using (R)-lacosamide 
or the chip designed in chapter 4, respectively, to measure binding affinity. 
[γ-32P]ATP can be substituted for ATP in the kinase assay to generate 
phosphorylated DPYSL2 protein that is radiolabeled.  This labeled protein can be used in 
several ways.  First, using the AB and CR strategy with compounds 1 and 2 followed by 
enrichment with streptavidin beads, the amount of radiolabeled DPYSL2 can be 
measured in the presence or absence of competing amounts of (R) or (S)-lacosamide.  
Enriched proteins can be resolved on a SDS-PAGE gel and the amount of DPYSL2 can 
be detected by autoradiography.   
Another hypothesis is that (R)-lacosamide can inhibit DPYSL2 phosphorylation.  
Using a similar approach, [γ-32P]ATP can be used to investigate whether (R)-lacosamide 
can modulate the phosphorylation of DPYSL2 by kinases such as Cdk5 or GSK-3β.  The 
in vitro kinase assay used in the previous experiments can be repeated in the presence of 
increasing amount of (R) or (S)-lacosamide.  After the kinase reaction, the amount of 
phosphorylated protein can be measured directly using autoradiography. 
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5.3 Screening of (R)-lacosamide against metabotropic glutamate receptors 
Extensive screening of (R)-lacosamide against a variety of GPCRs and ion channels 
has been reported previously but only partial binding was seen at voltage gated sodium 
channels.150  Binding to additional receptors is worth investigating, however.  It has been 
reported that (R)-lacosamide effectively reduces harmaline induced essential tremor in 
rats.220  Traditionally, it has been thought that harmaline tremor is mediated by activity at 
the NMDA receptor.221  It has been demonstrated recently that harmaline induced tremors 
are enhanced by the selective metabotropic glutamate receptor 1 (mGluR1) antagoinist 
JNJ 16259685, suggesting a possible inhibitory influence between mGlu receptors and 
harmaline induced tremor.222   
One series of mGluR2/3 agonists show potent anticonvulsant activity in a kindled 
rat model.223  Ligands for mGlu receptors tend to have molecular weights less than 300 
daltons and have structures that are derivatives of amino acids.  These characteristics are 
also shared by (R)-lacosamide and other functionalized amino acids, therefore activity at 
one or more metabotropic glutamate receptor may be possible.  To this end, receptor 
binding assays against metabotropic glutamate receptors at the Psychoactive Drug 
Screening Program (PDSP) using (R)-lacosamide is recommended.  Currently there are 7 
human metabotropic receptor assays available for testing (human mGluR1-7). 
Alternatively, animal evaluation of (R)-lacosamide in the presence of the glutamate 
receptor antagonist (2S,1′S,2′S)-2-methyl-2-(carboxycyclopropyl)glycine (MCCG) would 
provide a similar assessment of activity at the mGluR (group II) receptors.  This receptor 
antagonist has been used to evaluate the anticonvulsant activity of DCG-IV on the 
mGluR (group II) family. 
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5.4 Screening of (R)-lacosamide to latrophilin toxin receptors 
During the proteomic search, the calcium-independent α-latrotoxin receptor was 
identified using compounds 1 and 2.  This protein belongs to a family of 3 large G-
protein coupled receptors (~1000 AA) that bind α-latrotoxin, a toxin peptide from black 
widow spiders that stimulates strong release of glutamate.224  Currently their roles in vivo 
and natural ligands are unknown.  Stimulation of vesicle exocytosis appears to occur in a 
calcium independent fashion, but the receptor requires the core vesicle fusion proteins 
synaptobrevin, SNAP-25, Stxbp1, and syntaxin. 
 Knowing whether (R)-lacosamide could affect the potent activity of α-latrotoxin 
in stimulating glutamate release would be of great interest.  To assess this, individual 
latrophilin receptors could be transfected into PC12 cells and calcium release measured in 
the presence or absence of (R)-lacosamide as previously described.225  Alternatively, the 
release of radiolabeled glutamate or GABA could be measured from purified 
synaptosomes after treatment with α-latrotoxin.226 
   Single and double mutant knock-out mice for latrophilin-1 and 2 are available 
and show normal development and survival rates.  Using these strains, the efficacy of 
(R)-lacosamide in the MES seizure test could be reevaluated to investigate what changes 
may occur in the absence of the receptor.  If (R)-lacosamide shows activity at latrophilin-
1 or 2, protection from seizure development may be diminished. 
 
5.5 ATPase activity of NSF protein 
Neuronal sprouting has recently been reported to be a phenotype of neurons 
treated with (R)-lacosamide.  Although a number of unique pathways involving multiple 
  142 
proteins may mediate this process, some proteins identified in our proteomic search have 
been associated with this phenomenon.  NSF, the hexameric ATPase involved in 
disassembly of the SNARE complex, was identified specifically with the (R) entantiomer 
during the proteomic screen and the IC50 calculated to be 340 µM using the homologous 
competition assay. This was the lowest ICd of all three proteins tested.  Expression of a 
dominant negative (ATPase inactive) mutant in drosophila results in outgrowth at the 
neuromuscular synapse during development.227  If the ATPase activity of NSF 
contributes to synpase sprouting, then potentially (R)-lacosamide may affect NSF 
activity.  A standard ATPase assay using recombinant protein in the presence or absence 
of (R) and (S)-lacosamide would evaluate whether this hypothesis warrants further 
investigation. 
 
5.6 Metabolic profiling of (R)-lacosamide treated mice 
The majority of our efforts have relied solely on the results of a proteomic screen 
to identify potential protein targets that interact with (R)-lacosamide coupled with in vitro 
methods to measure labeling and binding affinity.  Alternative methods that provide 
greater insight into the biochemical changes elicited by (R)-lacosamide would help 
distinguish between physiologically relevant proteins identified during our screen with 
those that should be considered background.  As mentioned in chapter 2, advances in 
mass spectrometry now allow for simultaneous detection of hundreds of cellular 
metabolites from tissues to discern biochemical changes between samples.  This 
methodology has been successfully applied for the identification of the protein targets of 
several drug candidates.141 
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A similar approach could be taken with (R)-lacosamide by profiling the four sets 
of mouse brain tissue used to generate the mRNA-display libraries [normal (sham 
stimulated), (R)-lacosamide treated (20 mg/kg), 6 Hz stimulated (32 mA 3 sec), and 6 Hz 
stimulated (R)-lacosamide treated].  The results would generate unique metabolic profiles 
for each tissue treatment that could readily be mapped to biochemical pathways in the 
cell.  Changes in metabolites upon administration of (R)-lacosamide could then be 
integrated with the results of our proteomic screen, providing a better understanding of 
which biochemical pathways to pursue. 
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APPENDIX 
 
Mass Spectrometry Experiment Number 1 (03/04/08) 
Sample Drug Protein (ul) [Drug] Probe Purification Elution 
1 Compound 1 500 (0.8mg) 12 uM Biotin Muetin Streptavidin 
beads 
Biotin (4mM) 
2 Compound 1 500 (0.8mg) 12 uM Biotin Streptavidin beads Sample Buffer 
3 Compound 2 500 (0.8mg) 12 uM Biotin Muetin Streptavidin 
beads 
Biotin (4mM) 
4 Compound 3 500 (0.8mg) 12 uM Biotin Muetin Streptavidin 
beads 
Biotin (4mM) 
5 Compound 3 500 (0.8mg) 12 uM Biotin Streptavidin beads Sample Buffer 
5 No Drug 500 (0.8mg)  Biotin Streptavidin Beads Biotin (4mM) 
 
Protocol 
1. Aliquot 500ul of lysate (1.71mg/ml) per reaction.   
2. Add appropriate amount of drug 
3. Incubate at room temperature for 1h for NCS, for N3  UV crosslink for 15 min 
4. QUENCH reactions with 4mM methylhydrazine for 1h at R.T. for NCS 
compounds, for N3, pass through a Zeba column 
5. Add SDS to [1 %], boil for 5 minutes  
6. Add Click chemistry reagents Biotin-N3, TBTA, TCEP, CuSO4 (1:1:10:25)  
7. Incubate for 2h at R.T. rotating 
8. Add 100ul (Resin) streptavidin beads 
9. Incubate for 2h at 4°C 
10. Wash 4X with 1ml of 50mM HEPES pH 7.2 for regular streptavidin beads, wash 
muetin streptavidin beads with 3CV of wash buffer 
11. Elute with 100ul of elution buffer 
a. SDS-PAGE sample buffer 
b. 4mM Biotin 
12. Run eluted products on gel 
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Results of Experiment 1 
SCBO1 ATP synthase subunit beta, mitochodrial precursor 
  ATP synthase subunit alpha, mitochondrial precursor 
  Brain acid soluble protein 1 
  AP-2 complex subunit mu-1 
SCBO2 Actin, cytoplasmic 1 
  Citrate synthase 
  Creatine kinase, ubiquitous mitochondrial precursor 
  Creatine kinase, B-type 
  2',3'-cyclic-nucleotide 3'-phosphodiesterase 
  Phosphoglycerate kinase1 
  Phosphoglycerate kinase2 
SCBO3 Aspartate aminotransferase, mitochondrial precursor 
  Aspartate aminotransferase, cytoplasmic 
  Fructose-bisphosphate aldolase A 
  actin (can not identify isoform) 
  Fructose-bisphosphate aldolase C 
  Guanine nucleotide-binding protein G (can not identify isoform) 
  Calcium-independent alpha-latrotoxin receptor 
SCBO4 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta/delta 
  3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma 
  3-monooxygenase/tryptophan 5-monooxygenase activation protein eta 
  3-monooxygenase/tryptophan 5-monooxygenase activation protein beta/alpha 
  3-monooxygenase/tryptophan 5-monooxygenase activation protein sigma 
  3-monooxygenase/tryptophan 5-monooxygenase activation protein theta 
  ADP/ATP translocase 1 
  ADP/ATP translocase 2 
  Carbonic anhydrase 2 
SCBO5 Malate dehydrogenase, cytoplasmic 
  Malate dehydrogenase, mitochondrial precursor 
  Guanine nucleotide-binding protein G (can not identify isoform) 
  Syntaxin-1B 
  Clathrin light chain B 
SCBO6 Syntaxin-binding protein1 
  Dihydropyrimidinase-related protein 1 
  Dihydropyrimidinase-related protein 2 
  Serum albumin precursor 
  Myelin proteolipid protein 
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Mass Spectrometry Experiment 2 (04/20/08) 
Sample Drug Protein (ul) [Drug] Probe Purification Elution 
1 Compound 1 500 (0.8mg) 40 uM Biotin Streptavidin beads Sample Buffer 
2 AB-R-LCM 500 (0.8mg) 40 uM Biotin Streptavidin beads Sample Buffer 
3 No Drug 500 (0.8mg) 40 uM Biotin Streptavidin beads Sample Buffer 
 
Protocol 
1. Aliquot 500ul of lysate (1.71mg/ml) per reaction.   
2. Add appropriate amount of drug 
3. Incubate at room temperature for 1h for NCS 
4. QUENCH reactions with 4mM methylhydrazine for 1h at R.T. for NCS 
compounds 
5. Add Click Chemistry Reagents in accordance with (Salisbury Cravatte JACS 
2008 DOI ja074138u) 
a. 1ul of 20mM Biotin Probe 
b. .25ul of 1M TCEP 
c. 2.5 ul of 20mM TBTA 
d. .5 ul of 1M CuSO4 
6. Incubate for 2h at R.T. rotating 
7. Add 50ul (Resin) streptavidin beads 
8. Wash 2X with 50mM HEPES, 150mM NaCl with .2% SDS 
9. Wash 2X with 6M urea 
10. Wash 3X with 50mM HEPES, 150mM NaCl 
11. Elute with 50ul of elution buffer 
a. SDS-PAGE sample buffer 
12. Run eluted products on gel 
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Results of Experiment 2 
No. AB&CR 
1 ADP/ATP translocase 1 (MW 32883) 
  3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta/delta (MW 27754) 
  Keratin, type II cytoskeletal 1 
   Keratin, type I cytoskeletal 14 
   Keratin, type I cytoskeletal 15 
  Keratin, type I cytoskeletal 17 
   Keratin, type II cytoskeletal 8 
   Keratin, type II cytoskeletal 5 
2  Keratin, type II cytoskeletal 1b 
   Keratin, type I cytoskeletal 10 
3  Glyceraldehyde-3-phosphate dehydrogenase (MW 35787) 
  Malate dehydrogenase, mitochondrial precursor (MW 35589) 
   Keratin, type II cytoskeletal 1 
   Keratin, type I cytoskeletal 10 
   Keratin, type II cytoskeletal 2 epidermal 
   Keratin, type II cytoskeletal 4 
   Keratin, type II cytoskeletal 6A 
4 Actin, cytoplasmic 1 (MW 41710) 
   Keratin, type I cytoskeletal 10 
5 Elongation factor 1-alpha 1 (MW 50082) 
  Alpha-enolase (MW 47111) 
   Keratin, type II cytoskeletal 1b 
   Keratin, type II cytoskeletal 2 epidermal 
6 ATP synthase subunit alpha, mitochondrial precursor (MW 59716) 
  Spermatogenesis-associated protein 7 homolog (MW  65613) observed only one peptide 
   Tubulin alpha-1A chain 
   Keratin, type II cytoskeletal 1b 
   Tubulin beta-3 chain 
   Tubulin alpha-4A chain 
   Keratin, type I cytoskeletal 10 
   Keratin, type I cytoskeletal 18 
  Tubulin beta-2A chain  
7 Dihydropyrimidinase-related protein 1 or 2 (MW 62239) 
  Spermatogenesis-associated protein 7 homolog (MW  65613) observed only one peptide 
  Histone H4 (MW 11360) 
   Keratin, type I cytoskeletal 10 
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   Keratin, type I cytoskeletal 14 
   Keratin, type II cytoskeletal 8 
   Keratin, type II cytoskeletal 5 
   Keratin, type I cuticular Ha1 
   Keratin, type II cytoskeletal 1 
  Keratin type II cuticular Hb5 
8 - 
9 - 
10 - 
11 - 
12 - 
 
Mass Spectrometry Experiment 3 (05/21/08) 
Sample Drug Protein 
(ul) 
[Drug] Click Probe Purification Elution 
1 Compound 1 
(R) 
500 
(2.25mg) 
40 uM CuSO4 Biotin Streptavidin beads Sample 
Buffer 
2 Compound 1 
(S) 
500 
(2.25mg) 
40 uM CuSO4 Biotin Streptavidin beads Sample 
Buffer 
3 Compound 2 
(R) 
500 
(2.25mg) 
40 uM CuSO4 Biotin Streptavidin beads Sample 
Buffer 
4 Compound 2 
(S) 
500 
(2.25mg) 
40 uM CuSO4 Biotin Streptavidin beads Sample 
Buffer 
5 No Drug   CuSO4 Biotin Streptavidin beads Sample 
Buffer 
 
Protocol 
1. Preclear lysate with 500ul 50% slurry streptavidin beads 
2. Aliquot 500ul of lysate (4.5mg/ml) per reaction   
3. Incubate at room temperature for 30 min 
4. Add appropriate amount of drug 
5. Incubate at room temperature for 1h for NCS, for N3 incubate at R.T. for 30 min then hv crosslink 
for 20 min 
6. QUENCH reactions with 4mM methylhydrazine for 1h at R.T. for NCS and TCEP for N3 
7. Add Click Chemistry Reagents in accordance with (Salisbury Cravatte JACS 2008 DOI 
ja074138u) 
a. 1ul of 20mM Biotin Probe 
b. .25ul of 1M TCEP 
c. 2.5 ul of 20mM TBTA 
d. .5 ul of 1M CuSO4 
8. Incubate for 2h at R.T. rotating 
9. Add 50ul (Resin) streptavidin beads 
10. Wash 2X with 50mM HEPES, 150mM NaCl with .2% SDS 
11. Wash 2X with 6M urea 
12. Wash 3X with 50mM HEPES, 150mM NaCl 
13. Remove 1/3 of the beads to submit for mass spec 
14. Elute with 50ul of elution buffer 
a. SDS-PAGE sample buffer 
15. Run eluted products on gel 
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Sample Number Sample Name Sample Type Drug 
1 R.NCS.1 Gel Band Compound 1 (R) 
2 R.NCS.2 Gel Band Compound 1 (R) 
3 R.NCS.3 Gel Band Compound 1 (R) 
4 R.NCS.4 Gel Band Compound 1 (R) 
5 R.NCS.5 Gel Band Compound 1 (R) 
6 R.NCS.6 Gel Band Compound 1 (R) 
7 S.NCS.1 Gel Band Compound 1 (S) 
8 S.NCS.2 Gel Band Compound 1 (S) 
9 S.NCS.3 Gel Band Compound 1 (S) 
10 S.NCS.4 Gel Band Compound 1 (S) 
11 S.NCS.5 Gel Band Compound 1 (S) 
12 R.N3.1 Gel Band Compound 2 (R) 
13 R.N3.2 Gel Band Compound 2 (R) 
14 R.N3.3 Gel Band Compound 2 (R) 
  169 
15 R.N3.4 Gel Band Compound 2 (R) 
16 R.N3.5 Gel Band Compound 2 (R) 
17 S.N3.1 Gel Band Compound 2 (S) 
18 S.N3.2 Gel Band Compound 2 (S) 
19 S.N3.3 Gel Band Compound 2 (S) 
20 S.N3.4 Gel Band Compound 2 (S) 
21 S.N3.5 Gel Band Compound 2 (S) 
22 1 Streptavidin Beads Compound 1 (R) 
24 2 Streptavidin Beads Compound 1 (S) 
25 3 Streptavidin Beads Compound 2 (R) 
25 4 Streptavidin Beads Compound 2 (S) 
26 5 Streptavidin Beads No Drug 
 
Results of Experiment 3 
Protein 
 Bead 
R-NCS 
 Gel 
R-
NCS 
 Bead 
S-
NCS 
Gel S-
NCS 
Bead 
R-N3 
Gel 
R-N3 
Bead 
S-N3 
Gel S-
N3 
Sodium/potassium-
transporting 
ATPase subunit 
alpha-3 15  13  9  11 2 
Sodium/potassium-
transporting 
ATPase subunit 
alpha-2 precursor 9    7  6  
Sodium/potassium-
transporting 
ATPase subunit 
alpha-1 precursor  9  6    5  
Sodium/potassium-
transporting 
ATPase subunit 
beta-1 2  1    1  
ADP/ATP 
translocase 1 4   6   2 6 
ADP/ATP 
translocase 2 2   4    5 
ADP/ATP 
translocase 4 2        
3-
monooxygenase/try
ptophan 5-
monooxygenase 
activation protein 
zeta/delta 3  2 9 3   6 
3-
monooxygenase/try
ptophan 5-
monooxygenase   3      
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activation protein 
epsilon 
3-
monooxygenase/try
ptophan 5-
monooxygenase 
activation protein 
gamma     3  3  
3-
monooxygenase/try
ptophan 5-
monooxygenase 
activation protein 
sigma     2  2  
ATP synthase 
subunit beta 5  2    3  
ATP synthase 
subunit alpha, 
mitochondrial 
precursor   4 6   2 7 
Heat shock cognate 
71 kDa protein   2   4  3 
Heat shock protein 
HSP 90-alpha       2  
Heat shock protein 
HSP 90-beta       2  
Heat shock protein 
75 kDa, 
mitochondrial 
precursor       1  
Actin, cytoplasmic 
1 9 6 11 5 7 16 9 12 
Gamma-enolase 2 2    2  3 
Alpha-enolase    5   2  
Potassium-
transporting 
ATPase alpha chain 
1 2        
Dihydropyrimidina
se-related protein 2 8 2 5 3  6   
Triosephosphate 
isomerase 3  4  1 3   
Fructose-
bisphosphate 
aldolase A 4 2  2    2 
Pyruvate kinase 
isozymes M1/M2 1    3    
Cofilin-1 1        
Hemoglobin 
subunit beta-1 2  3    1  
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Guanine 
nucleotide-binding 
protein G(o) 
subunit alpha 1 2  2 2   2  
2',3'-cyclic-
nucleotide 3'-
phosphodiesterase 3 2 4    4  
Histone (can not 
identify isoform) 1  2    2  
Clathrin heavy 
chain 3  6    4  
Peptidyl-prolyl cis-
trans isomerase A 3        
Myelin proteolipid 
protein 3    2 1 4 1 
Creatine kinase B-
type 2  3    1  
4-aminobutyrate 
aminotransferase, 
mitochondrial 
precursor   1      
Succinate dehydrogenase 
[ubiquinone] flavoprotein 
subunit, mitochondrial 
precursor  2      
Glyceraldehyde-3-
phosphate 
dehydrogenase   3 2 1  6  
Ras-related protein 
(can not identify 
isoform)   1      
Malate 
dehydrogenase, 
mitochondrial 
precursor   1 1    3 
Malate 
dehydrogenase, 
cytoplasmic        1 
Dynamin-1   2      
Excitatory amino 
acid transporter 2   1      
Symplekin     2    
Vang-like protein 2     1    
Retinoblastoma-
binding protein 6     1    
2-oxoglutarate 
dehydrogenase E1 
component, 
mitochondrial 
precursor       2  
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Elongation factor 1-
alpha 1       1 2 
G1 to S phase 
transition protein 1 
homolog       1  
Structural 
maintenance of 
chromosomes 
protein 1A       1  
Syntaxin-binding 
protein 1    2  3   
Vesicle-fusing 
ATPase      3   
Stress-70 protein, 
mitochondrial 
precursor         
Carbonic anhydrase 
2        3 
Ubiquinol-cytochrome-c 
reductase complex core 
protein 2, mitochondrial 
precursor       3 
 
Mass Spectrometry Experiment 4 (06/29/08) 
Sample Drug Protein 
(ul) 
[Drug] Click Probe Purification Competition 
1 Compound 
1 (R) 
500 
(2.25mg) 
40 uM CuSO4 Biotin Streptavidin 
beads 
None 
2 Compound 
1 (S) 
500 
(2.25mg) 
40 uM CuSO4 Biotin Streptavidin 
beads 
None 
3 Compound 
2 (R) 
500 
(2.25mg) 
40 uM CuSO4 Biotin Streptavidin 
beads 
None 
4 Compound 
2 (S) 
500 
(2.25mg) 
40 uM CuSO4 Biotin Streptavidin 
beads 
None 
5 Compound 
1 (R) 
500 
(2.25mg) 
40 uM CuSO4 Biotin Streptavidin 
beads 
4mM NCS-R 
6 Compound 
1 (S) 
500 
(2.25mg) 
40 uM CuSO4 Biotin Streptavidin 
beads 
4mM NCS-R 
7 Compound 
2 (R) 
500 
(2.25mg) 
40 uM CuSO4 Biotin Streptavidin 
beads 
4mM NCS-R 
8 Compound 
2 (S) 
500 
(2.25mg) 
40 uM CuSO4 Biotin Streptavidin 
beads 
4mM NCS-R 
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Protocol 
1. Preclear lysate with 500ul 50% slurry streptavidin beads 
2. Aliquot 500ul of lysate (4.5mg/ml) per reaction  
3. Add competing Drug 
4. Incubate at room temperature for 30 min 
5. Add appropriate amount of drug 
6. Incubate at room temperature for 1h for NCS, for N3 incubate at R.T. for 30 min 
then hv crosslink for 20 min 
7. QUENCH reactions with 4mM methylhydrazine for 1h at R.T. for NCS and 
TCEP for N3 
8. Add Click Chemistry Reagents in accordance with (Salisbury Cravatte JACS 
2008 DOI ja074138u) 
a. 1ul of 20mM Biotin Probe 
b. .25ul of 1M TCEP 
c. 2.5 ul of 20mM TBTA 
d. .5 ul of 1M CuSO4 
9. Incubate for 2h at R.T. rotating 
10. Add 50ul (Resin) streptavidin beads 
11. Wash 2X with 50mM HEPES, 150mM NaCl with .2% SDS 
12. Wash 2X with 6M urea 
13. Wash 3X with 50mM HEPES, 150mM NaCl 
14. Remove 1/3 of the beads to submit for mass spec 
 
Results of Experiment 4 
 
no. of peptides 
Protein R-NCS S-NCS R-N3 S-N3 R-NCS S-NCS R-N3 S-N3 
Sodium/potassium-
transporting ATPase subunit 
alpha-3 10 9 6 10     8   
Sodium/potassium-
transporting ATPase subunit 
alpha-2 precursor 12 9 7 11         
Actin, (can not identify 
isoform) 6 6 7 5 2   6 9 
Sodium/potassium-
transporting ATPase subunit 
alpha-1 precursor 8               
ATP synthase subunit alpha, 
mitochondrial precursor 4   4       4 3 
Syntaxin-binding protein 1 2 3 1 3     3 2 
Hemoglobin subunit beta-1 1     2     3 2 
Fructose-bisphosphate 
aldolase A 2               
Glyceraldehyde-3-phosphate 
dehydrogenase 2 3 4 2     3 2 
2',3'-cyclic-nucleotide 3'-
phosphodiesterase 2 2 3 4 1   2 3 
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14-3-3 protein zeta/delta 2 6 1 3         
Ras-related protein Rab-3A 2               
Ras-related protein Rab-30 2               
ATP synthase subunit beta, 
mitochondrial precursor 4 2         4 2 
ADP/ATP translocase 1 3 5 3 1     5   
Elongation factor 1-alpha 1 1               
Guanine nucleotide-binding 
protein (can not identify 
isoform) 1 1   2         
Heat shock protein HSP 90-
alpha 2 2             
ADP/ATP translocase 4 3 3 4           
Pyruvate kinase isozymes 
M1/M2 1     3     3   
Plasma membrane calcium-
transporting ATPase 2 1               
Heat shock cognate 71 kDa 
protein (can not identify 
isoform) 2 4         2 2 
14-3-3 protein epsilon   4 1           
14-3-3 protein gamma   4           1 
Pyruvate kinase isozymes 
M1/M2   2           2 
Malate dehydrogenase, 
mitochondrial precursor   3             
Excitatory amino acid 
transporter 2   1 1 2         
14-3-3 protein theta   3             
Potassium-transporting 
ATPase alpha chain 1   3             
Abhydrolase domain-
containing protein 8   1 1           
Heat shock 70 kDa protein 
(can not identify isoform)   2         2   
Serine/threonine-protein 
kinase 6   1   1 1       
Creatine kinase B-type   2   2     3 1 
Clathrin heavy chain   3         2 2 
Myelin proteolipid protein   3   4   3 2 3 
Glutamate dehydrogenase 1, 
mitochondrial precursor       2     3   
Gamma-enolase       2         
Fructose-bisphosphate 
aldolase A             1   
Phosphate carrier protein, 
mitochondrial precursor             1   
 
 
